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Abstract 
This project developed, assessed and improved an existing virtual screening technology; the 
Investigational Novel Drug Discovery by Example (INDDEx) package; and uses the technology to 
discover new drug hits and leads. INDDEx performs ligand-based virtual screening: learning from 
molecules with known activity and fragmenting them into substructural elements. A model is built 
based on logical rules defining required distances between elements of substructure. 
In the optimisation phase of this project, the program’s speed was increased, a support vector 
machine method was implemented and a graphical output for the generated rules was added. 
In the investigation and screening phase, INDDEx screened the ZINC database to find new 
inhibitors for SIRT2, a poorly investigated target with few known inhibitors. The top ranked 
molecules were docked with GOLD to produce a consensus score. A new molecule was found with 
50% inhibitory concentration of 0.67µm against SIRT2. 
In the assessment phase, the performance of INDDEx as a virtual screening tool was assessed by 
benchmarking it on the DUD database and comparing it with the performances of eHiTS LASSO, 
PharmaGist and DOCK. INDDEx gave 1% Enrichment Factors of 69.2, 82.7 and 90.4, and 0.1% 
Enrichment Factors of 492, 631 and 707, both when learning from 2, 4 and 8 active ligands. A strength 
of INDDEx is its scaffold-hopping ability. Scaffold-hopping is important for developing new drug 
leads, and is regarded as a challenge. Considering only ligands structurally dissimilar to ones in the 
benchmarking learning data, INDDEx gave 1% Enrichment Factors of 52.3, 63.6 and 66.9 when 
learning from 2, 4 and 8 active ligands. 
In the improvement phase, an algorithm was implemented to take hits found by INDDEx and 
explore the synthetic space resulting from synthetic modification of those hits. This was realised using 
a library of virtual reactions and a method of predicting which molecules have the most potential for 
modification. Two assessments quantified the additional molecular space made available to search 
and qualified the new method as a significant improvement on a naïve approach. 
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Glossary of terms and abbreviations 
ΔG Gibbs free energy. The thermodynamic energy released by a system. 
Å Ångström. A unit of length equal to 10-10 metres. 
ACE Angiotensin-converting enzyme. A protein target in the DUD database (see 
Appendix B). 
ACHE Acetylcholine esterase. A protein target in the DUD database (see Appendix B). 
ADA Adenosine deaminase. A protein target in the DUD database (see Appendix B). 
ADMET Absorption, Distribution, Metabolism, Excretion, Toxicity. The five criteria that 
influence the kinetics, suitability and activity of a pharmacological drug. 
AGK2 A molecule known to inhibit SIRT2 (Outeiro et al., 2007). 
aLogP An atom-based predictive method for calculating the octanol-water partition 
coefficient of a molecule (Ghose et al., 1998). See also LogP. 
ALR2 Aldose reductase. A protein target in the DUD database (see Appendix B). 
AMBER Assisted Model Building with Energy Refinement. A force field for modelling and 
simulating the molecular dynamics of biochemicals (Pearlman et al., 1995). 
AmpC AmpC type beta-lactamase. A protein target in the DUD database (see Appendix 
B). 
AR Androgen receptor. A protein target in the DUD database (see Appendix B). 
Astex diverse set A dataset of 85 diverse protein-ligand complexes, suitable for testing and 
benchmarking docking software (Hartshorn et al., 2007). 
ATP Adenosine TriPhosphate. A nucleoside triphosphate coenzyme that is used for 
energy transfer in all aerobic organisms. 
AUROC Area Under the Receiver Operating Characteristic. The area under a ROC curve 
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(see ROC). 
BEDROC Boltzmann-Enhanced Receiver Operating Characteristic. A weighting of the 
AUROC measure that gives a much higher weight to the earliest retrieved 
positives. It incorporates the RIE function (Truchon and Bayly, 2007). 
BLAST Basic Local Alignment Search Tool. An algorithm used for a suite of tools that 
align query protein or DNA sequences with a database of library sequences 
(Altschul et al., 1990).  
Bonferroni correction A statistical method applied to the confidence values of a test to compensate for 
multiple hypothesis tests on a single set of data (Dunn, 1961). 
CAESA Computer Assisted Estimation of Synthetic Accessibility. A scoring function for 
ranking molecules in order of ease of synthesis (Gillet et al., 1995). 
Cambinol A molecule known to inhibit SIRT2 (Heltweg et al., 2006). 
CAOS Computer-Aided Organic Synthesis Program. A program that simulates the 
results of organic synthesis reactions on precursor reactants. 
CASE Collaborative Awards in Science and Engineering. Studentship award funding 
this project. 
CDK Chemistry Development Kit. An open-source library of Java functions designed 
for chemoinformatics and bioinformatics programming (Steinbeck et al., 2003). 
CDK2 Cyclin dependent kinase 2. A protein target in the DUD database (see Appendix 
B). 
CHARMM Chemistry at Harvard Macromolecular Mechanics. A force field used to describe 
the energy of a system of atoms for molecular simulations (MacKerell et al., 1998). 
ChemAxon A chemoinformatics software company. 
ChemAxon Reactor A ChemAxon product containing a database of structure-based rules for the 
reactivity of molecules (Pirok et al., 2006). The data from this underlies a lot of the 
work in Chapter 5. 
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ChEMBL Chemogenomics division of the European Molecular Biology Laboratory. A 
database of bioactivity data, containing a large number of bioactive compounds 
with activity data taken from reliable published bioassays. The database contains 
2D structures, physiochemical properties and target information associated with 
the compounds (Gaulton et al., 2011). 
ChemScore A scoring function used by the GOLD software to rank the binding affinity of 
docked ligands (Verdonk et al., 2003). See section 3.5.4. 
cLogP A fragment-based predictive method for calculating the octanol-water partition 
coefficient of a molecule (Ghose et al., 1998). See also LogP. 
COMT Catechol O methyltransferase. A protein target in the DUD database (see 
Appendix B). 
CONJURE Ligand-based virtual screening program that uses an evolutionary algorithm for 
de novo drug design. Developed by Vertex Pharmaceuticals (Walters et al., 1998). 
COX-1 Cyclooxygenase 1. A protein target in the DUD database (see Appendix B). 
COX-2 Cyclooxygenase 2. A protein target in the DUD database (see Appendix B). 
CPU Central Processing Unit of a computer. 
Cresset Cresset BioMolecular Discovery Limited. A company developing novel virtual 
screening and drug discovery methods, based around force field matching 
technology (Cheeseright et al., 2008, 2006). 
dalton A unit of atomic mass, defined as one twelfth of the mass of carbon-12. 
Daylight Daylight Chemical Information Systems, Inc. Producers of the Daylight 
fingerprinting method (James et al., 2005). 
de novo From the Latin “from the beginning.” A procedure which starts from nothing. 
DHFR Dihydrofolate reductase. A protein target in the DUD database (see Appendix B). 
DLD Dynamic Ligand Design (Miranker and Karplus, 1995). 
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DNA Deoxyribonucleic acid. A double-helix polymer of nucleotides, which encodes the 
genetic information of all organisms except viruses. First crystallised by Watson 
and Crick (1953). 
DOCK A structure-based screening program for docking ligands to 3D protein structures 
(Ewing et al., 2001). 
DREAM++ DREAM++ (Makino et al., 1999). 
DREIDING A force field used to describe the energy of a system of atoms for molecular 
simulations (Mayo et al., 1990). 
Drugs@FDA A database provided by the FDA that gives the structures of all drugs approved 
for sale in the United States. 
DSSTox Distributed Structure-Searchable Toxicity. A publically available broad-ranging 
toxicity database of dataset compiled by EPA’s National Center for 
Computational Toxicology. 
DUD Directory of Useful Decoys. A dataset for benchmarking virtual screening 
software (Huang et al., 2006). 
EC50 Half-maximal Effective Concentration. Measures the amount of a substance 
required to promote a biological process to halfway between the normal rate and 
the maximal rate. Used to measure the effectiveness of agonists. 
EF Enrichment Factor. A metric of retrieval performance, expressing the multiples of 
enrichment of the number of positives in a given percentage of the top ranked 
results as compared to the number of positives expected by chance. 
EGFr Epidermal growth factor receptor kinase. A protein target in the DUD database 
(see Appendix B). 
eHiTS LASSO electronic High Throughput Screening Ligand Activity by Surface Similarity 
Order) (Zsoldos et al., 2007) is a ligand-based virtual screening method that uses a 
neural network algorithm. 
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Equinox Pharma Ltd The developers of the INDDEx software. 
ER agonist Estrogen Receptor agonist. A protein target in the DUD database (see Appendix 
B). 
ER antag Estrogen Receptor antagonist. A protein target in the DUD database (see 
Appendix B). 
EROS Elaborations of Reactions for Organic Synthesis. A retrosynthesis analysis 
program (Gasteiger et al., 1990). 
FBDD Fragment-Based Drug Discovery. A virtual screening technique where molecules 
representing fragments are screened for binding affinity and then combined to 
produce a single molecule with high binding affinity (Hajduk Greer, 2007). 
FDA The Food and Drug Administration. A United States agency that regulates 
pharmaceutical drugs and approves them for sale. 
FGFr1 Fibroblast growth factor receptor 1. A protein target in the DUD database (see 
Appendix B). 
FlexX A structure-based screening program for docking ligands to 3D protein structures 
(Rarey et al., 1996). 
F-measure A statistical measure of the accuracy and performance of information retrieval 
(see section 4.2.1). It is equivalent to the harmonic mean of precision and recall. 
FN False Negative. A Boolean datum known to be TRUE and assigned the value 
FALSE in a predictive test. 
FOIL First Order Inductive Learner. A rule-based learning algorithm implementation of 
ILP (Quinlan and Cameron-Jones, 1995). 
FOX Forkhead bOX. A family of proteins that act as transcription factors, sharing a 
forkhead domain that binds to DNA. They regulate many genes including ones 
involved in cell growth, cell cycle, and longevity (Granadino et al., 2000). 
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FOXO1 Forkhead bOX protein O1. A FOX transcription factor that regulates genes 
involved in adipocyte differentiation (Nakae et al., 2003). 
FOXO3a Forkhead bOX protein O3a. A FOX transcription factor that regulates genes 
involved in apoptosis (Kops et al., 2002). 
FP False Positive. A Boolean datum known to be FALSE and assigned the value 
TRUE in a predictive test. 
FPR False Positive Rate. The rate of retrieval of False Positive data. 
FXa Factor Xa. A protein target in the DUD database (see Appendix B). 
GART Glycinamide ribonucleotide transformylase. A protein target in the DUD database 
(see Appendix B). 
GDB The Chemical Universe database GDB. A database of all possible small molecules 
up to a certain number of atoms; generated by enumerating every possible 
configuration of atoms and then filtering with rules for stability and synthetic 
feasibility (Blum and Reymond, 2009). 
Glide A structure-based screening program for docking ligands to 3D protein structures 
(Friesner et al., 2004). 
GOLD Genetic Optimisation Ligand Docking. A structure-based screening program for 
docking ligands to 3D protein structures (Verdonk et al., 2003). 
GoldScore A scoring function used by the GOLD software to rank the binding affinity of 
docked ligands (Verdonk et al., 2003). See section 3.5.4. 
GPB Glycogen phosphorylase beta. A protein target in the DUD database (see 
Appendix B). 
GR Glucocorticoid receptor. A protein target in the DUD database (see Appendix B). 
GW5074 A molecule known to inhibit SIRT2 (Huber et al., 2010). 
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HAT Histone acetyltransferases. A family of proteins that predominantly acetylate 
histones. 
HDAC Histone deacetylases. A family of proteins that predominantly deacetylate 
histones. 
HIVPR HIV protease. A protein target in the DUD database (see Appendix B). 
HIVRT HIV reverse transcriptase. A protein target in the DUD database (see Appendix 
B). 
HMGR Hydroxymethylglutaryl-coenzyme A reductase. A protein target in the DUD 
database (see Appendix B). 
HSP90 Human heat shock protein 90 kinase. A protein target in the DUD database (see 
Appendix B). 
HTS High Throughput Screening. 
Huber-9 A molecule known to inhibit SIRT2. Referred to as “9” in the paper by Huber et al 
(2010). 
IC50 Half-maximal Inhibitory Concentration. Measures the amount of a substance 
required to inhibit a biological process by half the normal rate. Used to measure 
the effectiveness of antagonists. 
ILP Inductive Logic Programming. A machine learning method (Muggleton, 1991). 
in silico From the Latin “within the silicon.” A procedure or experiment performed 
through computational simulation. 
in vitro From the Latin “within the glass.” A procedure or experiment performed in test 
tubes or Petri dishes. 
INDDEx Investigational Novel Drug Discovery by Example. Proprietary technology 
developed by Equinox Pharma that uses SVILP for drug discovery. 
INDDEx v1 INDDEx version 1. This is the version developed by Dr. Ata Amini prior to my 
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involvement with the program. 
INDDEx v2 INDDEx version 2. This is the version that I developed from INDDEx v1 over the 
course of the project described in this thesis. Its development and assessment are 
described in Chapter 4 and its application is describe in Chapter 3. 
INDDEx v3 INDDEx version 3. This is the version that I developed from INDDEx v2 over the 
course of the project described in this thesis. It Its development and assessment 
are described in Chapter 5. 
InhA Enoyl-acyl carrier protein reductase. A protein target in the DUD database (see 
Appendix B). 
InhibOx A company developing novel virtual screening and drug discovery methods. 
Initial reactant A term used in Chapter 5 to describe the initial molecule found by INDDEx and 
used as a basis to generate a library of synthesisable products from. 
KEGG LIGAND 
Database  
Kyoto Encyclopedia of Genes and Genomes Ligand Database. A database of all 
known compounds that are relevant to the biochemistry of life (Goto et al., 2002). 
LASSO See eHiTS LASSO. 
LHASA Logic and Heuristics Applied to Synthetic Analysis. A retrosynthesis analysis 
program (Johnson et al., 1992). 
LigandFit A structure-based screening program for docking ligands to 3D protein structures 
(Venkatachalam et al., 2003). 
Lipinski test / Lipinski 
rule of five 
A test of five physiochemical criteria for the likelihood of a molecule being an 
orally active drug (Lipinski et al., 1997). 
LogP The Logarithm of the Partition coefficient. The partition coefficient is the 
concentration ratio between the two phases, of a compound dissolved in two 
immiscible solvents (Leo et al., 1971). The two solvents used are usually octanol 
and water. It has no units. 
Mann–Whitney U test A non-parametric statistical test of the null hypothesis that two sets are sampled 
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from the same distribution against an alternative hypothesis that one population 
is sampled from a distribution with higher values (Mann and Whitney, 1947). 
MCF-7 Michigan Cancer Foundation-7. A cell line isolated in 1970 from an invasive breast 
ductal carcinoma. Used in breast cancer studies. 
MCSS Maximum Common Substructure. A measure of similarity between molecules (see 
1.8 Evaluating the similarity of molecules). 
MMFF94 Merck molecular force field. A molecular force field used to define the potential 
energy between intramolecular atoms for energy minimisation (Halgren, 1996). 
Molar refractivity A measure of the polarisability of one mole of a compound (Born et al., 1999), 
calculated by using the Lorentz-Lorenz relationship (Lorentz, 1880; Lorenz, 1880). 
It is proportional to weight divided by its density, and gives a measure of van der 
Waals binding affinity. The units of molar refractivity are in m3 mol-1. 
MR Mineralocorticoid receptor. A protein target in the DUD database (see Appendix 
B). 
MUV Maximum Unbiased Validation. A benchmark dataset for virtual screening 
(Rohrer Baumann, 2009). 
N The total size of a set. 
NA Neuraminidase. A protein target in the DUD database (see Appendix B). 
NAD Nicotinamide Adenine Dinucleotide. A common biomolecule that acts as a 
cofactor for many enzymes. 
NADPH The reduced form of Nicotinamide adenine dinucleotide phosphate. A coenzyme. 
Open Babel  An open-source chemoinformatics software toolbox. It allows the command-line 
interconversion of chemical file formats and energetic minimisation (O’Boyle et 
al., 2011). 
p38 [MAPK] P38 [Mitogen Activated Protein Kinase]. A protein target in the DUD database 
(see Appendix B). 
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p53 A protein in homo sapiens that suppresses tumours by regulating the cell cycle. 
PARP Poly(ADP ribose) polymerase. A protein target in the DUD database (see 
Appendix B). 
Partner reactant A term used in Chapter 5 to describe a fragment-like co-reactant used to combine 
with an initial reactant to generate a synthesisable product. 
PDB Protein Data Bank. A publically available database of 3D protein structures 
determined by experimental methods, maintained by the RCSB (Research 
Collaboratory for Structural Bioinformatics) (Berman et al., 2002).  
PDE5 Phosphodiesterase V. A protein target in the DUD database (see Appendix B). 
PDF###-## A series of molecules intended to inhibit SIRT2, synthesised and tested by Di 
Fruscia et al (2012) 
PDGFrb Platelet-derived growth factor receptor kinase beta. A protein target in the DUD 
database (see Appendix B). 
Pearson 
product-moment 
coefficient 
A statistical measure of linear correlation between two variables, which can have a 
value between +1 (perfect correlation) and -1 (perfect inverse correlation). R2 is the 
square of this value. 
Perl A high-level interpreted program language (Wall et al., 2000). 
PharmaGist A ligand-based virtual screening method, available as a web server (Dror et al., 
2009; Schneidman-Duhovny et al., 2008). 
Phyre2 Phyre2 (Kelley and Sternberg, 2009). 
PLoRRS Partial Logical-Rule Reactant Selection. A de novo design algorithm introduced in 
Chapter 5, designed to cut down on synthetic search space, by using logical rules 
to estimate the likelihood of a molecule being the precursor of an active molecule. 
PLS Partial Least Squares. A machine-learning method. 
PNP Purine nucleoside phosphorylase. A protein target in the DUD database (see 
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Appendix B). 
PPAR γ Peroxisome proliferator-activated receptor gamma. A protein target in the DUD 
database (see Appendix B). 
PR Progesterone receptor. A protein target in the DUD database (see Appendix B). 
PROGOL A rule-based learning algorithm implementation of ILP that uses an inverse 
entailment algorithm to search for the most specific clauses (Muggleton, 1995). 
PubChem A publically available, free database of chemical compounds, structures, and 
bioassays (Austin et al., 2004)(Wang et al., 2009). (Austin et al., 2004; Wang et al., 
2009) Maintained by the National Center for Biotechnology Information (NCBI). 
QSAR Quantitative Structure-Activity Relationship. A quantification of the relationship 
between structural features and the biological activity of a set of molecules. First 
described by Hansch and Fujita (1964). 
RIE Robust Initial Enhancement. A weighted metric developed to evaluate the 
performance of a ligand-based similarity search (Sheridan et al., 2001). 
ROC Receiver Operating Characteristic, or Relative Operating Characteristic. A curved 
line graph, plotting the detection of true positives against the detection of false 
positives in a binary classification system.  
RXR alpha Retinoic X receptor alpha. A protein target in the DUD database (see Appendix B). 
SAHH S adenosyl-homocysteine hydrolase. A protein target in the DUD database (see 
Appendix B). 
ScreenScore A scoring function for quantifying the quality of a ligand docking position (Stahl 
and Rarey, 2001). 
SIR2  Silent Information Regulation 2. A family of histone deacetylase genes in the 
yeast genome homologous to the sirtuins in Homo sapiens (Afshar and Murnane, 
1999). 
SIRT1-7  Silent Information Regulator Type 1-7. A gene that is a member of the sirtuins in 
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Homo sapiens. 
SMARTS SMiles ARbitrary Target Specification. A string line notation developed from the 
SMILES notation, and used for specifying molecular substructure pattern 
matching. 
SMILES Simplified Molecular Input Line Entry Specification. Developed by Weininger et 
al., (1988; 1989), is a string line notation for specifying molecular structure. 
SMIRKS  Simple Molecular Input Reaction Kinetic Strings. A string line notation 
developed from the SMILES notation, and used for specifying chemical reaction 
transformations (James et al., 2005),. 
Splitomicin-1 A molecule known to inhibit SIRT2 (Schemies et al., 2010). See Table 3.1. 
SRC Tyrosine kinase SRC. A protein target in the DUD database (see Appendix B). 
Student’s t-test A statistical test of the null hypothesis that two sets are sampled from the same 
normally distributed population against an alternative hypothesis that the two 
sets are from different populations. 
SVILP A combination of a Support Vector Machine with Inductive Logic Programming 
(Muggleton et al., 2006). 
SVM Support Vector Machine. A supervised machine learning method used for 
regression and classification of data. An introduction to SVMs is given by 
Cristianini and Shawe-Taylor (2000). 
SVM-Light SVM-Light version 6.02. An implementation of Cortes and Vapnik’s (1995) 
Support Vector Machine method (Joachims, 2008, 2002). 
Tanimoto coefficient A statistic used to measure similarity, calculated from the ratio of intersection 
between two binary sets (Tanimoto, 1957). See section 1.8. 
thrombin A protein target in the DUD database (see Appendix B). 
TK Thymidine kinase (type 1). A protein target in the DUD database (see Appendix 
B). 
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TN True Negative. A Boolean datum known to be FALSE and assigned the value 
FALSE in a predictive test. 
TOPAS TOPology-Assigning System. A method to generate synthetically accessible de 
novo molecules using a fingerprint similarity based matching method (Schneider 
et al., 2000). 
TP True Positive. A Boolean datum known to be TRUE and assigned the value TRUE 
in a predictive test. 
TPR True Positive Rate. The rate of retrieval of True Positive data. 
trypsin A protein target in the DUD database (see Appendix B). 
VEGFr2 Vascular endothelial growth factor receptor kinase. A protein target in the DUD 
database (see Appendix B). 
xLogP An atom-based predictive method for calculating the octanol-water partition 
coefficient of a molecule (Cheng et al., 2007). See also LogP. 
XML EXtensible Markup Language. A form of markup language for that annotates data 
in a format that is easily understandable and machine readable, by using tags in 
angle brackets that define where the structural hierarchy of each data entry The 
XML 1.0 specification is specified by the World Wide Web Consortium (Bray et 
al., 2008). 
ZINC ZINC Is Not Commercial. A publically available database of commercially-
available compounds (Irwin and Shoichet, 2005; Irwin et al., 2012). 
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Chapter 1 Introduction 
1.1 Summary 
This introductory chapter presents background information relevant to the development, 
application and assessment of a ligand-based virtual screening method called INDDEx 
(Investigational Novel Drug Discovery by Example) that forms this thesis. 
In this chapter: 
Section 1.2 introduces low molecular weight inhibitors of small molecule activity, describing the 
methods that are used to find novel inhibitors, defining the concepts involved, and noting need for 
virtual screening to explore chemical space. 
Section 1.3 describes methods that use the properties of a small molecule to define the likelihood 
of that molecule being a drug, in order to cut down the size of small-molecule space that needs to be 
screened, which allows screening to target areas of small-molecule space likely to be drug-like. 
Section 1.4 describes the development of drug discovery techniques, charting development, 
summarising the two classifications of structure-based and ligand-based screening, and describing the 
virtual screening techniques compared in this thesis. 
Section 1.5 describes the databases of compounds that are available for in silico drug discovery. 
Section 1.6 outlines the various estimates of small-molecule space that have been made, placing 
them in context, and observing that the entirety of small-molecule space is too large to be tractable to 
screening each individual compound. 
Section 1.7 Scaffold-hopping details the virtual screening problem of finding a diverse set of 
structures in screening results, and attempts to overcome this. 
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Section 1.8 describes how molecular similarity is measured. 
Section 1.9 details the development of virtual reactions, virtual libraries and de novo design; all 
efforts to extend search space beyond known molecules into the space of all synthesisable molecules. 
Section 1.10 charts the development of de novo design algorithms. 
Section 1.11 describes existing methods of integrating de novo design algorithms and virtual 
screening, as is done in Chapter 5. 
Section 1.12 explores the development of machine-learning techniques for drug discovery, 
outlining the general application of machine-learning techniques to drug discovery (1.12.1, 1.12.2, 
1.12.3), and then describing in detail the techniques of Inductive Logic Programming (ILP) (1.12.4, 
1.12.5), Partial Least Squares (1.12.6), Support Vector Machines (1.12.7) and the combination of ILP 
and Support Vector Machines to produce Support vector inductive logic programming (1.12.8) which 
plays an important role in the INDDEx program that forms a central part of this thesis. 
Section 1.13 details the methodology and capabilities of the INDDEx (Investigational Novel 
Drug Discovery by Example) program at version 1 of its development. 
Section 1.14 gives an overview of the scope of this thesis, and gives a brief summary of the 
subsequent chapters. 
1.2 Low molecular weight inhibitors of biological activity, or small-molecule drugs 
Low molecular weight inhibitors fall into the category of being a class of pharmaceutical drug, 
which are defined as any chemical compound that induces a physiological effect within an organism. 
In pharmacology, drugs are used for the treatment, cure or prevention of diseases. Drug discovery is 
the process by which new drug candidates are developed. Drug discovery often begins with a method 
known as “screening.” Screening is the search for compounds that display an inhibitory or enhancing 
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effect towards a particular target by predicting or observing the activity of the compounds in tests. 
Targets can be biological processes or individual components within those processes, for example, 
proteins or DNA. Screening may yield compounds with activity against a target, and these active 
compounds are known as “hits.” Hit molecules are developed by altering their molecular structure 
into “leads” that are further developed and pass through trials before eventually becoming new 
drugs. New drug hits and leads are always needed, and the rate of new drugs reaching the market is 
decreasing (Brown and Superti-Furga, 2003), but an obstacle to finding them is the large size of 
potential chemical space, and the challenge of searching through the space effectively. Adams and 
Brantner (2006) estimate the total cost of bringing a drug to market to be $500 million to $2 billion (the 
phases of costs of drug discovery are detailed in Appendix A), so it is important that the drug 
discovery phase is able to find valid leads with high accuracy. 
 
Figure 1.1. Searching for new molecules in the vast oceans of chemical space. Photo-manipulation of “Leiv Eriksson 
oppdager Amerika” (Krohg, 1893). 
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High throughput screening is used throughout the pharmaceutical and agrochemical industries, 
and allows the screening of thousands to millions of compounds through the use of automated testing 
(Janzen, 2008). Virtual screening is a means of performing screening through computer simulation of 
compound action, and can be used to virtually screen compounds at a far higher rate than high   
throughput screening and without the need for large-scale resources of compounds and automation 
facilities (Walters et al., 1998). Databases of drug-like molecules are available, and multiple virtual 
screening methods are available to scan them for potential drug leads. However, the chemical space of 
available molecules is just a fraction of the total chemical space available for all synthetically accessible 
molecules. Instead of physically testing compounds using high throughput screening, virtual 
screening is often used to simulate the bioactivity of compounds, in order to search as much of 
chemical space as possible in a reasonable amount of time. Multiple methodologies exist, so one 
course of action would be to take an existing technology, validate and benchmark it, and develop it to 
explore synthesisable space. 
A methodology based upon machine learning to search for molecules that are easily 
synthetically accessible is needed. This thesis describes the process of taking an existing logic based 
machine-learning approach to identifying bioactive compounds (INDDEx v1), developing this to 
make improvements and modifications to improve its power, speed and functionality for virtual 
screening, after which it became INDDEx v2. This methodology was further validated against other 
methodologies by a benchmarked assessment process, and INDDEx v2 was used to find new small-
molecule inhibitors against a protein target. INDDEx v2 was developed further into INDDEx v3 by 
integrating a method of searching synthetic space using virtual synthetic reactions and a filtering 
system based on the models INDDEx derives. INDDEx v3 was subsequently benchmarked in an 
assessment process. 
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1.3 What are the properties of a drug? 
1.3.1 Metrics used to quantify drug properties 
A series of criteria have been developed to define drug properties. This section describes some 
of the metrics used for this purpose. 
Binding affinity is calculated on a negative log scale from a measure of activity such as IC50 
(Half-maximal Inhibitory Concentration) or EC50 (Half-maximal Effective Concentration). IC50 is a 
measure used for antagonists (substances that inhibit a response from a target) that measures the 
amount of a substance required to inhibit a biological process to half its normal rate. EC50 is a measure 
used for agonists (substances that induce a response from a target) that measures the amount of a 
substance required to promote a biological process to halfway between its normal and maximal rate. 
Partition ratio, also called the partition coefficient or LogP, is the logarithm of the ratio of 
solubility between two immiscible solute phases. The standard two solutes used in QSAR methods are 
water and octanol (Sangster, 1997). The distribution of a drug throughout the body depends on the 
partition ratio. High partition ratios indicate hydrophobicity/lipophilicity, which indicates a 
preferential distribution to lipids in the body (Yokogawa et al., 1990), having high hepactic clearance 
(Ishizaki et al., 1997), and better permeability in biological membranes. Low partition ratios indicate 
hydrophilicity, which indicates a preferential distribution to aqueous areas of the body. Partition ratio 
also has a bearing on how well the molecule can be absorbed, and how well the molecule can pass 
from one phase to another, which is important in targeting drugs to the correct part of the body and 
for enabling a molecule to cross the blood brain barrier or the cell lipid bilayer. 
𝑙𝑜𝑔𝑃 = log�[𝑜𝑐𝑡𝑎𝑛𝑜𝑙][𝑤𝑎𝑡𝑒𝑟] � 
Equation 1.1. The partition ratio for the standard octanol and water phases. 
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While the partition ratio can be measured experimentally, when screening the large number of 
molecules involved in virtual screening it is necessary to calculate an estimate of the value. The 
partition ratio can be calculated by splitting the molecule into atoms or fragments and then assessing 
the contribution of each atom or fragment using a parameterised model. There are multiple methods, 
which include xLogP (Cheng et al., 2007), aLogP and cLogP (Ghose et al., 1998). xLogP and aLogP are 
generalised atom-based methods, while cLogP is a fragment-based prediction method. INDDEx uses 
xLogP for its partition coefficient calculations. These methods are accurate for organic compounds, 
and these methods can give Pearson product-moment correlations of over 0.9 with the observed 
values (Ghose et al., 1998). 
When developing leads, addition and substitution reactions will increase the weight of a 
potential drug molecule. Observations show that increasing potency during the lead optimisation 
phase generally results in the compound increasing in molecular weight (Hopkins et al., 2004), which 
will increase the likelihood of the compound developing ADMET problems (see section 1.3.2). 
Efficiency measures have been introduced to compensate for the increased potency due to increased 
molecular weight. 
Ligand efficiency is calculated as the negative logarithm of a measure of Binding Affinity 
divided by a measure of a physical property that will affect drug likelihood. The physical property 
used as a denominator is usually the number of heavy atoms, the molecular weight or the polar 
surface area of the molecule. There is also lipophilic efficiency, to take into account that higher 
lipophilicity is associated with greater absorption. 
Ligand Efficiency Index = (pKi, pKd or pIC50) / Number of heavy atoms (Hopkins et al., 2004) 
BEI (Binding Efficiency Index) = (pKi, pKd or pIC50) / Molecular weight (Abad-Zapatero and 
Metz, 2005) 
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SEI (Surface-binding Efficiency Index) = (pKi, pKd or pIC50) *100 / Polar surface area (Abad-
Zapatero and Metz, 2005) 
Lipophilic efficiency (LiPE) = (pKi, pKd or pIC50) - cLogP (Leeson and Springthorpe, 2007) 
1.3.2 Criteria for drug-like molecules 
In order to cut down on the size of molecular space to search, various filters have been 
developed to reduce molecular space by applying cut-offs to easily calculated physiochemical factors. 
There is always a trade-off between the number of potentially good compounds lost, and reducing the 
molecular data to a manageable size. 
A set of filtering rules that can quickly reject a molecule that is unlikely to be a drug are needed 
to reduce the size of chemical space to a more manageable size. These rules are derived from datasets 
of existing drug-like molecules, and they take into account physiochemical factors that affect both 
drug delivery and the likelihood of binding to a target. Five criteria that are often considered for the 
effectiveness of the drug are known by the acronym ADMET (Absorption, Distribution, Metabolism, 
Excretion, Toxicity). These five criteria influence the kinetics, suitability and activity of a 
pharmacological drug. Two particularly important rules that have an influence on ADMET are 
molecular weight and lipophilicity, and as development of a lead will tend to increase both of these, 
most filters incorporate rules for both of these criteria. All these rules are guidelines, offering only 
probabilistic measures of failure as a drug compound. 
A widely used set of filtration rules was formulated by Lipinski (1997) through analysis of the 
World Drug Index, and state that a molecule is unlikely to be an orally absorbed drug if it fulfils more 
than one of the following rules: 
• Molecular weight greater than 500 daltons. 
• Calculated LogP is greater than 5. 
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• More than 5 H-bond donors. 
• More than 10 H-bond acceptors. 
These rules were further refined by Ghose et al. (1999) through an analysis of the 
Comprehensive Medicinal Chemistry database. Ghose et al.’s rules state that the molecule is unlikely 
to be a drug if any of the following rules is not fulfilled: 
• Calculated LogP is within the range -0.4 to +5.6. 
• Molar refractivity is within the range 40 to 130 m3mol-1. Molar refractivity is a measure of 
polarisability, and gives a measure of van der Waals binding affinity for the binding of the 
drug to the receptor. An ideal drug will be a size that will not bind too weakly or tightly. 
• Molecular weight is within the range 160 to 480 daltons. 
• The total number of atoms is within the range 20 to 70. 
During lead-to-drug optimization, the addition of atoms to the molecules will increase 
molecular weight and lipophilicity. Teague et al. (1999) developed two rules for lead-like compounds 
to take this into account: 
• Molecular weight is within the range 100 to 350 daltons. 
•  cLogP is within the range 1 to 3. 
Fragment-like molecules are low molecular weight compounds (Carr et al., 2005; Rees et al., 
2004). They are usually weak inhibitors, but due to their molecular weight they will have high ligand 
efficiency (see section 1.3.1 for metrics used to quantify drug properties) so can be used as the start 
points for a series. They are useful in combinatorial chemistry as the building blocks of larger 
molecules, and can be useful in addition and substitution organic reactions when optimising a 
molecule. The “Rule of 3” for identifying fragment-like molecules for fragment-based drug discovery 
(Congreve et al., 2003): 
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• Molecular weight < 300 daltons 
• Number of hydrogen-bond donors ≤ 3 
• Number of hydrogen-bond acceptors ≤ 3 
• Partition coefficient (cLogP) ≤ 3 (see section 1.3.1) 
An increasing number of aromatic rings increases the lipophilicity of the molecule, meaning that 
a compound with more than three aromatic rings is at a higher risk of attrition in lead development, 
though there are compounds under development with 6 aromatic rings (Ritchie and Macdonald, 
2009). 
Recently, Hopkins introduced a desirability score (Bickerton et al., 2012) that analyses the 
properties of a set of compounds from the ChEMBL DrugStore database of approved therapeutic 
drugs (Overington et al., 2006). Asymmetric double sigmoidal functions are fitted to the distributions 
of a set of molecular properties across these compounds and each function is weighted to provide an 
overall score for drug desirability. Hopkins’ distribution for the molecular weight property of a 
“desirable” drug molecule has a 95% confidence of being between 40 and 625 daltons. The dataset was 
more curated and reliable than those used before, and this was an attempt to model the data and give 
a probabilistic value, rather than providing a set of filtration rules. 
1.4 Drug discovery 
1.4.1 Overview 
A crude assessment of drug likelihood can be done using drug likelihood profiles, which are 
sets of rules determined from the analysis of pharmacokinetic and physiochemical properties of 
databases of drugs, as described in section 1.3. They were designed to filter out molecules that have no 
chance of being an active drug. To make a more specific prediction of drug activity, there are four 
main circumstances for drug discovery: 
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1. When the structure of the binding site and the structure and pose of the active ligand are 
both known. 
2. The structure of the binding site and the ligand are both known, but the binding pose is not. 
3. The structure of the binding site is known, but not the structure of the ligand. 
4. Structures of ligands are known but not the structure of the binding site. 
For the first two circumstances, molecular modelling (Durrant and McCammon, 2011; Mobley 
and Dill, 2009), which includes docking and molecular dynamics, can be used to ascertain the binding 
mechanism between active site and ligand. For the third and fourth circumstances, virtual screening 
must be used. The focus of this thesis is on virtual screening methods, so they are the ones that will be 
discussed further. 
Virtual screening is a computational technique used for automatically screening a large library 
of compounds to identify the compounds that have a high probability of being biologically active 
(Walters et al., 1998). It is used when high throughput screening would be unfeasible because of cost, 
time, or the number of compounds involved, but it can also be used to complement high throughput 
screening by identifying a list of candidate compounds for testing (Mestres, 2001). There are two main 
types of virtual screening strategy: structure-based for situation 3 (structure of the binding site is 
known, but not the structure of the ligand) and ligand-based (structures of ligands are known but not 
the structure of the binding site). 
1.4.2 Structure-based screening 
Structure-based screening uses the 3D structure of the target by trying to dock potential 
compounds to the target, and applying a scoring function to rank the potential activity of each 
compound (Cavasotto and Orry, 2007; Kitchen et al., 2004; Lyne, 2002). Commonly used structure-
based screening programs are FlexX (Rarey et al., 1996), DOCK (DesJarlais et al., 1988; Ewing et al., 
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2001), GOLD (Verdonk et al., 2003) and Glide (Friesner et al., 2004). Other commonly used structure-
based screening programs include FRED, SURFLEX and QXP, as described and compared in 
Kellenberger et al (2004). All of these docking programs score potential binding positions by using 
either an energy function such as a standard force field, for example, the DREIDING (Mayo et al., 
1990) or CHARMM (MacKerell et al., 1998) force fields, or a customised docking scoring function such 
as ScreenScore (Stahl and Rarey, 2001) or ChemScore (Verdonk et al., 2003). 
Some structure-based screening approaches use pharmacophore models (as do some ligand 
based approaches, as described in section 1.4.3), which are frameworks of features that are used to 
search a chemical database for matching molecules (Gund, 1977; Li et al., 1999). A pharmacophore is 
an abstract concept that contains information about the 3D relationship of the steric and electronic 
features required for a small molecule to bind to a target protein receptor, though it may not 
necessarily represent a real molecule (Leach et al., 2010). In structure-based screening, 
pharmacophores are derived from the intended binding site. The pharmacophore concept was 
introduced by Kier (1971), who identified features by visual inspection. Problems with using 
pharmacophores for screening are that the search is computationally intensive, and searching for 
candidate alignments of the ligands is non-trivial and must deal with conformational flexibility. 
A pharmacophoric approach to structural modelling was implemented in Chem-X (Murray and 
Cato, 1999). Murray’s approach identifies pharmacophoric centres of the binding site, calculates all 
possible complementary pharmacophores that could fit these centres, and then uses these 
pharmacophores to scan a chemical database. An implementation of this was used in the THINK 
software that forms InhibOx’s Screensaver project, which used massively distributed grid computing 
(Davies et al., 2002; Richards, 2002) to rapidly dock compounds to binding sites. 3.5×109 compounds 
were screened against cancer and anthrax targets, and in a second stage, the ligands were docked to 
proteins more rigorously using the LigandFit software. 
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The advantages of structure-based docking are that leads can be found when none are known; it 
can find entirely structurally different drugs with unique scaffolds, providing new directions to search 
for leads; the availability of 3D protein structure is now very large, with 58,886 structures publically 
available in the PDB (Berman et al., 2002) as of July 2009. Disadvantages are that there is a low ratio of 
hits compared to the computational cost and CPU time, due to the complexity of the structural 
alignment calculations (Fukunishi, 2009). Relying on the 3D structure of unbound proteins can be 
unreliable when finding a molecule to fit the protein binding site, because proteins undergo an 
induced fit when binding to ligands (Koshland, 1958), and 60% of ligands do not bind in a minimum 
energy conformation (Perola and Charifson, 2004). Algorithms have been developed to 
simultaneously optimise protein and ligand conformations, simulating induced fit (Davis and Baker, 
2009). The quality of docking depends on the quality of 3D structure, and the process requires the 3D 
structure of target protein to be known, meaning that the process cannot work when the structure 
cannot be elucidated. This causes problems in the cases of transmembrane and disordered proteins, 
where crystallisation and hence structural elucidation can be difficult (Canaves et al., 2004). Structure-
based docking results usually include the correct docking position, as determined by the 
experimentally observed bound structure, in their output of potential docking positions; Warren et al. 
(2006) benchmarked FlexX, Flo+, Glide, Gold, and MVP on a sample dataset and found they identified 
the correct binding position 32%, 54%, 30%, 39% and 41% of the time respectively, but were unable to 
rank binding affinity across a series of compounds, with the programs giving negative or insignificant 
correlations with the correct affinities. 
After pre-docking scoring methods, we come to the more accurate post-docking ligand–protein 
scoring functions, in which binding affinity is ranked using 3D coordinates from crystallised protein-
ligand complexes, or non-bonded small-molecule crystal structures. These scoring functions are 
system specific, and show better ranking than when docking is used without any binding knowledge. 
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Post-docking ligand-protein scoring functions include Drugscore (Pfeffer et al., 2008; Velec et al., 
2005), and LigScore (Krammer et al., 2005). SVILP has been used in structure based screening (Amini 
et al., 2007b), using crystallography coordinates and ligand binding affinities as background 
knowledge in SVILP input to derive system-specific scoring functions. 
Improvements in the accuracy of the scoring functions, are also observed when a consensus 
score (also called data fusion), combining more than one scoring method, is used, and this holds true 
whether ligand-based (Baber et al., 2006; Sheridan and Kearsley, 2002) or structure-based (Charifson et 
al., 1999; Clark et al., 2002) methods are used for the consensus. 
1.4.3 Ligand-based screening 
Ligand-based screening covers various methods that use information about known ligand 
activities to identify common patterns and features within the active ligands. The methods can be 
broadly divided into similarity search and compound classification methods (Bajorath, 2002). 
Similarity search methods compare screened molecules with a query structure in a pairwise manner 
and rank the screening data in order of determined similarity. Similarity search methods include 
finding common substructure (Raymond et al., 2002), fingerprint similarity comparison (Willett, 2006; 
Xue et al., 2001), 3D shape matching (Hawkins et al., 2007) and building pharmacophore models (Sun, 
2008). Compound classification methods predict a class for each screened molecule based on learned 
data, and includes the use of machine-learning to generate a predictive model (Chen et al., 2007; 
Ivanciuc, 2009). Ligand-based methods need at least one existing bioactive to learn from, but can also 
learn from multiple actives. 
Finding common substructure can be performed either by searching for a query substructure or 
by comparing the overall similarity between two molecules by evaluating the amount of common 
substructure (Willett et al., 1998). The use of common substructure to evaluate similarity as used in 
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this thesis is discussed in more detail in section 1.8. The structure can be also abstracted by being 
represented by a reduced graph (Gillet et al., 2003), where graph nodes correspond to ring systems, 
functional groups and other structural elements. 
Molecular fingerprinting is a method of decomposing a molecular structure into a 2D binary 
bitstring which is intended to encode as much of the structural information as possible. Each bit in a 
fingerprint represents a single property of a molecule: either the presence of one or more structural 
features or a physiochemical measure. Once decomposed, pairwise comparisons between two 
fingerprints can be made at very low computational expense to provide an estimate of similarity. The 
accuracy of fingerprinting methods compared to structural comparison methods is discussed and 
estimated in section 1.8. The Boolean status of fingerprint bits depends on the presence of 
substructural elements and the values of chemical descriptors. Examples of fingerprint methods are 
those proprietary to Daylight Chemical Information Systems (James et al., 2005), Barnard Chemical 
Information Inc. and Tripos Inc. (2D UNITY fingerprints) (Wilton et al., 2003). The features related to 
fingerprint bits can be fragments of substructure, and these are known as extended-connectivity 
fingerprints (Rogers and Hahn, 2010). A subtype of these are circular fingerprints, where the fragment 
of substructure is an atom connected to neighbouring atoms (Bender et al., 2009). 
3D shape matching compares the similarity of the 3D shape of the screened molecule to the 3D 
shape of the query bioactive. The Ultrafast Shape Recognition method used by InhibOx performs a 
similarity search using a vector of descriptors for shape recognition (Ballester and Richards, 2007; 
Ballester et al., 2009). A second method overlays and aligns molecules, scores their likeness (on 
volume, hydrophobicity and hydrogen-bond placement), then uses Pareto ranking to rank the scores 
(Taylor et al., 2012). A third method described the use of transforms to decompose the molecular 
interaction fields of ligands into wavelet thumbnails, allowing them to be quickly aligned and 
manipulated with greatly reduced computational expense (Martin et al., 2012). 
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Pharmacophores are a further abstraction of both 3D shape matching and fingerprinting, where 
steric and electronic features are represented in a 3D framework (Mason et al., 2001). Pharmacophores 
are also used in structure-based screening and have been defined above in section 1.4.2, but in 
structure-based screening, the pharmacophore is derived from the features of the intended binding 
site and in ligand-based screening, the pharmacophore is derived from one or more bioactive ligands. 
One example is the Field method used by Cresset, which calculates a force field based on steric and 
hydrophobic forces. The positions and intensities of the fields at their local maxima are calculated, and 
similarity searches are made for molecules with similar field points (Cheeseright et al., 2008, 2006). 
The Phase software package produced by Schrödinger is another popular screening package which 
includes both pharmacophore and 3D shape matching methods (Dixon et al., 2006). 
Machine-learning techniques can be combined with fingerprints or pharmacophores. This 
allows the machine-learning method to train on multiple active and inactive ligands to generate a 
multi-dimensional predictive model of activity (Chen et al., 2007). Machine-learning methods are 
applied to the similarity search methods described above, converting them into compound 
classification methods. Examples include the combination of extended connectivity fingerprints with 
Bayesian Analysis to retrieve hit molecules from a test set (Rogers et al., 2005) and a study by Keiser et 
al. (2009) that used a Similarity Ensemble Approach (Keiser et al., 2007) to combine Daylight 
fingerprints with a statistical model of similarity. 
The advantages of ligand-based screening are firstly that it does not need the 3D structure or 
any other knowledge of the target, and once the search model has been generated, the library search is 
fast. Secondly, ligand-based approaches can be effectively used to screen for molecules that exhibit 
polypharmacology, as ligand-based methods can build models for effectiveness against multiple 
targets. Thirdly, the target of a ligand-based method does not have to be a single protein. It can be a 
process or biochemical cascade, or take advantage of paralogous proteins with similar binding sites to 
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target a whole set of related processes. 
The disadvantages are firstly that comparing compounds by similarity is making the 
assumption that compounds with chemical similarity will have similar levels of biological activity. 
Compounds with high activity that are structurally distinct can be missed, meaning that conventional 
ligand-based approaches are not effective at predicting new hit compounds with distinct scaffolds (see 
section 1.7 on scaffold-hopping). Secondly, there needs to be at least one known bioactive compound 
as input, and machine-learning techniques need to learn from multiple actives. 
1.4.4 Screening methods compared in this thesis 
Three alternative virtual screening methods (two ligand-based and one structure-based) are 
compared with INDDEx in this thesis: eHiTS LASSO, PharmaGist, and DOCK. eHiTS LASSO 
(electronic High Throughput Screening Ligand Activity by Surface Similarity Order) (Zsoldos et al., 
2007) is a ligand-based method that uses a neural network algorithm to learn from a training set of 
multiple known compounds and produce a set of ligand conformers which are screened using surface 
property descriptors (Reid et al., 2008). PharmaGist (Schneidman-Duhovny et al., 2008) is a ligand-
based method that models pharmacophores from a training set of up to 32 existing compounds. 
DOCK (Ewing et al., 2001) is a structure-based method that flexibly docks molecules in multiple 
conformations into the binding sites of known protein structures, and scores each position. 
1.5 Databases of compounds used for in silico drug discovery 
Structural and ligand-based virtual screening both often rely on databases of molecular 
structures. Several widely used molecular structure resources are publically available, and in addition, 
pharmaceutical companies hold proprietary databases of compounds. The ZINC database (Irwin and 
Shoichet, 2005; Irwin et al., 2012) is a curated database of compounds tailored for use in virtual 
screening. The compounds are associated with physiochemical properties, commercial availability 
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and vendors. The information provided includes 3D structural data for all the molecules, generated by 
OpenEye’s Omega program (Boström et al., 2003). The latest release is ZINC 12 (May 2012), containing 
over 21 million purchasable compounds, and available to download. 
The Drugs@FDA database contains all drugs approved by the U.S. Food and Drug 
Administration. The subset of approved drugs that are small molecules total 1,441 compounds as of 
April 2012 (U.S. Food and Drug Administration, 2012). The ChEMBL database (Gaulton et al., 2011) is 
a curated database, compiled from journal literature, of small molecules and the results of bioassays of 
those molecules against target proteins. As of June 2012, the ChEMBL database contains 1,143,682 
distinct compounds. 
1.6 How large is small molecule chemical space? 
1.6.1 Introducing small molecule space 
Small molecule chemical space is an abstract space that includes all chemically possible 
molecules and compounds below a size that would preclude them acting as drugs. Drug-like chemical 
space is a subset of this space that has been filtered by properties that indicate the likelihood of being a 
drug (see section 1.3). Estimates of the size of the small molecule and drug-like chemical spaces vary 
widely, but it is generally agreed that they are too large to search comprehensively. Sections 1.6.2 and 
1.6.3 detail the number of all possible drug-like molecules and the number of synthesisable small 
molecules respectively, with the numbers visually compared in Figure 1.3. 
It is of interest to note that the number of small molecule compounds currently known to exist in 
the human organism is a tiny fraction of small molecule space, and is in the order of thousands of 
compounds: the KEGG LIGAND Database (Goto et al., 2002) contains 16,834 compound entries as of 
February 2012. 
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1.6.2 Estimating the number of all possible drug-like molecules 
The most often given value is around 1060 based on the estimate of Bohacek et al. (1996). Several 
publications and presentations have given estimates of 1018 to 10200 for the size of small molecule 
chemical space (Medina-Franco et al., 2008; Petit-Zeman, 2003; Sun, 2005). 
Bohacek et al. (1996) estimate a space of 1063 molecules based on the formula shown in Equation 
1.2. Bohacek et al. used values for c, n, r, and b of 6, 30, 4 and 4 respectively, giving a value of 2.4×1063, 
approximated to 1063. 
(𝑐𝑛𝑛𝑟+2𝑏) �𝑛2 − 1�𝑟 
Equation 1.2. Formula used by Bohacek et al. (1996) to estimate the size of small molecule chemical space: c = average 
number of possible elements each atom could be, n = maximum number of heavy atoms, r = maximum number of ring 
systems, b = number of possible branching points in the structure. Estimates by Bohacek et al. (1996) for the parameters 
were c = 6, n = 30, r = 4 and b = 4. 
Geysen et al. (2003) estimated the number of drug-like molecules as being between 1014 and 1030, 
and Ogata et al. (2007) used 100 protein-ligand structures extracted from the Protein Data Bank 
(Berman et al., 2002) to build a dataset of typical molecular backbones, and then calculate the number 
of possible combinations of C, N, O, S and Cl species substitutions on the molecules to give an 
estimate of between 108 and 1019 drug-like molecules. 
1.6.3 Estimating the number of synthesisable small molecules 
There have been several attempts to estimate the entire space of small molecules that are feasibly 
synthesisable using standard organic chemistry reactions. From the number of known synthesis 
pathways, Ertl (2003) estimated there were between 1020 and 1024 synthetically feasible molecules. 
Weininger (1998) gave an estimate of 1029 compounds by estimating small molecule space to be 
formed from a hexane core with each of the hexane’s valence bonds available to 150 possible 
substituents. 
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A comprehensive database known as GDB-11 of molecules of up to 11 atoms of carbon, 
nitrogen, oxygen and fluorine was generated by Fink and Reymond (2007), using algorithms to filter 
out unstable and unsynthesisable molecules. For all molecules up to 11 atoms, the database contained 
107.4 compounds, and this was later expanded for molecules up to 13 atoms, the GDB-13 database of 
109.0 compounds (Blum and Reymond, 2009). An exponential curve can be fitted to the numbers of 
compounds in the GDB database (see Figure 1.2) with near perfect Pearson product-moment 
correlation (an R2 of 0.999). A pure hydrocarbon must have less than around 30 heavy atoms to satisfy 
the Lipinski rule for a drug-like molecule (Lipinski et al., 1997) of having a weight of less than 500 
daltons (see section 1.3.2), and so projecting for all entries with 30 carbon atoms or less gives an 
estimate of 1.18×1023 for the total number of possible drug-like molecules. 
 
Figure 1.2. Logarithmically scaled line graph, showing the exponential relationship between the number of structures in the 
GDB (Blum and Reymond, 2009) and increasing heavy atom counts. 
Lastly, Walters et al. (1998) extrapolated from 10,000 synthesisable scaffolds with 1000 possible 
side chains attached at an average of three possible positions. 10,000 scaffolds × (1,000 side chains)3 to 
give an estimate of 1013 compounds. 
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Figure 1.3 below represents the various estimates and database sizes described in sections 1.6.2 
and 1.6.3 on a logarithmic scale of the number of molecules in the database or estimate. This shows 
that the size of estimated synthesisable drug-like molecular space is many orders of magnitude 
greater than existing databases of molecules, meaning that searching existing databases only examines 
a small fraction of potential molecules. 
 
Figure 1.3. Log scale comparison of the estimates of chemical space and the size of known databases as described in sections 
1.6.2 and 1.6.3. Estimates with upper and lower bounds are represented by concentric circles of dark blue (lower bound) and 
light blue (upper bound). The bounds of the estimates are also shown on the linear scale by solid rectangles; coloured grey, 
green, violet and black to aid discrimination. For comparison is the estimated number of grains of sand on earth (sand 
texture is “File:Sand.jpg” from WikiCommons). 
1.7 Scaffold-hopping 
In a medicinal chemistry context, a scaffold refers to a core structure shared by a group of 
molecules, or the molecular framework that remains when all terminal groups are removed from ring 
structures (Schuffenhauer et al., 2007). Scaffold-hopping is acknowledged as a difficult problem 
(Jenkins et al., 2004; Vogt et al., 2010), but there are a range of benefits. Scaffold-hopping can be useful 
to increase potency by moving out of a minima in structural space, identifying drug-like molecules 
that are synthetically tractable from known natural ligands (Jenkins et al., 2004; Lee and Schneider, 
2001), increasing the selectivity of a molecule between homologous proteins (Byvatov et al., 2005; 
Lange and Kruse, 2005), preventing toxicity problems or other unwanted pharmacological properties 
that may affect a chemotype (Rush et al., 2005), and moving from a search space protected by a 
Number of molecules 
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composition of matter patent to an unprotected one. 
Because of uncertainty over differentiating between the parts of a molecule that constitute the 
core structure and the side chains, there is no consensus on a universal method of defining the 
scaffold of a molecule. Attempts to systematise scaffold-hopping have been through topology 
classification schemes such as Bemis and Murcko’s (1996) method to define the scaffold as the 
combination of the ring systems and linkers in the molecule, or Xu and Johnson’s (2001) method to 
reduce the molecule to an index based on graph connections. A variety of related scaffold 
classification methods have been developed (Gillet, 2008). 
1.8 Evaluating the similarity of molecules 
For molecular fingerprinting in this project, the default CDK (Steinbeck et al., 2003) 
fingerprinting method, which employs a path-counting algorithm based on Daylight fingerprints 
(James et al., 2005), was used. A standard cut-off for similarity between molecules has been 0.85 using 
Tanimoto similarity of 2D fingerprints, based on the observation that if a molecule has 0.85 similarity 
to a known active molecule, then it has an 80% chance of showing some level of activity (Martin, 2006; 
Patterson et al., 1996) though other studies have shown probabilities for sharing activity at 0.85 
similarity to be lower, at 50-60% (Delaney, 1996) or 30% (Martin et al., 2002). 
Similarity of structure can be measured using several metrics (Willett et al., 1998). The metric 
used in this thesis is the Tanimoto coefficient (τ); an index for measuring the similarity of binary sets 
introduced by Jaccard (1901) and later extended by Tanimoto (1957). The Tanimoto coefficient, shown 
below in Equation 1.3, gives a measure of similarity between two sets where a feature measure can be 
applied to the individual sets and to the union set. For molecules, this can be done using bitstrings of 
features or counts of elements of structure in the maximum common substructure. 
  58  Introduction 
 
𝜏 = 𝑁𝐴𝐵
𝑁𝐴 + 𝑁𝐵 − 𝑁𝐴𝐵  
NA Number of features in A. NB Number of features in B. 
NAB Number of features common to A and B.   
Equation 1.3. Formula for the Tanimoto coefficient as defined by Tanimoto (1957). It calculates the similarity between two 
feature sets. 
The maximum common substructure (MCSS) is a similarity measure calculated from the largest 
segment of substructure, ignoring hydrogen atoms, which two molecules have in common. The 
numbers of non-hydrogen atoms in each of the two molecules are used for the variables NA and NB, 
and the number of non-hydrogen atoms in the MCSS is used for NAB. 
 
 Atoms Bonds Total 
𝑁𝐴 30 33 63 
𝑁𝐵 26 28 54 
𝑁𝐴𝐵 18 21 39 
𝑁𝐴
𝑁𝐴 + 𝑁𝐵 − 𝑁𝐴𝐵 0.47 0.53 0.50 
 
 Molecule A Molecule B 
Figure 1.4. Diagram showing how similarity is calculated between two molecules. In this example, two active ligands from 
the DUD Acetylcholine esterase target set are shown on the left as Molecule A and Molecule B. In the table on the right, the 
numbers of atoms and bonds of these molecules are totalled and used to calculate the Tanimoto coefficient, which in this case 
is 0.50. NA = Number in molecule A; NB = Number in molecule B; NAB = Number in the maximum common substructure 
of molecules A and B. 
In this thesis, MCSS between two molecules is detected with the Small Molecule Subgraph 
Detector Library (Rahman et al., 2009), which examines the nodes and edges of the molecular 
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subgraph, and identifies the maximum contiguous substructure shared by two molecules. The 
number of atoms and bonds are counted in two molecules and the MCSS area is counted, and used to 
calculate the Tanimoto coefficient (Tanimoto, 1957). 
Figure 1.5 shows Tanimoto similarity calculated from fingerprints plotted against Tanimoto 
similarity calculated from Maximum Common Substructure. The two graphs are all-against-all 
similarity comparisons firstly for the smallest of the DUD target sets, COMT, including all actives and 
decoys, and secondly for 100 randomly selected actives and 400 randomly selected decoys taken from 
all pooled DUD target sets. 
 
Figure 1.5. Scatter plots of fingerprint Tanimoto similarity against MCSS Tanimoto similarity. The R2 values for the 
Pearson product-moment correlation of the two similarity metrics are shown at the top of each graph, both given to 3 
significant figures. Left: all-against-all similarity comparisons for all the actives and decoys in the COMT target. The 
COMT target contains 441 molecules, giving 97,020 comparisons. Right: all-against-all similarity comparisons for 100 
randomly selected actives and 400 randomly selected decoys taken from all pooled DUD target sets. The 500 randomly 
selected molecules give 124,750 comparisons. 
The COMT plot demonstrates that fingerprints have a low correlation with MCSS for measuring 
similarity at high MCSS similarity levels. For this study, it is necessary to measure where a molecule is 
dissimilar enough to another that it can be described as a distinct structure. The cut-off value for 
R2 = 0.178 (3SF) R2 = 0.540 (3SF) 
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where a molecule ceases to be defined as “similar” to another molecule, and can be defined as 
“distinct,” is debatable, as placing the cut-off for distinctness on a spectrum of similarities must be a 
matter of opinion. Comparing the 2D-fingerprint similarity values used in the studies mentioned in 
the first paragraph of this section (Delaney, 1996; Martin, 2006; Martin et al., 2002; Patterson et al., 
1996) with the correlations shown in Figure 1.5, 0.5 has been chosen as a conservative measure of 
distinctness when measuring with MCSS. With a cut-off of 0.5 MCSS similarity, only 0.013% of the 
comparisons in the COMT plot and 0.088% of the comparisons in the randomly selected plot would 
exceed the 0.5 cut-off when measured by fingerprint similarity. Figure 1.6 shows a spectrum of MCSS 
Tanimoto similarity for molecules from the DUD dataset to demonstrate how molecular structure 
becomes more similar with higher values. 
 
Figure 1.6. Tanimoto similarity spectrum, showing six molecules from the DUD AChE target set arranged along a 
numbered bar indicating their Tanimoto similarity to the molecule on the furthest right. The areas of Maximum Common 
Substructure are highlighted in red. 
Tanimoto 
similarity 
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1.9 Virtual reactions, virtual libraries and de novo design 
Chapter 5 describes the integration of virtual reactions with INDDEx screening. Accordingly, 
this introduction reports previous work in the area. 
High Throughput Screening (HTS) screens a large library of chemical compounds in vitro 
(Thompson and Ellman, 1996), but this cannot cover more than a fraction of the possible synthetic 
space. Another combinatorial technique that has been developed to overcome this limitation is 
Fragment-Based Drug Discovery (FBDD) (Hajduk and Greer, 2007; Murray and Rees, 2009), where 
small molecules representing fragments of larger molecules are screened, so that several fragments 
that are found to exhibit some binding affinity can be combined to produce a single molecule with 
high binding affinity from all the individual fragments (Rees et al., 2004). FBDD is increasingly used in 
industry as using it means that less compounds need to be screened. Fragment-based virtual synthesis 
applies this scheme to virtual synthesis. There are about 109 chemically stable synthesisable 
compounds with up to 13 atoms of C, N, O, F (Blum and Reymond, 2009) compared to 1060 drug-like 
molecules (Bohacek et al., 1996), so chemical space can be covered more efficiently by considering 
fragment-like molecules. 
When searching for potentially active molecules using virtual screening, the same problems still 
apply; the ZINC database covers only a tiny proportion of all potentially synthetically feasible space, 
and when searching molecular databases for new potentially active molecules, search space needs to 
cover as many positives as possible. By searching a virtual space of derivatives, there are far more 
molecules to examine. There are two methods of searching virtual space: a de novo design approach 
and a virtual library approach. 
De novo design is a process by which a design algorithm is used to generate a molecule to fulfil 
criteria rather than searching existing molecules for one that matches the criteria. The ligand must be 
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designed to fit into the binding site as well as possible, both sterically and with complementary 
physiochemical properties on the interface between the ligand and the site. Synthetically feasible and 
drug-like compounds are generated using de novo design algorithms (see section 1.10). The methods 
and algorithms that can be used in de novo design are summarised by the flowchart in Figure 1.7. 
 
Figure 1.7. Flowchart showing the method hierarchy of de novo design. 
A design algorithm can search chemical space by brute force, subgraph addition, or by matching 
skeletons: 
• Brute force search: Systematically generates and tests all possible solutions. 
• Subgraph addition: Using building blocks of common molecular substructures to alter the 
molecule. Building blocks can be atoms, functional groups, or simply any fragment of a 
molecule. 
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• Spacer skeletons: Lewis and Dean (1989) introduced the concept of “spacer skeletons”; which 
are topological shapes representing molecular substructures. Spacer skeletons can be fitted to 
binding sites on enzymes, and a database can then be searched for a molecular substructure 
that would fit the topology and minimise the potential energy of the interaction with the 
binding site. 
In graph theory, searches can proceed in a breadth-first or depth-first manner (Knuth, 1997). 
Depth-first searching retains the highest scoring solution only and searches on from that, so it can 
become stuck in local minima, but is computationally efficient. Breadth-first searching retains multiple 
solutions and explores all minima in the fitness landscape: it finds the global minimum, but is 
computationally expensive due to the increased amount of search space to explore. Many algorithms 
use a balance between the two approaches, retaining only a pre-defined number of the top-scoring 
minima. 
The search space must be traversed smoothly when optimising a fitness function. 
Neighbourhood behaviour (the relationship between structural space and chemical space) must be 
taken into account (Horvath and Jeandenans, 2003). Chemical changes that are too drastic must not be 
made, because they will alter the biological function of the compound too much. Similarity functions 
like the Tanimoto coefficient (Tanimoto, 1957) are used to measure similarity. Section 1.8 contains a 
detailed description of calculating the Tanimoto coefficient. 
With machine-learning methods, fitness functions can be derived from training data of active 
and inactive molecules. The machine-learning methods generate a QSAR model, which evaluate the 
activity of subsequent compounds (Schneider and Wrede, 1994). 
Methods of searching through chemical space are evolutionary algorithms or a library approach. 
The library approach involves using an algorithm to generate a virtual library of as many compounds 
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as possible. The evolutionary, approach involves altering existing molecules that score highly to try 
and make them score more highly. Two evolutionary algorithms used for molecular design are the 
simple evolutionary, and particle swarm, algorithms (Schneider et al., 2009). Simple evolutionary 
algorithms (Bäck and Schwefel, 2011) attempt to optimise a fitness function by methods analogous to 
those of natural selection in nature. A population of multiple potential solutions is generated, and the 
fitness function for each solution is used as its chance of surviving to the next generation. At each 
generation, surviving solutions can reproduce, mutate by randomly altering the solutions, and 
recombine by combining different solutions. Particle swarms (Eberhart and Kennedy, 1995) are 
advanced evolutionary algorithms, where a series of “particles” are each assigned to different points 
on the search space, and the fitness function for each particle is calculated, and the particles all 
attempt to optimise fitness, and points with high fitness in the search space are remembered and exert 
an attractive force on all the particles to cause the particles to preferentially explore regions of the 
search space which have already scored highly. Both an advantage and a disadvantage of the 
evolutionary approach are the huge amount of solutions generated. Because it is not possible to search 
chemical space thoroughly, evolutionary methods are stochastic processes, and can produce a 
different result each time. 
1.10 De novo design algorithms 
De novo design algorithms proceed by assembling new molecules from units of “building 
blocks.” These building blocks can be single atoms, or a library of molecular fragments. The fragment 
library can be made up of purchasable small fragment-like molecules that are used in real organic 
synthesis, or can be pseudo-fragments generated by cleaving molecules into commonly occurring 
structural motifs. Pseudo-retrosynthesis, by programs like RECAP (Lewell et al., 1998), can be used for 
this. Atom-based design algorithms give rise to more variety and give access to all of chemical space 
to search, but this generates a huge number of solutions, which cannot all be searched through, and 
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also gives rise to many redundant synthetically inaccessible and chemically unstable molecules. 
Fragment-based design algorithms give rise to a more manageable number of solutions, and with less 
variety, but the solutions generated are much more likely to be chemically stable. 
There are several different types of structure sampling methods (Schneider and Fechner, 2005): 
Linking methods such as LUDI (Böhm, 1992a, 1992b), NEWLEAD (Tschinke and Cohen, 1993), HOOK 
(Eisen et al., 1994), and BUILDER (Roe and Kuntz, 1995), place building blocks on key interaction 
sites. Interaction sites are defined as positions on the binding site surface that are suitable for forming 
hydrogen bonds or hydrophobic interactions with a ligand. These building blocks are then connected 
to each other using molecular linkers, to form a single molecule. The linkers and building blocks used 
are optimised to give the most favourable potential-energy interaction with the binding site. CAVEAT 
(Lauri and Bartlett, 1994) is a design tool that searches a molecular database for substructure linkers 
that match vector templates generated from the conformation required to hold the placed functional 
groups in place. 
Like linking methods, growth de novo methods also use key interaction sites. One or more 
building blocks are placed at key interaction sites as seeds, and additional building blocks are 
iteratively added to the seeds to fill the enzyme cavity with optimised interactions and link all the 
seed building blocks into a single molecule. LEGEND (Nishibata and Itai, 1993) and Genstar (Rotstein 
and Murcko, 1993a) grow molecules using individual atoms, GrowMol (Bohacek and McMartin, 1994) 
incorporates the ability to grow by functional groups as well as atoms. GroupBuild (Rotstein and 
Murcko, 1993b) and SMoG (Small Molecule Growth) (DeWitte and Shakhnovich, 1996; DeWitte et al., 
1997) grow molecules using a library of molecular fragments. GROW (Moon and Howe, 1990) designs 
peptide ligands using a database of amino acid conformations, and a peptide is placed in the binding 
site, and grown by the iterative addition of amino acids. As the ligand structure changes, it is moved 
around the binding site to optimise binding affinity. All compounds designed are synthesisable since 
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all growth proceeds by a peptide condensation reaction. 
Evolutionary algorithms proceed by optimisation of structure (Schneider and Fechner, 2005), by 
assigning fitness values to promising compounds and then attempting to grow the compounds by the 
addition of molecular fragments. Ideally these new molecules should be readily synthesisable, and the 
CONJURE program developed by Vertex Pharmaceuticals (Walters et al., 1998) uses a library of 
allowed reactions and building blocks to grow molecules. The other approach is to have a CAOS 
(Computer-Aided Organic Synthesis) Program. The CAOS paradigm has been adapted for the high 
throughput world with CAESA (Computer Assisted Estimation of Synthetic Accessibility), which 
ranks molecules in order of ease of synthesis (Gillet et al., 1995) by searching for possible precursor 
molecules, and using causal networks (Pearl, 1988) to estimate the ease of synthesis. 
Lattice-based sampling methods, such as MCDNLG (Monte Carlo De Novo Ligand Generator) 
(Gehlhaar et al., 1995) or DLD (Dynamic Ligand Design) (Miranker and Karplus, 1995), proceed by 
filling up the binding site with a “super-molecule” grid structure of random atoms, each with multiple 
bonds to each other, where atom valences and positioning do not yet obey any physical rules. The 
method then uses a Metropolis Monte Carlo algorithm (Metropolis et al., 1953) to randomly add, 
remove and move atoms, or change the atom and bond types. A fitness function increases as the 
molecule obeys more physical laws, and increases interaction favourability with the binding site. 
Transitions driven by molecular dynamics simulations randomly position building blocks in the 
binding sites, and then use molecular dynamics simulations to move the building blocks around 
within the site to maximise the potential energy functions of their interactions with the binding site. 
After a few steps, one or more building blocks are joined together. CONCEPTS (Creation of Novel 
Compounds by Evaluation of Particles at Target Sites) (Pearlman and Murcko, 1993), is atom-based 
molecular dynamics, and CONCERTS (Creation of Novel Compounds by Evaluation of Residues at 
Target Sites) (Pearlman and Murcko, 1996) is fragment-based. They use the AMBER (Pearlman et al., 
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1995) molecular dynamics package to move the seed building blocks around the site, to find the 
enthalpic minimum position, before linking the building blocks together. 
Graph-based sampling is a ligand-based virtual screening process where ligand-based screening 
methods, such as pharmacophores (Lloyd et al., 2004), or similarity based matching such as in TOPAS 
(Schneider et al., 2000) are used to provide the fitness function. SPROUT (Gillet et al., 1995, 1994, 1993) 
is a structure-based method that uses a primary structure generation where atoms are positioned at 
interaction sites around the enzyme binding site, and topological templates, as described by Silla and 
Mutter (1995), each representing multiple fragments, are used to link them together and satisfy the 
steric requirements of the site. A subsequent phase of the program fits appropriate fragments to the 
shape of the template, to produce the correct physiochemical properties for the enzyme site. 
The approach of Patel et al. (2009) is to generate reaction vectors from a library of known 
reactions and apply them to generate novel synthetic molecules. These known reaction vectors can be 
used to perform a breadth-first search from an initial fragment, with pruning at each step of applying 
the reaction vectors to generate the target molecule. A similar method that looks at known reactions to 
decide if a reaction can take place generates sets of reaction rules from the bond changes between 
atom pairs (Wagner et al., 2011). 
The T-ANALYZE and T-MORPH methodologies have been developed by Sheridan et al (2005), 
and attempt to simulate the way in which chemists look at QSAR series. The Maximum Common 
Substructure between molecules in the series is found, and the remaining atoms checked to see if a 
chemical transformation between two molecules is possible, and if possible suggests where this 
chemical transformation could be applied to other molecules in the series to explore their activity. 
1.11 Integration of virtual screening and chemical synthesis 
Molecules produced by de novo design may not be synthetically feasible, or have negligible 
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yields from their synthetic routes. In order to avoid including synthetically inaccessible molecules in 
the search, methods have arisen to integrate chemical synthesis and virtual screening. Gasteiger (1990) 
identifies 3 methods for virtual reactions: 
• Virtual reactions by analogy with a known reaction. 
• Deriving rules through machine learning. 
• Deriving equations to quantify reactivity from structure. 
PRO_SELECT (PROmetheus’ Systematic Elaboration of Libraries Enhanced by Computational 
Techniques) introduced the idea of using virtual synthetic reactions to a structure-based screening 
linking method (Murray et al., 1997). A development of PRO_LIGAND (PROmetheus’ Logically 
Integrated Generation of Active Novel Drugs) (Clark et al., 1995), which fits rigid molecular scaffolds 
to a set interaction sites, and joins them with linkers. Chemical synthesis is simulated by searching a 
library of substituents, derived from common reactions and reagents, for appropriate substituents to 
attach to the scaffold. 
DREAM++ (Makino et al., 1999) uses a growth method, that grows molecules via virtual 
synthetic reactions. Molecules are docked to an enzyme binding site using the DOCK algorithm 
(Ewing and Kuntz, 1997; Kuntz et al., 1982), then chemical reactions are performed on the docked 
molecule, and the reaction product’s interaction with the binding site evaluated with a fitness 
function. This method’s chemical reaction algorithms use a library of standard reaction functional 
group transformations. 
TOPAS (Schneider et al., 2000) (TOPology-Assigning System) is a fingerprint similarity based 
matching method, that generates de novo molecules from a set of about 25,000 molecular fragment 
building blocks and eleven typical combinatorial chemistry schemes to join the fragments together, to 
generate synthetically accessible molecules. Fragments were generated by cleaving a database of 
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molecules along these same reaction schemes. One reaction fragmentation scheme is RECAP 
(Retrosynthetic Combinatorial Analysis Procedure) (Lewell et al., 1998), which uses eleven default 
bond cleavage types to cleave molecules into fragments at bonds which are formed by typical 
synthetic reactions. 
Retrosynthesis analysis programs such as CAESA (Gillet et al., 1995), WODCA (Fick et al., 1995; 
Gasteiger et al., 2002), LHASA (Johnson et al., 1992) and EROS (Gasteiger et al., 1990), can be used to 
predict possible synthesis routes for de novo designed molecules, and score them by synthetic 
accessibility. This method filters out synthetically inaccessible molecules after they have been 
generated, but is very computationally expensive. Less computationally expensive complexity 
analysis methods exist to predict synthesis difficulty by scoring molecules simply based on 
substructural features and generalised reaction schemes (Boda and Johnson, 2006; Boda et al., 2007). 
A brute-force approach to finding synthetically synthesisable molecules is to generate 
unfocussed combinatorial virtual libraries of synthesisable molecules. Taking commercially available 
compounds as their starting points, InhibOx have introduced VSPACE (InhibOx Ltd, n.d.), which is a 
virtual library of molecules developed using ChemAxon’s virtual reaction toolkits (Pirok et al., 2006) 
and the Oracle Database (Loney, 2009). By applying virtual reactions to fragment starting points, they 
generate a virtual library of billions of compounds. A more focussed approach to combinatorial 
library design is used by COLIBREE (Combinatorial Library Breeding) (Hartenfeller et al., 2008), 
where an algorithm is used to design molecules to match template pharmacophores, thus populating 
the region of search space around these pharmacophores. Molecular scaffolds are then decorated with 
molecular building blocks, and each new molecule is scored using a fitness function and this is then 
optimised using particle swarm optimisation. 
Compared to virtual libraries, virtual synthesis methods potentially allow the search of more 
space, as virtual libraries must be limited to a subset of synthetic space. With virtual synthesis 
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methods, often a series of compounds synthesised from a common precursor are found, which can 
lower the time and cost of synthesising compounds for laboratory testing. Because of the number of 
potential solutions, virtual synthesis methods have to ignore a lot of the breadth of search space; 
searching in depth around small islands in search space, and can become stuck in local minima in the 
fitness topology of the search space. 
The Reactor product produced by ChemAxon (JChem version 5.2.0, 2009) (Pirok et al., 2006) 
contains a database of 145 reactions, with each of the reactions assigned its own series of rules. The 
ChemAxon Reactor algorithm works by each reaction having a series of chemical rules, which it tests 
against the reactants to check if they have the potential to react. Chapter 5 describes a method to 
integrate the ChemAxon reaction schemes into INDDEx, to give INDDEx the ability to design and 
screen virtual libraries of synthesisable molecules. 
1.12 Machine-learning techniques for drug discovery 
1.12.1 Application of machine-learning techniques to drug discovery 
One major approach for drug discovery involves using available structure activity relationship 
modelling to take molecules with known biological activity, and establish quantitative equations that 
use regression analysis to correlate the structural features and physicochemical properties of the 
known molecules with their known activities, using a form of machine-learning. These methods are 
based on the association of structure with activity in the form of Quantitative Structure-Activity 
Relationships (QSAR), as introduced by Hansch and Fujita (1964) and Free and Wilson (1964). These 
earliest methods used statistical regression to associate structure with activity and various other 
statistical techniques have been proposed, including Partial Least Squares (described in section 1.12.6). 
In order to establish more complex QSARS, a wide variety of machine-learning techniques have been 
developed. Sections 1.12.2 and 1.12.3 give overviews of the machine-learning field, and the remaining 
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sections describe in detail the machine-learning techniques directly related to the approach followed 
in this thesis. 
1.12.2 Supervised and unsupervised machine-learning 
Machine-learning techniques are concerned with learning from existing data (training data) and 
generating a model that can be used to make predictions about future data. The two main branches of 
machine-learning learning can be supervised or unsupervised. Supervised means that the algorithm 
learns from “labelled” examples, where the desired types of classification are known and a model is to 
be generated to make these classifications on future data. Unsupervised learns from “unlabelled” 
examples, where the classifications of the training data are unknown and machine-learning is used to 
look for patterns and clusters within the data. Since virtual screening is attempting to predict desired 
chemical properties of molecules, virtual screening machine-learning is usually supervised. 
1.12.3 Overview of machine-learning techniques 
Substructural analysis was the first application of machine learning to molecular design by 
Cramer et al. (1974), where it was used to compare the activity frequencies of substructural elements 
in active and inactive molecules. Representation learning (Bengio et al., 2013) attempts to transform 
the data in some way, usually by applying functions to the data. One type of this method is the 
Support vector machine algorithm described in detail in section 1.12.7. Many machine-learning 
methods are based on Decision trees (Quinlan, 1986), which use a recursive partitioning algorithm to 
group members of a training set by variable characteristics, generating a decision tree predictive 
model that can be used to classify additional data. Network based methods model systems as graph-
based networks where data points are interconnected nodes: Neural networks (Haykin, 2004) attempt 
to emulate the central nervous system by allowing examples to increase or decrease the strength of the 
connections between nodes, and Bayesian networks (Lampinen and Vehtari, 2001) calculate the 
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strength of the connections between nodes using Bayesian probability methods. There are rule-based 
methods such as Association rule learning (Agrawal et al., 1993), which constructs rules that connect 
data together, or Inductive logic programming (described in detail in section 1.12.4). Clustering 
methods (Jain et al., 1999) are primarily used for unsupervised learning. 
1.12.4 Inductive logic programming 
The method of virtual screening used in this project is ligand-based, and uses machine-learning 
techniques to build a rule-based model. The method of machine learning is Inductive Logic 
Programming (ILP), which was developed by Muggleton (1991). Inductive logic describes the process 
of inferring the properties of a general population of objects from the recurring properties observed in 
a sample of those objects. ILP can be programmed with background knowledge, consisting of logical 
clauses known as predicates defining the properties of, and relationships between, objects. A rule-
based learning algorithm such as PROGOL (Muggleton, 1995), or FOIL (Quinlan and Cameron-Jones, 
1995) constructs relational hypotheses between these predicates, with each hypothesis being a clause 
containing multiple relationships; the algorithm then finds the most parsimonious set of hypotheses 
that describe the predicate knowledge. 
When applying ILP to learning rules of molecular structure, the descriptors used have 
similarities with CATS (Chemically Advanced Template Search); a descriptor method also intended 
for scaffold-hopping that expresses molecular structure as distances between pairs of generalised 
atom types (Schneider et al., 1999). CATS treats each molecule as an individual pharmacophore 
fingerprint, but ILP derives logical rules of distances between substructure from a sample of positive 
and negative examples of compounds. 
ILP has been previously used in ligand-based screening (Tsunoyama et al., 2008), and rule 
generation was applied to drug design knowledge by King et al. (1992), where it was used to model 
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quantitative structure-activity relationships of protein-binding ligands from atom and bond 
connectivity data. ILP represents the structural and positional aspects of drugs as logical statements, 
so it was proposed that the easily understood rules produced by ILP could provide chemical insight 
for future drug design by King et al. (1993). King et al. (1996) subsequently performed a comparison of 
ILP with statistical and neural network methods on a dataset of mutagenic compounds compiled by 
Debnath et al. (1991): ILP was used to generate rules of structural constraint for the mutagenic 
molecules from atom and bond connectivity data, with each molecule expressed as a graph of bond 
types connecting atoms that were expressed as elements with partial charges. The ILP method was 
compared with linear regression and neural network methods learning from a set of mutagenic 
features identified by Debnath et al. (1991) leading to the conclusion that “in domains that are 
naturally structural, ILP will significantly outperform simpler feature-based methods that can only 
use pre-selected attributes” (King et al., 1996). ILP has also been used for predicting the 
carcinogenicity of compounds from their structure (Srinivasan et al., 1997), and to discover rules for 
protein binding site structures that confer protein–ligand specificity (Kelley et al., 2009). Kelley et al. 
(2009) is the only method to use a metric distance derived from the 3-dimensional binding site 
structure, the other methods all use topological distances derived from bond connections in a graph 
representation of a molecule. 
1.12.5 Rules derived from inductive logic concepts 
In the case of ligand-based virtual screening, the background knowledge on the physiochemical 
make-up of each molecule includes predicates defining atoms and bonds, as well as higher level 
chemical substructures within the molecule, such as functional groups, and common molecular 
substructures. Utilising this data cuts down on the chemical search space by predefining chemical 
groups that are likely to be involved in the activity of the molecule. When a pharmaceutical target for 
activity is chosen, a list of molecules which have activity on this target are mixed with a similarly 
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sized list of inactive molecules, and the molecules described as ILP predicates. The activity 
classifications are then given as background knowledge to PROGOL, which derives logical rule 
clauses that entail each example molecule. 
The sequence of rule construction is to first generate hypotheses and then class some of the 
hypotheses as rules. Hypotheses are generated from every possible combination of features, and for 
each hypothesis, a compression is calculated by the formula in Equation 1.4. Rules are classed as 
hypotheses when they have a compression above a cut-off defined by the user, and all hypotheses 
falling below the cut-off are discarded. In the method used in this thesis, and described in section 
2.4.2, no compression cut-off was used, so all hypotheses become rules. 
𝑅𝑢𝑙𝑒 𝑐𝑜𝑚𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 𝑃[𝑝 − (𝑛 − 𝑓)]
𝑝
 
Equation 1.4. Formula for rule compression, adapted from Kelley et al. (2009). P = total number of positive examples, p = 
number of positive examples covered by the rule, n= number of negative examples covered by the rule, f = number of 
features in the rule. 
The true ILP method constructs rule clauses that can relate any number of features to each other, 
but the simplified ILP method described in section 2.4.2 and used throughout this thesis is limited to 
logical clauses relating a maximum of two features. Table 1.1 shows two example of ILP rules derived 
from a background knowledge consisting of chemical substructure together with their distance within 
a 3-dimensional molecule. As can be seen from Table 1.1, the rules that ILP derives can be readily 
translated into easily understood chemical knowledge. Intelligible rules have the benefit that they can 
provide chemical information to chemists, being informative as to what structural elements are 
important in the compound, and allow them to use this knowledge when performing further 
synthesis on the compounds in order to increase the activity of the compound. 
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Table 1.1. Examples of two PROGOL rules, and their chemical meanings derived by ILP. 
ILP rule Meaning 
active(A):- phenyl(A, B), methyl(A, C), 
 distance(A, B, C, 5.623, 1.00). 
molecule defined as active if the distance from a phenyl 
group to a methyl group is 5.623 ± 1.00 Ångströms 
active(A):- nitro(A, B), methyl(A, C), 
 distance(A, B, C, 3.121, 1.00). 
molecule defined as active if the distance from a nitro 
group to a methyl group is 3.121 ± 1.00 Ångströms 
1.12.6 Partial Least Squares 
The Partial Least Squares (PLS) method is another tool for multivariate analysis. It takes two 
matrices, of responses and predictions, and finds the matrix that projects both the responses and 
predictions to a new space, where a multivariate linear regression can be fitted between them (Wold et 
al., 2001). INDDEx v1 incorporates the nonlinear iterative partial least squares algorithm (Noonan and 
Wold, 1977) for its PLS. 
1.12.7 Support Vector Machines 
A Support Vector Machine (SVM) is a supervised learning method for classification and 
regression, by finding the optimal separation hyperplane that separates two different vector sets in n-
dimensional space. Vapnik and Lerner (1963) proposed the generalised portrait method for binary 
linear classification method using a hyperplane. SVMs have n features, resulting in an n-dimensional 
matrix, where each data point is an n-dimensional vector of features. The data points are separated by 
a hyperplane classifier with n-1 dimensions which is fitted though the data to give the maximum 
possible margin of separation of the two datasets (Cortes and Vapnik, 1995). The use of a maximal 
margin means that SVMs are less likely to produce a classification model overfitted to the training 
data, when compared with other machine-learning methods. Support vector machines incorporate the 
kernel method (Aizerman et al., 1964), which uses a kernel function to map the training data to a 
transformed higher-dimensional feature space. A kernel function is a matrix that transforms an 
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n-dimensional point to a higher-dimensional space (Aizerman et al., 1964). A modification to 
incorporate a cost function for the distance of the training data points from the hyperplane separator 
allows the SVM to perform regression (Drucker et al., 1996). 
 
Figure 1.8. Diagram of SVM methodology. The n-dimensional data points in the left-hand graph (here reduced to two 
dimensions) are the training data, classified into two sets (here green or purple). The SVM maps the data to an 
n-dimensional feature space and constructs an (n-1)-dimensional hyperplane that maximises separation between the classes. 
In this thesis, all rules, physiochemical properties and structural feature properties are 
considered as individual dimensions when used as data points in training data. 
1.12.8 Support vector inductive logic programming (SVILP) 
Support vector inductive logic programming (SVILP) is a method developed by Muggleton et al. 
(2012) that combines SVM and ILP to produce a method where each dimension in the SVM can be 
used to represent a rule, and each vector is a molecule from the background knowledge. The position 
of a vector in each dimension can be set at 1 or 0 depending on whether it fulfils the corresponding 
rule or not, and then the SVM can be used to separate the active from the inactive molecules. This 
generates a predictive model of activity from the ILP rules that can be used to score molecules for 
activity. The application of SVILP has been used in a paper that used PROGOL with SVMs (Amini et 
al., 2007a). A description of how SVILP was implemented in this project is given in section 2.4.2. 
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1.13 INDDEx v1 
Dr Amini developed INDDEx v1. INDDEx is a ligand-based virtual screening tool that uses ILP 
techniques. INDDEx uses a supervised learning technique to learn logical rules from a training set of 
active and inactive molecules. INDDEx produces these rules in the form of pairwise distances between 
two required fragments as described in section 1.12.5. The logical rules define the substructural 
features that contribute to activity and inactivity. The rules are weighted and used to build a 
predictive model that can be used to screen a database of compounds. The rule-based methodology 
means that the rules can be understood by chemists and indicate a route for hit to lead via a synthetic 
chemistry programme, can account for the flexibility and multiple conformers of ligands and has the 
potential for scaffold hopping. The method used by INDDEx v1 is shown in Figure 1.9. 
 
Figure 1.9. Flowchart showing the process involved in the INDDEx package to obtain predicted activity and informative 
rules from input data of molecules with known activity. 
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1.14 Thesis overview 
Chapter 2 describes the development of INDDEx v1 to INDDEx v2.0 and INDDEx v2.1. 
Chapter 3 describes an application of INDDEx v2.0 to a medicinal chemistry development 
project searching for novel compounds to inhibit the SIRT2 protein. INDDEx was combined with 
docking using GOLD to produce a consensus score that was used to identify molecules with novel 
scaffolds and high activity. 
Chapter 4 describes an assessment of the virtual screening process where INDDEx v2.1 is 
benchmarked against three other ligand-based and structure-based virtual screening methods: eHiTS 
LASSO (electronic High Throughput Screening Ligand Activity by Surface Similarity Order) (Zsoldos 
et al., 2007), PharmaGist (Schneidman-Duhovny et al., 2008) and DOCK (Ewing et al., 2001). 
Chapter 5 describes a development of INDDEx v3 to run virtual reactions. A method for 
incorporating the ChemAxon Reactor database of virtual reaction rules is described. 
Chapter 6 summarises the results, identifying areas for future research and further development 
of the research in this thesis. 
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Chapter 2 Development of INDDEx 
2.1 Summary 
This chapter describes the development of the existing INDDEx v1 program to INDDEx v2.0 
and v2.1 used in Chapter 3 and Chapter 4. 
In this chapter: 
Section 2.2 describes the features added during the development of INDDEx v1 to INDDEx v2.0, 
v2.1 and v3. 
Section 2.3 lists the programming tools used for the work in this thesis. 
Section 2.4 explores the methodology of the INDDEx program used in this assessment, first 
describing the development of INDDEx v2 from INDDEx v1 (2.4.1), then outlining the complete 
INDDEx v2 process (2.4.2), and detailing the aspects of cross-validation (2.4.3), fragmentation (2.4.4) 
and visualisation (2.4.5). 
2.2 Features in the INDDEx development stages 
The work performed in this thesis led to the development of INDDEx v3. As well as debugging 
to prevent errors and improving the speed and memory handling of the program, additional features 
are added. The versions of INDDEx are given version numbers to denote the increased number of 
features. INDDEx v1 is initially developed into INDDEx v2.0 for Chapter 3, then INDDEx v2.1 for 
Chapter 4 and into INDDEx v3 for Chapter 5. Table 2.1 shows the features appearing in each version. 
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Table 2.1. Feature table for the four versions of INDDEx mentioned in this thesis. 
 INDDEx v1 INDDEx v2.0 INDDEx v2.1 INDDEx v3 
Used in n/a Chapter 3 Chapter 4 Chapter 5 
ILP logical rules     
Fragmentation methods 0 to 9 and 11     
Fragmentation methods 10 and 12     
Partial Least-Squares (PLS)     
Support Vector Inductive Logic 
Programming (SVILP) 
    
Dependent on external Open Babel 
software 
    
Automated fragmentation optimisation     
Visualisation of output     
Pre-calculated descriptors     
Virtual reactions     
Partial Logical Rule Reactant Selection 
(PLoRRS) 
    
2.3 Materials 
All programming of the INDDEx was performed using the Java programming language 
(Gosling et al., 2005), incorporating the Chemistry Development Kit (CDK), an open-source library of 
Java functions designed for chemoinformatics and bioinformatics programming (Steinbeck et al., 
2003). Additional programming was performed using the Perl programming language (Wall et al., 
2000). 
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2.4 INDDEx methodology 
2.4.1 Development of INDDEx v2 
The methodology of INDDEx v1 is described in section 1.13. In outline, INDDEx technology 
uses logic-based machine learning, weighted by PLS, to identify quantitative structure-activity 
relationships (QSAR) and then to use these QSARs to search for other active molecules. 
In the first step, INDDEx uses machine learning to generate a set of logic-based rules about the 
relative positions of structural fragments in the ligands that are responsible for ligand activity. These 
rules can be easily used by chemists to understand the mechanism of activity and help guide the hit-
to-lead process. 
In the second step, regression is used to develop a model that can be used to predict the activity 
of other molecules. This model can be further used to screen databases of millions of available 
molecules and output a list of molecules predicted to have high activity against that target. 
The improvements made to INDDEx v1 were pre-calculating screening descriptors to improve 
the speed of the program, adding Support Vector Machine (SVM) technology, developing a readable 
rule output and debugging the program to prevent crashes. The speed improvements are 
demonstrated in section 4.3.7, where trials show a more than ten-fold improvement in time as 
demonstrated in section 4.3.7. SVMs have an advantage over PLS systems that they have the ability to 
model nonlinear relationships (Thissen et al., 2004), and SVMs have been shown to produce 
significantly less error than PLS when analysing chemical structures (Balabin and Lomakina, 2011). 
When SVMs and PLS are combined with ILP, SVILP has been shown to have significantly less average 
mean square error between observed and predicted than ILP combined with PLS (Amini et al., 2007a). 
Examples of the readable rule output are shown in Table 4.6. INDDEx v2 also no longer needs Open 
Babel installed, as all file handling is carried out internally. 
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2.4.2 The INDDEx process 
Figure 2.1 illustrates the INDDEx v1 process in overview. 
 
Figure 2.1. Graphical visualisation of the INDDEx process. Stock images in this collage provided by iStockphoto®. 
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Figure 2.2 shows the INDDEx process when performing a single activity prediction run; training 
on a set of known data, and producing informative rules, and then predicting the activities of 
molecules with unknown activity. The grey-shaded area contains the processes occurring within the 
INDDEx program (shaded in red), and these processes are described in more detail below. 
 
Figure 2.2. Flowchart showing a single run of the INDDEx method and how it is applied to training on a set of molecules 
with known activity. 
1. INDDEx uses as input a training data set containing the energetically minimised 3D structures 
of active and inactive molecules. The energetic minimisation field used is the MMFF94 Merck 
molecular force field (Halgren, 1996). 
2. The molecules in the training data are computationally decomposed into fragments of 
molecular substructure with physiochemical relevance. The fragmentation process is described 
in detail in section 2.4.3. INDDEx can use multiple different fragmentation methods, 
individually or in combination, and the fragmentation methods used can be optimised to give 
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the best results on cross-validation of the training data. 
3. An inductive logic programming algorithm is used to derive rules relating activity to the 
presence or absence of structural feature requirements. The rules are as described in section 
1.12.5. For each molecule in the training data, each fragment of substructure is related by 
pairwise distance rule to every other fragment, in the format: “Fragment A must be x 
Ångströms distant from Fragment B.” The rules cover every possible combination of features, 
irrespective of the prevalence of the rules in the positive and negative examples, so the set of 
rules generated for each molecule is equal to the leading and upper diagonal of a matrix of all 
the fragments compared against themselves (see Equation 2.1), and includes each fragment’s 
relationship to itself, where both fragments are the same and have a distance separation of zero 
(this rule corresponds to the requirement for the presence of a fragment). 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑢𝑙𝑒𝑠 = 𝑓(𝑓 + 1)2  
Equation 2.1. Formula for the total number of rules generated for a molecule, where f is the number of fragments in the 
molecule. 
4. The rules are pooled and redundant rules, defined as rules that share the same two fragments 
and have a distance separation of less than 1 Ångströms difference, are deleted. 
5. A coverage score of each molecule is calculated for each rule. If the two fragments in a rule are 
present, the rule coverage is scored according to Table 2.2 from the difference between the 
pairwise distance separation of the fragments within the molecule and the distance separation 
specified by the rule. These coverage scores were derived empirically by Dr Amini. 
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Table 2.2. Values for deriving the coverage score of a molecule from a rule. 
Difference of pairwise distance from rule separation Coverage score 
difference < 0.5 1.0 
0.5 ≤ difference < 1.0 0.5 
1.0 ≤ difference < 1.5 0.1 
1.5 ≤ difference < 2.0 0.05 
2.0 ≤ difference < 2.5 0.01 
2.5 ≤ difference < 3.0 0.005 
difference ≥ 3.0 0.0 
6. A range of physiochemical descriptors are calculated from the molecules in the training data 
set using the descriptor calculators provided in the Java Chemistry Development Kit (CDK). 
Different descriptors are effective on different QSAR series (Olah et al., 2004). Descriptors 
calculated fall into five categories described by Olah et al (2004): 
• Size: molecular weight, mass distribution and atom counts. 
• Hydrophobic: LogP. 
• Electronic: representing charge, polarisability, molecular orbital 
• Hydrogen bonding: hydrogen donors and acceptors. 
• Topological: calculated from graph representations of molecules. 
7. A coverage matrix is formed corresponding to the one shown in Table 2.3. The training 
molecules form one vector, and the rules and physiochemical descriptors form the other. The 
data points of the matrix contain the coverage of a molecule by a rule or the value of the 
physiochemical descriptor for that rule. 
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Table 2.3. Summary of a coverage matrix used by INDDEx to generate an SVILP model. 
 
Rule 1 → Rule n 
Physiochemical 
descriptor 1 
→ 
Physiochemical 
descriptor n 
Molecule 1 Coverage  Coverage Value  Value 
↓       
Molecule n Coverage  Coverage Value  Value 
8. The rules and descriptors of the coverage matrix are used as feature vectors for the SVM. The 
target value of each feature is the activity of each molecule (either the actual value of activity 
for regression or 1 and -1 for active/inactive classification). The SVM software used was SVM-
Light version 6.02 (Joachims, 2008, 2002) using the default linear kernel. The kernel is used to 
calculate an (n-1)-dimensional hyperplane which provides the maximum separation between 
the active and inactive molecules (Cortes and Vapnik, 1995). The resulting matrix is the QSAR 
model. 
9. To calculate a predicted score when screening a target molecule, a single vector of the coverage 
matrix is calculated for the target molecule as in steps 5-7, giving the coverage score of the 
rules against the molecule and the values of the physiochemical descriptors. This vector is 
multiplied the QSAR matrix to give a predicted score/classification. 
2.4.3 Fragmentation methods 
The fragmentation process is a process of decomposing molecular structure into a set of 
topological features, analogous to the decomposition used in extended connectivity fingerprinting. 
Thirteen fragmentation methods dissect the molecules into substructural fragments from which 
logical rules can be induced. Fragmentation methods 1 to 10 were included in INDDEx v1, while 
fragmentation methods 11 and 12 were developed for INDDEx v2. 
Different fragmentation methods produce different types of substructures or representations of 
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steric and electronic features. INDDEx has a library of fragmentation methods, and considers a variety 
of physiochemical properties such as weight, LogP and hydrophobicity. Fragmentation methods 
incorporate the concepts of neighbouring atoms directly and indirectly bonded to a central atom, 
counts of various atom types in the substructure, aromatic rings and areas of charge. Fragmentation 
methods can be used individually or multiple fragmentation methods can be applied together. Table 
2.4 defines the first five fragmentation methods employed by INDDEx (all versions). 
Table 2.4. Definitions of fragmentation methods 1 to 5 used by INDDEx (all versions) to fragment molecules into 
substructure. 
Fragmentation method Fragmentation process 
1 Central atom only. 
2 Central atom plus atoms one bond distance away (first shell). 
3 Central atom plus atoms two bond distances away (second shell). 
4 Central atom plus atoms one bond distance away plus atoms two bond distances 
away (first and second shells). 
5 Central atom plus elements and connecting bond types of all the atoms in the first 
shell plus the total number of hydrogen atoms connected to the atoms in the 
fragment. 
Figure 2.3 shows the process of fragmentation by shells of atoms used in the first five methods 
of fragmentation. For each atom in a molecule, all the atoms up to two atomic bonds away are 
considered. For fragmentation 1, a fragment consists of only the central atom type, where atom type is 
defined as the atomic element and its hybridisation. For fragmentation 2, a fragment consists of the 
central atom type and all the atom types in the first shell (shaded green in Figure 2.3). For 
fragmentation 3, a fragment consists of the central atom type and all the atom types in the second shell 
(shaded red in Figure 2.3). For fragmentation 4, a fragment consists of the central atom type, all the 
atom types in the first shell and all the atom types in the second shell. 
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Figure 2.3. An example fragmentation process extending from a central sp2 carbon atom, showing all atoms a maximum of 
two bonds away. Left: the fragment with the bonds and hybridisation types of each atom. Right: the atoms divided into 
shells around the central carbon atom. The first shell of atoms is highlighted in green and the second shell in red. 
For fragmentation 5, a fragment consists of the atomic element of the central atom (ignoring 
hybridisation) together with the elements and connecting bond types of all the atoms in the first shell 
(shaded green in Figure 2.3), and the total number of hydrogen atoms connected to the atoms in the 
fragment. The five fragments generated by each of these methods when centred on the central carbon 
atom in Figure 2.3 are shown in Figure 2.4. 
 
Figure 2.4. The five fragments generated by the first five fragmentation methods of INDDEx from the example structure 
shown in Figure 2.3. 
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For fragmentation 6, a fragment consists of a central atom and the first shell of surrounding 
atoms, as in fragmentation 2, but bases the atom types around a custom set that takes into account 
aromaticity and hydrogenation. For fragmentation 7, a fragment consists of one of a set of custom 
fragments based around aromatic and hydrophobic structural elements. For fragmentation 8, a 
fragment consists of the partial charge of positively and negatively charged atoms, with partial charge 
calculated using the iterative method developed by Gasteiger and Marsili (1980). For fragmentation 9, 
a fragment consists of one of a set of custom fragments based around hydrophobic centres, positive 
and negative charge centres, hydrogen donors and acceptors and aromatic rings. For fragmentation 
10, a fragment consists of the central atom type, all the atom types in the first shell, all the atom types 
in the second shell and all the atom types in the third shell. For fragmentation 11, a fragment consists 
of all possible pairs of heavy atoms in the molecule, with each atom pair also containing the shortest 
number of bond links between those two atoms. For fragmentation 12, a fragment consists of four 
joined consecutive heavy atoms, where at least two of the atoms in the fragment are non-carbon. 
2.4.4 Initial cross-validation to identify fragmentation method 
An additional feature in INDDEx v2 is an automated procedure of multiple cross-validations to 
determine the optimum fragmentation method. Cross-validation is performed by systematic 
sampling: arranging the activity values in order and then assigning the entries to the folds in a cyclical 
order. To identify the optimum fragmentation method, all twelve different methods of fragmenting 
molecular data are cross-validated on the data, and the twelve fragmentations tried individually and 
in combination to find a method that produces the best correlation between the known values and the 
predicted cross-validation values. 
A program was developed to automate the selection of fragmentation method(s). The algorithm 
of this program is to perform a greedy beam-search (Bisiani, 1987) to obtain the optimised set of 
fragments. A beam search is able to explore a tree graph that has many branching nodes by only 
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exploring the branches of the most promising nodes. The breadth-first beam search requires each level 
of the tree to be searched before pruning and moving to the next level, but parallelisation allows the 
multiple nodes on a single tree level to be searched in parallel. An example of this method is shown in 
Figure 2.5. For the fragmentation methods, each node represents a 5-fold cross-validation of the 
dataset using a different method. For each method, the cross-validation Pearson’s product-moment R2 
value between predicted and actual is calculated. At the first level, only a single fragmentation 
method is used in each test. At the second tree level, only the methods in the top 50% of R2 values 
have their nodes expanded for cross-validation using two fragmentation methods together. After the 
chosen nodes at the second tree level have been searched, only the nodes scoring in the top 50% of R2 
values, across all nodes searched so far at all tree levels, are taken to be expanded at the next tree level. 
Each tree level is searched in parallel, speeding up the search. Successively higher tree levels continue 
to be searched, potentially up to the twelfth level where all fragmentations are combined or until a 
level is reached where none of the combinations fall into the top 50% of R2 values. 
 
Figure 2.5. Diagram showing an example of the first two tree levels of the beam-search method used to parse the 
fragmentation cross-validations, simplified to only five fragmentation methods (from the twelve actually used). 
Fragmentation method “5 & 3” is not tested because it is identical to method “3 & 5.” 
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2.4.5 Visualisation of output 
INDDEx v1 only gave text-based rule output in the form of ILP rules, as shown in Table 1.1, 
making it difficult to visualise how these rules fitted the training data, or how the rules applied to the 
predicted screening molecules. For INDDEx v2.1, an output was added that listed all the training data 
molecules that were covered by each rule, and an option to print out automatically generated 
visualisations of the rules projected onto the molecules they covered together with descriptions of the 
rules. Two of these visualisations are shown in Table 4.6 of Chapter 4. 
2.4.6 Identifying a fragmentation method to use in testing 
To acquire datasets of drug molecules for testing purposes, publically available small molecule 
high throughput screening bioassays were downloaded from PubChem (Wang et al., 2009) on 
December 2009. The selection criteria for the bioassays were for confirmatory screenings on known 
Homo sapiens protein targets with a deposit date within the previous three years that had more than 
1000 compounds tested. Datasets for screenings on G-proteins were removed at this stage and 
reserved for further testing at a later date. Of the 36 datasets, the seven with the largest number of 
actives (with actives defined as compounds with an IC50 or EC50 of less than 1.0μM) were selected. 
These bioassays had the PubChem IDs: 886, 1339, 1418, 1458, 1688, 1769 and 1778. 
 Each bioassay was used to form a balanced dataset containing an equal number of inactive and 
active compounds in keeping with machine-learning methodology (Batista et al., 2004). The inactives 
were a set equal in number to the number of actives, randomly chosen from the set of inactives in the 
bioassay. 
To find which fragmentation method consistently yields the best correlation between observed 
and predicted results, the INDDEx fragmentation methods were performed with 5-fold cross-
validation on each of these bioassays. Figure 2.6 shows the different fragmentations tested on the 
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PubChem datasets. Fragmentation 5 gave the highest average of the seven correlation values across 
the sample datasets, and so was used as the default fragmentation method for the large-scale 
assessment in Chapter 3. 
 
Figure 2.6. Bar graph showing the R2 Pearson product-moment correlation between observed and predicted activity values 
when using INDDEx with twelve different fragmentation methods (1 to 12). Each fragmentation method was tested on 
seven sample datasets formed from PubChem bioassay data. 
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Chapter 3 Application of INDDEx to identify inhibitors of SIRT2 
3.1 Summary 
This chapter reports an application of the INDDEx v2 software. It reports collaborative research 
into finding a small molecule inhibitor for the SIRT2 protein, describing how data on SIRT2 inhibition 
was used as training data for INDDEx v2 and the results of a large-scale screening of a molecular 
database that identified novel active molecules. There is an analysis of the scaffold-hopping ability of 
INDDEx v2 in this project and an example of how INDDEx can be used to further guide lead 
development. 
In this chapter: 
Section 3.2 introduces the topic of applying INDDEx to finding hits for the SIRT2 protein and 
describes the contents of this chapter. 
Section 3.3 explains the biology of SIRT2, its role as a member of the sirtuin protein family 
(3.3.1), its structure and mechanism of action (3.3.2), the mechanism by which it is inhibited (3.3.3), 
and the effects of its inhibition (3.3.4). 
Section 3.4 summarises previous work on designing and testing small molecule inhibitors of 
SIRT2, listing the structures and activities of known inhibitory molecules that were used as training 
data for INDDEx. 
Section 3.5 lists the software and metrics used to predict the binding affinities of molecules and 
cluster molecules by structure to identify distinct structural groups for testing. 
Section 3.6 details the method used for screening a database to find molecules to inhibit SIRT2, 
and the subsequent methods of experimental testing. 
Section 3.7 describes the results of the screening and testing of the novel molecules, giving the 
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predicted and experimentally ascertained activities of the molecules found. 
Section 3.8 discusses the scaffold-hopping performance of the search for new leads, and how 
structurally different the known active molecules are to the novel predicted molecules. 
Section 3.9 discusses the significance of the results, the limitations of the method and the 
potential for extending the study. 
3.2 Introduction 
It is important to be able to demonstrate INDDEx in a practical way as opposed to a benchmark. 
INDDEx was applied to a known activity training set to identify molecules potentially active towards 
a specific target protein from the ZINC structural database, and then the activity of the selected 
compounds were experimentally verified. The protein that is being looked at is SIRT2 (Silent 
Information Regulator Type 2). It is one of a family of proteins known as sirtuins. For the work 
described in this chapter, INDDEx v2.0 was used, which was a beta-test version of INDDEx v2.1 
during its development, incorporating the SVILP method. The learning, screening and fragmentation 
methods were the same as those of INDDEx v2.1, but it lacked the visualisation of output and pre-
calculated descriptors (see Table 2.1). 
This work was performed in collaboration with a medicinal chemistry group who were 
searching for compounds with activity and selectivity against a target protein. This work used their 
published data on compound activity and inactivity against the SIRT2 protein as learning data for 
INDDEx, and performed a screening search to identify new compounds with potential activity against 
the target. Paolo di Fruscia performed docking studies on the compounds identified by INDDEx as 
the most active, in order to give a consensus result to increase the chances of finding active 
compounds. These compounds were then tested by the Manfred Jung group at Freiburg University, to 
confirm or disprove the activity predictions. 
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3.3 The biology of SIRT2 
3.3.1 The sirtuin protein family 
Sirtuins are a family of proteins homologous to the Silent information regulator 2 (Sir2) protein 
in yeast (Afshar and Murnane, 1999), the seven types of which were characterised by Frye (2000, 
1999). In humans, the sirtuins act as regulators of gene transcription through a chromatin remodelling 
mechanism (Marks et al., 2001). Sirtuins are NAD+-dependent deacetylases that use nicotinamide 
adenine dinucleotide (NAD+) as a co-factor to catalyse the deacetylation of lysine residues on proteins. 
Because of its role as a co-factor, the NAD+ binding site is a target for drug discovery when searching 
for small molecules to inhibit the sirtuins. Figure 3.1 shows the structure of NAD+. 
 
Figure 3.1. Molecular structure of Nicotinamide Adenine Dinucleotide (NAD+). Note the positive charge on the nitrogen 
atom of the pyridine ring to the right. 
Seven members of the SIRT family, SIRT1-7, have been described in humans (Jung et al., 2008). 
They are part of a group of histone deacetylases (HDACs) which, together with histone 
acetyltransferases (HATs), control the level of acetylation of histones and other proteins (Saunders 
and Verdin, 2007).  
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3.3.2 SIRT2 structure and mechanism 
The sirtuin chosen for this study is SIRT2, a single chain protein with two domains. Figure 3.2 
shows the SIRT2 protein as crystallised by Finnin et al (2001). 
 
Figure 3.2. SIRT2 protein surface model with the active site shaded in four colours to indicate the four sub-pockets. 
Magenta = acetylated substrate binding site; Orange = sub-pocket A binding the nicotinamide ribose moiety of NAD+; Red 
= sub-pocket B binding the adenine moiety of NAD+; Blue = sub-pocket C which forms a hydrophobic environment deep in 
the binding cleft. Crystal model taken from the PDB, entry 1J8F, chain B (Finnin et al., 2001). Figure rendered using 
PyMol (Delano, 2002). 
SIRT2 binds an acetylated substrate in a binding site in a large groove (shown in magenta in 
Figure 3.2), and NAD+ as a co-factor. The NAD+ binding pocket is a Rossmann motif, which contains 
three sub-pockets to accommodate the NAD+. Sub-pocket A (shown in orange in Figure 3.2), which 
binds the adenine-ribose moiety of NAD+, sub-pocket B (shown in red in Figure 3.2), which binds the 
nicotinamide-ribose moiety of NAD+, and sub-pocket C (shown in blue in Figure 3.2), deep inside the 
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binding pocket, which does not bind directly to the NAD+ but instead provides a hydrophobic 
environment for the NAD+ binding (Min et al., 2001). 
SIRT2 is predominantly located in the cytoplasm where it deacetylates α-tubulin and the 
forkhead box (FOX) transcription factors: FoxO1 (Jing et al., 2007) and FoxO3a (Wang et al., 2007). 
SIRT2 also migrates into the nucleus, where it deacetylates histones (North et al., 2003). In a 
deacetylated state, the lysine residues at the N-terminus of histone proteins have a strong positive 
charge, causing them to bind tightly to the negatively charged DNA, and so silencing transcription of 
the DNA. Histone acetyltransferases acetylate lysine residues, neutralising the charge and opening the 
chromatin structure, allowing transcription, while HDACs remove acetyl groups from the histone 
lysines, condensing chromatin structure (Saunders and Verdin, 2007). 
SIRT2 is involved in the cell cycle, with SIRT2 migrating into the nucleus during the transition 
from the G2 interphase to the mitosis phase (Wang et al., 2007). SIRT2 down-regulation was found to 
arrest mitosis by sustaining the microtubulin spindle checkpoint and preventing cell apoptosis (Inoue 
et al., 2009), suggesting SIRT2 is responsible for a mitotic checkpoint that prevents chromosomal 
instability. Through the regulation of FOX transcription factors, SIRT2 regulates adipocyte 
differentiation by the deacetylation of FOXO1, and causes cell apoptosis in conditions of oxidative 
stress and caloric restriction by the deacetylation of FOXO3a (Wang et al., 2007). 
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Figure 3.3. Diagram showing how SIRT2 deacetylates lysine residues, its role in deacetylating microtubulin and histones, 
the transcriptional silencing effects of histone deacetylation and how this leads to cell apoptosis. Adapted from Saunders and 
Verdin (2007) and Li et al. (2010). Cell undergoing sirtuin apoptosis adapted from the Wikimedia Commons file 
“Hypertrophic Zone of Epiphyseal Plate.jpg.” Nucleus texture rendered by User:borysses at deviantart.com. The sphere 
images used for histones and tubulin are from iStockphoto. 
3.3.3 Mechanism of SIRT2 inhibition 
The modes of action of most sirtuin modulators are unknown (Nguyen et al., 2013) which has 
hindered their rational design, but a range of mechanisms are thought to be involved depending on 
the inhibitor. Gertz et al (2013) crystallised the inhibitor Ex-527 in complex with SIRT2 and found that 
Ex-527 occupies sub-pocket C (shaded in blue in Figure 3.2) and contacts the ribose of NAD+, thus 
stabilising the sirtuin enzyme in a closed conformation and prevents the release of the acetyl product. 
Nguyen et al (2013) found that a crystal structure of SRT1720 in complex with SIRT3 found that the 
inhibitor occupied the binding site for the acetylated peptide (shaded in magenta in Figure 3.2), 
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explaining its uncompetitive inhibition with NAD+. 
3.3.4 The effects of inhibiting SIRT2 
Tumourigenesis was observed in SIRT2 deficient mice, indicating that SIRT2 had anti-tumour 
activity, thought to be through regulating cell mitosis and DNA repair (Kim et al., 2011), which SIRT2 
does via a mitotic checkpoint. There is also evidence that the SIRT2 inhibitor cambinol has antitumour 
activity (Heltweg et al., 2006). 
Inhibition of SIRT1 and SIRT2 produced p53 mediated cell apoptosis in MCF-7 cells (Peck et al., 
2010). SIRT2 down-regulation caused apoptosis in MCF-7 breast cancer cell lines but not normal cells 
by p53 accumulation, through the p38 MAPK degradation pathway, which leads to p300 degradation 
and p53 stabilisation (Li et al., 2010) (see Figure 3.3). 
The sirtuin deacetylases are strongly associated with neurodegenerative diseases, with the 
evidence summarised in a review by Herskovits and Guarente (2013). Multiple studies have shown 
that SIRT2 inhibition prevents the amyloid toxicity that is the cause of dopaminergic cell death in 
Parkinson’s disease (Green et al., 2008; Outeiro et al., 2007) through a mechanism that remains 
unclear, though it may be through the promotion of larger, and hence fewer, inclusion bodies (Garske 
et al., 2007). Another study has shown that inhibition of SIRT2 down-regulates sterol biosynthesis, 
which could potentially combat Huntington’s Disease, a neurodegenerative disorder that proceeds 
through sterol overproduction in neuronal cells (Luthi-Carter et al., 2010). 
3.4 Known small molecule inhibitors of SIRT2 
Inhibitors of SIRT2 are known, but potency is low, with none of them showing sub-micromolar 
IC50 and most do not show selectivity for SIRT2 over the other sirtuins. The active inhibitors taken into 
account in this study, and used to generate the model in this study were: dibenzazepine derivatives 
PDF170-01 (18μΜ) and PDF228-01 (78 μΜ) from (Di Fruscia et al., 2012), AGK2 (3.5μΜ) from (Outeiro 
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et al., 2007), indolinone GW5074 from (Trapp et al., 2006) (15.6 ± 1 for SIRT2 and 41.6 ± 0.7 SIRT1 
(Huber et al., 2010)), cambinol (59uM ± 4 μM SIRT2 and 56 ± 2 μM for SIRT1) (Heltweg et al., 2006), 
splitomicin derivative Splitomicin-1 (1.5 μM) (Schemies et al., 2010), and Huber-9 (10.4uM ± 1.4 μM 
SIRT2 and 30.2% inhibition at 50 μM for SIRT1) from Huber et al (2010). 
The work by Di Fruscia et al. (2012) considered the tricyclic 10,11-dihydro-5H-
dibenz[b,f]azepine scaffold that is used as a core structure in antidepressant drugs (Scuvée-Moreau 
and Dresse, 1979) and has structural similarity to existing SIRT inhibitors (Napper et al., 2005; Suzuki 
et al., 2006). Di Fruscia et al. (2012) generated analogues from the dibenzazepine scaffold, and in vitro 
fluorimetric enzymatic assays (Heltweg et al., 2005) were conducted on the effect of these analogues 
against SIRT1 and SIRT2. As mentioned in the list of inhibitors, two of the analogues, PDF170-01 and 
PDF228-01, showed some moderate inhibitory activity of SIRT2, with IC50s of 18μM and 78μM 
respectively. The rest of the dibenzazepine analogues were inactive, and were used as a set of 
inactives from which INDDEx could learn negative rules. All these active inhibitors and inactives are 
summarised together with their SIRT2 inhibitory activity in Table 3.1. 
Table 3.1. Original data of SIRT2 inhibition activity of various compounds. The compounds showing no activity, were 
assigned an IC50 activity of 500μM (3.3 pKi) to avoid having infinite numbers in the regression. pKi was calculated from 
IC50 activity, not measured. 
Compound 
name 
SIRT2 IC50 
activity 
(μM) 
SIRT2 pKi 
activity  
(-log(M)) Compound structure Source 
Splitomicin-1 1.5 5.82  Schemies et al. (2010) 
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Compound 
name 
SIRT2 IC50 
activity 
(μM) 
SIRT2 pKi 
activity  
(-log(M)) Compound structure Source 
AGK2 3.5 5.46  Outeiro et al. (2007) 
Huber-9 10.4 4.98  Huber et al. (2010) 
GW5074 15.0 4.82  
Structure from 
Trapp et al. (2006), 
inhibition data from 
Huber et al. (2010)  
PDF170-01 18.0 4.74  Di Fruscia et al. (2012) 
Cambinol 59.0 4.23  Heltweg et al. (2006) 
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Compound 
name 
SIRT2 IC50 
activity 
(μM) 
SIRT2 pKi 
activity  
(-log(M)) Compound structure Source 
PDF228-01 78.0 4.11  Di Fruscia et al. (2012) 
PDF123-01 No activity n/a  Di Fruscia et al. (2012) 
PDF131-01 No activity n/a  Di Fruscia et al. (2012) 
PDF163-01 No activity n/a  Di Fruscia et al. (2012) 
PDF164-01 No activity n/a  Di Fruscia et al. (2012) 
PDF168-01 No activity n/a  Di Fruscia et al. (2012) 
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Compound 
name 
SIRT2 IC50 
activity 
(μM) 
SIRT2 pKi 
activity  
(-log(M)) Compound structure Source 
PDF173-01 No activity n/a  Di Fruscia et al. (2012) 
PDF179-01 No activity n/a  Di Fruscia et al. (2012) 
PDF185-01 No activity n/a  Di Fruscia et al. (2012) 
PDF190-01 No activity n/a  Di Fruscia et al. (2012) 
PDF209-01 No activity n/a  Di Fruscia et al. (2012) 
PDF213-01 No activity n/a  Di Fruscia et al. (2012) 
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Compound 
name 
SIRT2 IC50 
activity 
(μM) 
SIRT2 pKi 
activity  
(-log(M)) Compound structure Source 
PDF216-01 No activity n/a  Di Fruscia et al. (2012) 
PDF229-01 No activity n/a  Di Fruscia et al. (2012) 
Figure 3.4 shows the distribution of the activity of the compounds used to generate the model, 
showing a large number of inactives and a sparse population of the active range. Section 3.8 further 
discusses the similarity of the compounds in this dataset and shows that the series developed by Di 
Fruscia et al. (2012) (termed the PDF series) are closely related in structure. 
 
Figure 3.4. Histogram of the activities of the molecules in the SIRT2 activity dataset. 
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3.5 Software and metrics used to evaluate molecules for testing 
3.5.1 Software pipeline 
Figure 3.5 shows the pipeline of software methods used to evaluate molecules to identify the 
most suitable ones for testing based on a consensus of methods for predicting binding affinity and 
druglikeness, as well as novelty of structure. 
 
Figure 3.5. Pipeline showing the methods and materials used to evaluate molecules for testing as SIRT2 inhibitors. 
3.5.2 INDDEx v2.0 
INDDEx is a ligand-based virtual screening method described and assessed in Chapter 4. 
INDDEx v2.0 included the same SVILP algorithm as INDDEx v2.1 used in the benchmarking 
described in Chapter 4, but lacked features that related to stability and computational efficiency. The 
feature differences are shown in Table 2.1. In INDDEx v2.0, descriptors for the screened molecules 
were calculated on the fly, which in the large benchmark would have been inefficient. 
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3.5.3 Lipinski test 
The Lipinski test (Lipinski et al., 1997) is a simple set of criteria, described in detail in section 
1.3.2, that was developed to identify orally-active small molecule drugs and is now often used to class 
molecules as drug-like or otherwise. To decrease the probability that false negatives identified by 
Lipinski test are not excluded, the molecules were divided into a set filtered by the Lipinski test and 
an unfiltered set, and the highest ranked by INDDEx v2 from each set were merged. 
3.5.4 GOLD 
GOLD is a structure-based virtual screening method that docks ligands to specified binding sites 
of 3D protein structures and gives a measure of the quality of the docking pose. GOLD scores docking 
poses using three measures: GoldScore, ΔG and ChemScore (Verdonk et al., 2003). This study used a 
consensus of GoldScore and ChemScore, which is noted as providing the highest docking accuracy by 
Verdonk et al. (2003). 
GoldScore is a dimensionless default scoring function developed for the GOLD software and 
optimised for ligand-protein binding affinity. 
ΔG is an empirical measure of predicted binding affinity in units of Kcal/mol. It is calculated 
from a regression model that was trained on a dataset of 82 protein-ligand complexes. 
ChemScore is a dimensionless scoring function that incorporates both the calculated ΔG value 
and includes further terms to represent protein-ligand interactions and the internal energy of the 
ligand, which will vary with different interaction poses. 
3.5.5 Clustering 
Single-linkage agglomerative clustering was used, also known as nearest neighbour clustering. 
Here, each molecule is represented as a node, and the distance between two nodes is the Tanimoto 
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coefficient of Maximum Common Substructural Similarity (see section 1.8). This clustering method 
takes into account the all-against-all distance and groups the molecules into clusters by grouping the 
two nodes with the lowest distance, and then successively grouping nodes with the next lowest 
distances until a distance cut-off is reached. A hierarchy of clusters is produced as the distance cut-off 
is varied. In this evaluation, the clustering was used to assist the identification of clusters of molecules 
with structural uniqueness, allowing the choice of a distinct set of molecules for a varied test set. For 
this study, distance cut-offs for the Tanimoto coefficient were chosen at 0.5, 0.6, 0.7 and 0.8, and then 
expert opinion was used to assess the validity of the structural clusters. 
3.5.6 Cost and availability 
For the initial in vitro testing, the molecules to be tested were purchased if commercially 
available or synthesised to order. For this, the cost and availability of the molecules identified had to 
be taken into account by the evaluation. Cost was taken into account at an early stage to filter out any 
molecules that would be prohibitively expensive to purchase. The ZINC database used is intended as 
a repository of purchasable molecules, but availability varies over time. Where possible, when a 
molecule was not available it would be replaced by another from the same structural cluster. 
3.6 Method for finding a molecule to inhibit SIRT2 
The workflow shown in Figure 3.5 was used to screen the ZINC database for molecules with 
inhibitory activity against the SIRT2 protein. The process produced eight molecules that were selected 
and purchased for in vitro testing. Figure 3.6 shows the number of molecules at each stage of the 
process. 
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Figure 3.6. Graphic showing the attrition in potential compounds at each filtration step. 
For this SIRT2 screening study, the steps of the process in detail were: 
1. The initial training data consisted of seven active molecules with IC50 activities between 1.5 µM 
and 78 µM and thirteen inactive molecules (structures and references given in Table 3.1). 
2. INDDEx v2.0 was employed to scan all molecules in the ZINC 11 database. 25,008,975 
molecules were screened in total. 
3. The molecules screened by INDDEx were ranked by predicted activity. From these, a set of the 
top 200 molecules was obtained by progressing down the rank list from INDDEx and selecting 
only those molecules that passed ZINC’s implementation of the Lipinski (2000) test 
(150 daltons ≤ Molecular weight ≤ 500 daltons, xLogP ≤ 5, rotatable bonds ≤ 7, polar surface 
area < 150 Å2, hydrogen-bond donors ≤ 5 and hydrogen-bond acceptors ≤ 10). In addition, the 
top 50 ranked molecules were added to this set irrespective of whether they passed ZINC’s 
implementation of the Lipinski rules. These two sets overlapped, sharing 14 molecules that 
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pass the Lipinski test in the top 50 molecules ranked by INDDEx. The resultant set contained 
236 molecules. 
4. For testing purposes, the most important criteria were that each molecule was immediately 
available and cost less than 100 dollars for a sample. Filtering the molecules with these criteria 
gave a set of 97 molecules. 
5. Paolo di Fruscia docked these molecules at the active site of the SIRT2 enzyme crystal structure 
derived by Finnin et al. (2001) (PDB ID: 1J8F). The docking software used was GOLD (Verdonk 
et al., 2003) and the compounds were ranked by GoldScore fitness function as shown in Table 
3.2. A previous study to evaluate docking software and scoring protocols found GOLD to be 
the best software and GoldScore to be the best scoring function (Surpateanu and Iorga, 2012). 
Table 3.2. Molecules top ranked by GoldScore fitness function when docked with GOLD. GoldScore, ChemScore and ΔG 
were calculated by Paolo di Fruscia using the GOLD docking tool (see section 3.5.4). GoldScore and ChemScore fitness 
functions have no units. Increasingly better-predicted binding is associated with lower INDDEx rank and ΔG prediction, 
and with higher INDDEx prediction, GoldScore and ChemScore. 
Molecule ID / 
GoldScore rank 
INDDEx prediction 
(-log(IC50)) 
INDDEx 
rank 
GoldScore ChemScore ΔG (Kcal/mol) Sent for 
testing 
Reference 
(Splitomicin-1) 
  68 40 -46  
1 8.40 350 77 33 -44 Yes 
2 8.40 345 77 21 -36  
3 8.49 155 75 40 -54 Yes 
4 8.90 4 75 34 -47 Yes 
5 8.51 120 75 32 -45  
6 8.71 17 75 31 -45  
7 8.71 16 72 33 -41  
8 8.59 52 72 29 -41 Yes 
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9 8.47 174 72 28 -54  
10 8.40 328 70 32 -44 Yes 
11 8.51 128 70 28 -41 Yes 
12 8.47 181 70 17 -31  
13 8.65 27 69 25 -41 Yes 
14 8.41 319 68 32 -40  
15 8.37 427 68 28 -43  
16 8.61 40 67 36 -46 Yes 
17 8.50 141 67 31 -39  
6. Molecules with high consensus INDDEx prediction and GoldScore were clustered, using 
agglomerative single-linkage clustering (see section 3.5.5), into structurally related groups to 
identify molecules with similar common substructure. 
7. By inspection, eight of those top 50 were selected by inspection for in vitro testing against 
SIRT1 and SIRT2, based on high INDDEx scores and GOLD docking scores, and belonging to 
different structural clusters. 
8. To ascertain an observed activity, the compounds were screened in vitro with a fluorescence-
based enzymatic assay for their inhibitory activities towards the SIRT1 and SIRT2 proteins. The 
in vitro work was conducted by the Manfred-Jung group at Freiburg University. 
3.7 Results 
Manfred-Jung’s group at Freiburg University determined the inhibitory effect in fluorimetric 
enzymatic assays (Heltweg et al., 2005). The results were that Molecule 3 (see Table 3.2) was shown to 
have an IC50 of 3.9µM against SIRT2 and an IC50 > 500 µM against SIRT1. This shows that Molecule 3 
showed moderate activity against SIRT2 and was highly selective. Molecule 16 (see Table 3.2) showed 
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some moderate activity of 37.5µM and the IC50 for SIRT1 was undeterminable (estimated >100 µM). 
Molecule 3 was resynthesised by the Fuchter group at Imperial College London, and retested in a 
confirmatory fluorescence-based biochemical assay by the Reaction Biology Corporation in 
Pennsylvania, USA, and was shown to have an IC50 of 665 nM. 
The GOLD docking studies performed by Dr di Fruscia suggested that Molecule 3 occupied the 
SIRT2 binding site for the acetylated peptide (shaded in magenta in Figure 3.2) in a similar mechanism 
to that described for SRT1720 by Nguyen et al. (2013) and this may well be the inhibitory mechanism 
of Molecule 3. 
Figure 3.7 is a scatter plot of the top molecules docked by GOLD as given in Table 3.2 (17 
molecules and the Splitomicin-1 reference). The activity values predicted by the INDDEx model for 
each molecule are plotted against the GoldScore fitness function assigned by the GOLD docking 
software. The molecules that were tested are highlighted by coloured circles, with blue circles 
indicating inactives, and red circles indicating active inhibitors with their observed inhibitory activity 
shown as an accompanying number. The plot shows no apparent correlation between the INDDEx 
predictions and GoldScore and no apparent pattern to the active and inactive observations, 
demonstrating the high number of false positives even after applying filters of druglikeness and two 
independent virtual screening methods. 
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Figure 3.7. Scatter plot of the top ranking molecules docked by GOLD as given in Table 3.2. GoldScore (no units) is plotted 
against the activity predicted by INDDEx v2.0 (-Log10IC50) with the data points shown as blue crosses. The red and blue 
coloured circles show tested molecules, with red indicating activity and blue indicating inactivity. The numbers in red 
above the red circles give the experimentally determined IC50 values as –log10 of their value in μM. Observed pKi values for 
active molecules are shown as red numbers next to the corresponding circle. The red circle on the left of the plot indicates 
the Splitomicin-1 reference that was used for the docking procedure, and was a member of the set used for training by 
INDDEx. 
3.8 Scaffold-hopping 
Figure 3.8 is a heat map of the Tanimoto coefficient of Maximum Common Substructure, with 
the training compounds and top ranked predicted compounds shaded by activity and similarity. 
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Figure 3.8. Heat map of all-against-all compound similarity for the training set and the molecules predicted to be active. 
Similarity is measured by the Tanimoto coefficient of Maximum Common Substructure. The map shows the molecules used 
as training data (labelled “Training”) and the 17 compounds top ranked by GoldScore of all those docked with GOLD 
(labelled “Predicted”). The hue of each cell denotes activity (Green = Most Active; Red = Least Active; Monochrome = 
Untested) and the brightness indicates similarity (Fully saturated in the red-green spectrum or black = Tanimoto coefficient 
of 1 = Identical; White = Tanimoto coefficient of 0 = Distinct). The molecules in both the training and screening portions 
are arranged from most to least active, so the molecules in the screening portion of the heat map are: 3, 16, 13, 11, 10, 8, 4, 
1, 17, 15, 14, 12, 9, 7, 6, 5, 2. 
In the top-left quadrant of the heat map in Figure 3.8, the training compounds are compared 
against each other. The lightness of the left and top of this quadrant shows that the most active 
compounds are quite diverse, but the bottom-right of this quadrant is dominated by a large cluster of 
very similar compounds, only the first of which shows much activity (an IC50 of 78.0µM). This is the 
chemically related PDF series (see Table 3.1) that was synthesised in the research of Di Fruscia et al. 
(2012). In the bottom-left and top-right quadrants (which are mirror-image equivalents), the training 
compounds are compared to the predicted compounds. The overall lightness of this area shows the 
strong distinctness between the compounds used as training data and those predicted by INDDEx. 
The most active molecule found by INDDEx (Molecule 3) was structurally similar to five other 
molecules in the predicted set, only two of which were tested, and of those, only Molecule 3 was found 
  114  Application of INDDEx to identify inhibitors of SIRT2 
 
to have activity. Figure 3.9 shows that all of the predicted molecules had less than 0.4 Maximum 
Common Substructure Tanimoto similarity to any of the molecules used for training. This 
demonstrates a wide structural variation in the predicted molecules and a strong scaffold-hopping 
performance. 
 
Figure 3.9. Bar chart of the maximum similarity of each of the predicted molecules to any of the molecules used for training. 
The similarities were calculated using the Tanimoto similarity of Maximum Common Substructure (see section 1.8). 
Molecule 3 has 0.269 as its maximum similarity to any molecule in the training set (closest match 
is AGK2, and Molecule 16 has 0.197 as its maximum similarity to any molecule in the training set 
(closest match is Splitomicin-1). These low similarities show that these novel active molecules are 
highly distinct in structure from existing active molecules, demonstrating the scaffold-hopping 
potential of the method described in this chapter, and meaning that these new molecules provide 
novel scaffolds which can be used as stating points to increase potency and selectivity (see section 1.7). 
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3.9 Discussion 
One limitation of this study is the small number of active compounds to learn from, although 
Chapter 4 will show INDDEx v2’s strength at learning from a limited number of compounds. Another 
limitation is that experimental verification is subject to variation depending on who performed the 
test because of different conditions, such as procedures, compound purity and enzyme purification. 
More generally, the procedure involved a series of decisions made by subjective judgement, which 
hinders the development of a repeatable benchmarking method, however, this sort of subjective 
judgement is often the way that lead finding is performed in the screening community. 
This study demonstrated the ability of INDDEx v2.0 to develop a predictive model from a low 
number of actives (seven actives, none with sub-micromolar activity), and the effectiveness of the 
process used in this study and the consensus approach with structure-based docking. Two novel 
actives were identified, one with activity against SIRT2 greater than any of the previously known 
actives that were used to form the model. Both these novel actives had structures that were 
significantly novel when compared to the compounds used to from the training data. 
Further work on this study could include using INDDEx to rank molecule activity against 
SIRT1. The procedure described in section 3.5 could be evaluated, and a more general method could 
be developed, combining INDDEx with GOLD docking scores. In addition, previous work showed 
that an INDDEx-type approach can develop scoring rules for protein ligand interactions which could 
complement the QSAR model generated by INDDEx in this investigation (Amini et al., 2007b). 
The model derived by INDDEx could be used to guide lead development of the highly active 
Molecule 3, with the INDDEx rules being used to developing a QSAR (Quantitative Structure-Activity 
Relationship) series of variations on the molecule for further in vitro testing. Further cycles of testing 
data can be used for subsequent training of INDDEx, thus generating an improved model.  
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Chapter 4 Assessment of virtual screening power of INDDEx v2 
4.1 Summary 
This chapter reports published research (Reynolds et al., 2012). It describes an assessment of 
virtual screening power on the DUD benchmark dataset, and a comparison of the method with other 
methods on the same benchmark. Results are discussed with reference to how they relate to the 
current state of the drug discovery field, and there is a discussion of scaffold-hopping ability. 
In this chapter: 
Section 4.2 describes the methods used to evaluate virtual screening performance, including the 
statistical measurements (4.2.1, 4.2.2, 4.2.3, 4.2.4, 4.2.5, 4.2.6, 4.2.7), details of the test datasets (4.2.8, 
4.2.9), and the method used to benchmark INDDEx v2 (4.2.11, 4.2.10). 
Section 4.3 summarises and explains the results of the assessment, giving values for the retrieval 
rate of known active compounds (4.3.1), comparing the performance against other methods (4.3.2), 
discussing the results (4.3.3, 4.3.4), and giving values for scaffold-hopping performance (4.3.6), speed 
and timing (4.3.7). 
Section 4.4 discusses the results and implications of the testing and considerations that should 
be taken into account. 
Section 4.5 concludes the chapter and notes the key results. 
4.2 Evaluation of virtual screening performance 
4.2.1 Information retrieval measures 
Information retrieval theory (Powers, 2011) divides retrieved data into four different categories 
as enumerated in Table 4.1. 
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Table 4.1. Corresponding observed and predicted Boolean values for information retrieval data types. 
Name Abbreviation Observed Predicted 
True positives TP TRUE TRUE 
False positives FP FALSE TRUE 
True negatives TN FALSE FALSE 
False negatives FN TRUE FALSE 
Total number N TRUE or FALSE TRUE or FALSE 
Four information retrieval measures are used in this thesis; precision, recall, specificity and 
F-measure. Formulae for these measures are given in Equation 4.1. 
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =  𝑇𝑃
𝑇𝑃 + 𝐹𝑃 
𝑅𝑒𝑐𝑎𝑙𝑙 = 𝑇𝑃
𝑇𝑃 + 𝐹𝑁 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 = 𝑇𝑁
𝑇𝑁 + 𝐹𝑃 
𝐹 −𝑚𝑒𝑎𝑠𝑢𝑟𝑒 = 2 × 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 × 𝑟𝑒𝑐𝑎𝑙𝑙
𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 + 𝑟𝑒𝑐𝑎𝑙𝑙  
Equation 4.1. Formulae for four measures of information retrieval: precision, recall, specificity and F-measure. 
Precision gives the fraction of data classed as positive that were correctly classified, recall gives 
the fraction of genuine positive data that was correctly classified, specificity gives the fraction of 
genuine negatives that were correctly classified and the F-measure combines the precision and recall 
measures using the harmonic mean, giving a measure of overall predictive power. 
4.2.2 Correlation measures 
The Pearson product-moment correlation coefficient, formulated in Equation 4.2, measures the 
strength of linear correlation between the data points of two variables. 
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𝑟 = ∑ (𝑥𝑖 − ?̅?)(𝑦𝑖 − 𝑦�)𝑛𝑖=1
�∑ (𝑥𝑖 − ?̅?)2 ∑ (𝑦𝑖 − 𝑦�)2𝑛𝑖=1𝑛𝑖=1  
Equation 4.2. Formula for the Pearson product-moment correlation coefficient for samples. 
The r-value is dimensionless and falls between 1, indicting perfect positive correlation, and -1, 
indicating perfect negative correlation. An r-value of 0 indicates no linear correlation, but does not 
necessarily mean that no relationship exists between the variables. r gives the strength of the linear 
relationship but not the statistical significance of the relationship. 
The statistical significance of the Pearson correlation coefficient can be tested by observing 
where the r-value falls on the t-distribution. This has the assumption that the data being sampled from 
a normal is normally distributed. One-tailed tests are used and a value that falls above the 95% 
cumulative level of the t-distribution is considered significant. Bonferroni correction (Dunn, 1961) has 
been used to correct for the increased chance of false positives from the multiple correlation tests. For 
the 28 distinct Pearson correlation coefficients used in section 4.3.4, the level of the t-distribution used 
to indicate significance becomes 99.82% with the Bonferroni correction (100 - 5/28). The degrees of 
freedom are determined by the number of data points in the sample minus two. The r-value is 
converted to a t-statistic with the formula shown in Equation 4.3. 
𝑡 = 𝑟 ∙ � 𝑛 − 21 − 𝑟2 
Equation 4.3. Formula to convert Pearson product-moment coefficient r-value to a t-statistic. 
Figure 4.1 shows that to have greater than 99.82% one-tailed significance, the r value needs to be 
greater than 0.467, and for greater than 95% one-tailed significance, the r value needs to be greater 
than 0.312 (values to 3 significant figures). 
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Figure 4.1. Line graph showing the one-tailed t-distribution for a set with 40 data points (38 degrees of freedom), together 
with the r-values that the t-values map to. 
4.2.3 Enrichment factors 
The standard Enrichment Factor (EF) gives a measure of retrieval performance, by expressing 
the multiples of enrichment of the number of positives in a given percentage of the top ranked results 
as compared to the number of positives expected by chance. It is calculated as the ratio of the number 
of positives retrieved to the number expected if the molecules had been picked out by random chance. 
It is calculated using Equation 4.4. 
Enrichment Factor% sample of population =
activessample compoundssample�activespopulation compoundspopulation�  
Equation 4.4. The enrichment factor of a given percentage sample of a population consisting of a number of compounds all 
defined as either active or inactive. 
EF1 is often taken as a standard measure of enrichment in studies of virtual screening (Kitchen et 
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al., 2004). In a real pharmaceutical confirmatory screening phase, testing 1% of a database would be 
impractical given that molecular databases used in virtual screening usually contain millions of 
compounds. To provide a more practically relevant measure of predictive power for hit finding, EF0.1 
has also been used in this thesis, which gives the ratio of actives in the top 0.1% of results to the 
number of actives in the entire population. The DUD database used for the benchmarking in this 
thesis contains between 11 and 444 active compounds per target each combined with 95,171 decoy 
inactive compounds. The EF1 measure considers the top ranked 951 to 961 compounds, and EF0.1 
considers the top ranked 95 or 96 compounds. 
4.2.4 Enrichment curves 
Enrichment curves plot the percentage of the ranked molecules sampled on the x-axis 
(compoundssample/compoundspoplulation) against the percentage of known active ligands in the sample 
(activessample/activespopulation) on the y-axis. An enrichment curve can be used to find the enrichment 
factor for any given sample percentage size, by reading off the y-axis value at the sample percentage 
value on the x-axis, and then dividing it by the x-axis value. 
4.2.5 Receiver Operating Characteristic (ROC) curves 
The Receiver Operating Characteristic (ROC) curve (Fawcett, 2004) plots the True Positive Rate 
(TPR) on the y-axis, against the False Positive Rate (FPR), equivalent to one minus the specificity, on 
the x-axis. As the fraction of actives in the population decreases, the ROC curve will tend towards the 
enrichment curve. TPR and FPR are calculated by the equations shown in Equation 4.5. 
𝑇𝑃𝑅 = 𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 =  𝑎𝑐𝑡𝑖𝑣𝑒𝑠𝑠𝑎𝑚𝑝𝑙𝑒𝑎𝑐𝑡𝑖𝑣𝑒𝑠𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
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𝐹𝑃𝑅 = 𝐹𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝐹𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝑇𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 = 𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑒𝑠𝑠𝑎𝑚𝑝𝑙𝑒𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑒𝑠𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 
Equation 4.5. Formulae for the True Positive Rate (TPR) and False Positive Rate (FPR) of a population consisting of a 
number of compounds all defined as either active or inactive. 
A metric commonly derived from the ROC curve is the Area Under the Receiver Operating 
Characteristic (AUROC), which gives a measure of performance calculated from the true positive 
retrieval rate over the whole retrieval process. 
4.2.6 Robust initial enhancement 
Robust Initial Enhancement (RIE) was developed by Sheridan et al (2001), as a metric to evaluate 
the performance of a ligand-based topological similarity search. RIE is shown in Equation 4.6, and 
weights the early retrieval of active compounds in an ordered list (the “early recognition” problem), 
and is intended for evaluating datasets where there is a high ratio of inactive to active compounds. 
𝑅𝐼𝐸 = ∑ 𝑒−∝𝑥𝑖𝑛𝑖=1
〈∑ 𝑒−∝𝑥𝑖𝑛𝑖=1 〉𝑟
 
Equation 4.6. Formula for Robust Initial Enhancement (RIE) as defined by Sheridan et al (2001). It calculates a weighted 
metric to evaluate retrieval performance of a population of ranked compounds all defined as either active or inactive. 
In the above equation, xi represents the rank of the ith active compound. 1/α represents the 
fraction of the top ranked results defined as being “early recognition” and hence more highly 
weighted. n is the number of actives. The denominator between the angled brackets is the number of 
active compounds expected in the “early recognition” fraction if they were distributed randomly. It is 
calculated using a bootstrapping process: the average of multiple simulations of randomly 
distributing actives throughout the population. 
4.2.7 BEDROC 
The Area Under the Receiver Operating Characteristic gives a measure of true positive rate over 
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the whole prediction set, but as it is unfeasible to test more than a fraction of the entire screening 
database, virtual screening success should be measured by the true positive rate towards the start of 
the prediction set. A weighting of the AUROC measure has been developed, known as the Boltzmann-
Enhanced Receiver Operating Characteristic (BEDROC) (Truchon and Bayly, 2007) which aims to 
address the early recognition problem of virtual screening by giving a much higher weight to the 
earliest retrieved positives. The RIE equation has been altered to include a version of the denominator, 
which calculates the number of actives expected in the “early recognition” fraction if they were 
uniformly distributed throughout the population. The new equation is shown in Equation 4.7. 
𝑅𝐼𝐸 = ∑ 𝑒−∝𝑥𝑖𝑛𝑖=1
𝑛
𝑁
�
1−𝑒−∝
�𝑒
∝
𝑁� �−1
�
 
Equation 4.7. Modified version of the Robust Initial Enhancement (RIE) metric of Sheridan et al (2001) given in Equation 
4.6, as redefined by Truchon and Bayly (2007). 
The RIE value is corrected for the intrinsic variance of the active compounds and for the 
“saturation effect” where a high number of early retrievals can cause the performance metric to reach 
its maximum value too early. The resulting equation for BEDROC is given in Equation 4.8. 
𝐵𝐸𝐷𝑅𝑂𝐶 = 𝑅𝐼𝐸 × 1𝑁 sinh �∝2�cosh �∝
2
� − cosh �∝
2
−
∝𝑛
𝑁
�
+ 11 − 𝑒∝�𝑁−𝑛𝑁 � 
Equation 4.8. Formula for the Boltzmann-Enhanced Receiver Operating Characteristic (BEDROC) as defined by Truchon 
and Bayly (2007). It calculates a weighted metric to evaluate retrieval performance of a population of ranked compounds all 
defined as either active or inactive. 
The α value scales the weighting of the metric: 1/α is defined as the “early recognition” fraction 
of the population that is more highly weighted. Through empirical testing, Truchon and Bayly (2007) 
recommend an α value of 20 as providing the best performance for virtual screening. This value of α 
has been used for all BEDROC calculations in this thesis. 
  123  Assessment of virtual screening power of INDDEx v2 
 
4.2.8 The DUD targets 
There are 40 DUD targets. Each target is a different protein, and for every target there is a 
dataset of compounds active and inactive against that target. The size of the active target datasets 
varies between 11 and 444 compounds, totalling 3,238 compounds (distribution shown in Figure 4.2). 
Some of these compounds are stereoisomers, but these were not removed for the evaluation. Each 
target has a second dataset of inactive decoy ligands. Each decoy dataset is 36 times the size of the 
corresponding active dataset, and the decoys have been selected from the drug-like subset of the 
ZINC database, with compounds chosen as decoys because they resemble the active ligands in 
physiochemistry but differ in structural topology. Some of the decoys in the decoy dataset of one 
target are duplicated in another. Pooling all the inactives from all the target decoy datasets gives 
127,679 compounds, and removing duplicates gives 95,171. These 95,171 compounds were used as 
decoys for all assessments. All active and decoy compounds in the DUD database are provided as 3D 
energy-minimised structures, minimised by the Merck force field MMFF94 (Irwin et al., 2012). 
For every target, there are datasets of molecules given a binary classification of active or inactive 
against that target. Active or inactive classification is defined by whether the compound is known to 
bind to that protein target. See Appendix A for details of each target and a description of its function. 
Figure 4.2 shows the distribution of compound numbers in the 40 target sets. 
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Figure 4.2. Box and whisker plots showing the distribution of the numbers of compounds in the 40 different target sets. Box 
and whisker plots visually represent a five-number summary of a set of numbers. The three horizontal lines making up the 
central box mark the lower quartile, median and upper quartile of the set, and the whiskers coming out of the central box 
extend to the maximum and minimum values of the set. The left-hand plot shows the total active ligands in the target sets, 
and the right-hand plot shows the total with stereoisomers removed. 
4.2.9 Previous work on DUD database 
There have been many other papers that have used the DUD database. The DUD benchmarking 
results used in this paper for LASSO and DOCK are taken from Reid et al (2008), and the data for 
PharmaGist are from Dror et al (2009). The assessment described in this chapter used the same 
benchmarking method on the same targets. The compounds used for training were randomly selected 
without replacement so were inevitably different when testing each methodology. 
4.2.10 Benchmark methodology 
The methodology in this paper duplicates the method used to assess LASSO and DOCK by Reid 
et al (2008), and to assess PharmaGist and DOCK by Dror et al (2009). The data employed is derived 
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from the Directory of Useful Decoys (DUD) (Huang et al., 2006). The DUD database used in this thesis 
was release 2, downloaded April 2011, generated by Huang et al (2006). Further details of the DUD 
data used are given in section 4.2.8, and descriptions of the target proteins and their functions are 
given in Appendix A. 
To assess the power of the virtual screening method, we need to compare it with other methods. 
The methods used in this thesis are two ligand-based virtual screening methods: eHiTS LASSO 
(Zsoldos et al., 2007) and PharmaGist (Schneidman-Duhovny et al., 2008); and a structure-based 
virtual screening method: DOCK (Ewing et al., 2001). For a fair comparison, the same datasets must be 
used, and the same methods for selecting the training data. 
The standard benchmarking method is to compare how well the method under assessment 
performs at retrieving known active ligands from known inactive ligands. Benchmarking tools that 
have been set up for this purpose include the Directory of Useful Decoys (DUD) dataset (Huang et al., 
2006), the Maximum Unbiased Validation (MUV) datasets (Rohrer and Baumann, 2009) and the Astex 
diverse set (Hartshorn et al., 2007). 
The DUD database contains 40 protein targets, each containing a number of known active 
molecules and a much larger number of decoy inactive molecules. Figure 4.3 shows the methodology 
used to form the training and test sets for testing the machine-learning methods. 
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Figure 4.3. Flowchart showing the process of the benchmarking methodology. 
The machine learning method builds a model from the training set that is then used to screen a 
test dataset containing all the target dataset actives not present in the training set, mixed with the 
pooled decoys from all 40 targets with duplicate decoys removed. The compounds were ranked by the 
predicted activity attributed to them by the model, and the ranked data was evaluated using the 
metrics described in section 4.2. For the repeated assessments, the enrichment curves were vertically 
averaged. Vertical averages produce a curve that uses the mean of all the y-values for the curve at all 
points along the x-axis. 
The training set is a subset of the active molecules in a target set. Assessments were made when 
the training data contained 2, 4, 8, 16 and 32 active compounds, and each assessment was repeated 
five times with the compounds selected randomly without replacement, or until there not enough 
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ligands remaining in the dataset to perform another assessment. Equation 4.9 summarises this 
formula. 
𝑅𝑒𝑝𝑒𝑡𝑖𝑡𝑖𝑜𝑛𝑠 𝑜𝑓 𝑎𝑠𝑠𝑒𝑠𝑠𝑚𝑒𝑛𝑡 = 𝑚𝑖𝑛 �5,𝑓𝑙𝑜𝑜𝑟 �𝑎𝑐𝑡𝑖𝑣𝑒 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑𝑠 𝑖𝑛 𝑑𝑎𝑡𝑎𝑠𝑒𝑡
𝑎𝑐𝑡𝑖𝑣𝑒𝑠 𝑖𝑛 𝑡𝑟𝑎𝑖𝑛𝑖𝑛𝑔 𝑑𝑎𝑡𝑎 �� 
Equation 4.9. Formula to decide how many assessment repetitions to perform on each DUD target when learning from 
different numbers of active ligands. “floor” denotes a function that rounds down to the nearest integer. 
Random selection of actives meant that different actives are selected for training data in 
individual assessments when comparing the different virtual screening methods, and the repetitions 
of the assessment are intended to minimise the effects of this variation. For each of the 40 DUD 
targets, there were up to five assessments using different numbers of actives in the training data. This 
gave a total of 737 assessments that were performed, with the numbers of actives, decoys and 
assessments for each individual target shown in Table 4.2.  
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Table 4.2. Each dataset from DUD, showing for each target the number of active ligands, number of decoys, ratio of decoys 
to actives and the number of assessments at each training data size level. Explanations of the abbreviations for the targets in 
the “Target dataset” column and a description of each target’s biological function are given in Table B.1. 
   
Repetitions of assessment 
  
ID Target dataset 
Total active 
ligands 2 4 8 16 32 Decoys 
Decoy : Active 
ratio 
1 HIVRT 40 5 5 5 2 1 1,519 38 
2 VEGFr2 74 5 5 5 4 2 2,906 39.3 
3 ALR2 26 5 5 3 1 0 995 38.3 
4 CDK2 50 5 5 5 3 1 2,074 41.5 
5 COX-1 25 5 5 3 1 0 911 36.4 
6 PDE5 51 5 5 5 3 1 1,978 38.8 
7 InhA 85 5 5 5 5 2 6,532 76.8 
8 COMT 11 5 2 1 0 0 468 42.5 
9 PDGFrb 157 5 5 5 5 4 5,980 38.1 
10 SRC 155 5 5 5 5 4 6,319 40.8 
11 thrombin 65 5 5 5 4 2 2,456 37.8 
12 AChE 105 5 5 5 5 3 3,892 37.1 
13 trypsin 44 5 5 5 2 1 1,664 37.8 
14 COX-2 348 5 5 5 5 5 13,289 38.2 
15 ADA 23 5 5 2 1 0 927 40.3 
16 MR 15 5 3 1 0 0 636 42.4 
17 TK 22 5 5 2 1 0 891 40.5 
18 HIVPR 53 5 5 5 3 1 2,038 38.5 
19 ER agonist 67 5 5 5 4 2 2,570 38.4 
20 PARP 33 5 5 4 2 1 1,351 40.9 
21 GR 78 5 5 5 4 2 2,947 37.8 
22 AmpC 21 5 5 2 1 0 786 37.4 
23 P38 MAP 256 5 5 5 5 5 9,141 35.7 
24 Fxa 142 5 5 5 5 4 5,745 40.5 
25 FGFr1 118 5 5 5 5 3 4,550 38.6 
26 EGFr 444 5 5 5 5 5 15,996 36 
27 AR 74 5 5 5 4 2 2,854 38.6 
28 PR 27 5 5 3 1 0 1,041 38.6 
29 GPB 52 5 5 5 3 1 2,140 41.2 
30 HSP90 24 5 5 3 1 0 979 40.8 
31 HMGA 35 5 5 4 2 1 1,480 42.3 
32 NA 49 5 5 5 3 1 1,874 38.2 
33 PPAR γ 81 5 5 5 5 2 3,127 38.6 
34 PNP 25 5 5 3 1 0 1,036 41.4 
35 ACE 49 5 5 5 3 1 1,797 36.7 
36 GART 21 5 5 2 1 0 879 41.9 
37 SAHH 33 5 5 4 2 1 1,346 40.8 
38 DHFR 201 5 5 5 5 5 8,367 41.6 
39 ER antag 39 5 5 4 2 1 1,448 37.1 
40 RXR alpha 20 5 5 2 1 0 750 37.5 
 
Sum 3,238 200 195 163 115 64 127,679 
 
 
Average 81.0 5.0 4.9 4.1 2.9 1.6 3,192 35.7
 
Std. Dev. 91.3 
     
3,432 76.8 
In the case of INDDEx, inactive molecules are required for use as training data to learn negative 
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rules that indicate inactivity. As the decoys in the DUD database are used for screening, it would have 
been an unfair advantage to INDDEx to be able to learn negative rules from any of the decoys in the 
DUD database. To give a fair test, negative examples were provided by randomly selecting twenty 
molecules from the entries in the drug-like subset of the ZINC database (version 11, downloaded May 
2011) with the molecules in the DUD removed, and making the assumption that they would be 
inactive for all of the targets. The number twenty was chosen to provide a balance between positive 
and negative examples. These same twenty molecules were used as negative examples in the training 
data of all runs of INDDEx in this assessment. The ZINC ID numbers of the molecules used as 
inactives for all training data were: 290973; 337363; 1058986; 2973208; 3909444; 4384514; 4982113; 
5018499; 5065168; 5356968; 5536756; 5752659; 6938389; 8527733; 8817402; 9102259; 9449998; 9571864; 
9950656; 10139965. 
For the multiple targets of the DUD database, fragmentation method 5 was used in this 
assessment because it was known to be a consistently powerful method, as determined in section 
2.4.4. 
4.2.11 Benchmarking INDDEx v2.1 
INDDEx v1 used PLS regression and crashed often. INDDEx v2.1 uses SVM regression and has 
bug fixes to prevent crashes, decreased memory usage and increased speed; when descriptors for a 
screening set are pre-calculated, INDDEx v2.1 has increased speed over INDDEx v1 by a factor of 16.6 
(see section 4.3.7). These enhancements to the methodology allowed a large-scale benchmark to be 
undertaken. Stability problems in INDDEx v1 took the form of crashing when trying to handle certain 
molecules, resulting in incomplete screening and being unable to screen molecular structure files over 
100 megabytes. 
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4.3 Results 
4.3.1 Retrieval data 
Table 4.3 shows the results of the benchmark assessment. Figures are given for performance on 
all forty datasets in DUD. For each dataset, the abbreviation of the target name is given. The third and 
fourth columns show the number of active ligands and decoys for each target. The fifth column is the 
geometric mean Tanimoto similarity between the active ligands in the target set. The sixth to eleventh 
columns give EF1 and EF0.1 values when learning on 2, 8 and 32 active ligands. There are no 
enrichment factor values for training on 32 molecules where there are less than 32 ligands in the target 
dataset. The twelfth and thirteenth columns give the mean AUROC and BEDROC values when 
training on 2, 4 and 8 active ligands. 
For comparison of similarity, 600 compounds were randomly selected from both the entire 
ZINC database and the drug-like subset of the ZINC database and their mean similarities calculated. 
The ZINC compounds in general had a mean similarity of 0.163, and the ZINC drug-like compounds 
had a mean similarity of 0.180. 
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Table 4.3. Summary of results for the DUD screening. Explanations of the abbreviations for the targets in the second column, and a description of each target’s biological 
function are given in Table B.1. Mean similarity is calculated as the geometric mean of the Maximum Common Substructure Tanimoto coefficient. Figures for EF1, EF0.1, 
AUROC and BEDROC are given for training on 2, 8 and 32 active ligands. The BEDROC alpha value is set to 20, as recommended for virtual screening by Truchon and 
Bayly (2007) (see section 4.2.7). There are no enrichment factor values for training on 32 molecules where there are less than 32 ligands in the target dataset. In the case of 
PARP, which has an active dataset size of 33, only one molecule is left to form the test set when training with 32 molecules. This molecule fell outside the 1% ranking 
cut-off, resulting in Enrichment Factors of zero. Data previously published (Reynolds et al., 2012). 
ID 
Target 
dataset 
Active 
ligands Decoys 
Mean 
similarity 
EF1 EF0.1 AUROC BEDROC 
2 8 32a 2 8 32 2 8 32 2 8 32 
1 HIVRT 40 1519 0.219 15.2 35.4 55.6 74 273 556 0.688 0.847 0.955 0.195 0.460 0.702 
2 VEGFr2 74 2906 0.199 22.4 37.3 67.8 101 192 412 0.790 0.868 0.970 0.336 0.503 0.791 
3 ALR2 26 995 0.255 31.7 48.1   275 426   0.890 0.943  0.446 0.652   
4 CDK2 50 2074 0.198 21.5 51.3 80.0 166 360 640 0.717 0.922 0.981 0.304 0.646 0.842 
5 COX-1 25 911 0.276 27.0 58.8   165 255   0.881 0.957  0.429 0.760   
6 PDE5 51 1978 0.204 24.2 61.1 82.1 181 408 564 0.741 0.931 0.990 0.319 0.698 0.896 
7 InhA 85 6532 0.254 58.3 65.9 97.2 529 615 888 0.815 0.871 0.995 0.607 0.681 0.981 
8 COMT 11 468 0.265 60.0 66.7   444 667   0.983 0.993  0.796 0.888   
9 PDGFrb 157 5980 0.262 37.1 72.9 95.6 298 512 668 0.806 0.932 0.995 0.448 0.781 0.970 
10 SRC 155 6319 0.286 58.1 76.2 90.7 401 572 703 0.890 0.955 0.991 0.650 0.813 0.935 
11 thrombin 65 2456 0.347 67.4 77.8 89.1 620 699 780 0.885 0.929 0.959 0.714 0.805 0.898 
12 AChE 105 3892 0.353 65.9 79.8 88.0 537 699 816 0.886 0.958 0.981 0.699 0.821 0.914 
13 trypsin 44 1664 0.384 75.2 82.6 92.3 684 751 923 0.917 0.979 1.000 0.786 0.881 1.000 
14 COX-2 348 13289 0.278 65.9 84.7 91.0 198 218 240 0.959 0.977 0.985 0.785 0.899 0.931 
15 ADA 23 927 0.415 67.1 85.1   436 762   0.992 0.998  0.882 0.962   
16 MR 15 636 0.452 87.7 85.7   585 857   0.974 0.991  0.879 0.900   
17 TK 22 891 0.554 84.0 85.7   390 464   0.995 0.998  0.916 0.961   
18 HIVPR 53 2038 0.248 69.3 86.1 96.2 650 755 962 0.925 0.982 1.000 0.733 0.887 0.997 
19 ER agonist 67 2570 0.345 56.3 87.1 94.3 206 508 600 0.959 0.995 0.998 0.685 0.929 0.965 
20 PARP 33 1351 0.498 85.5 87.9 0.0  818 840 0  0.971 0.978 1.000 0.892 0.911 1.000 
21 GR 78 2947 0.346 74.5 88.3 98.9 671 780 946 0.947 0.993 1.000 0.793 0.927 0.997 
22 AmpC 21 786 0.409 78.9 88.5   547 808   0.968 0.994  0.835 0.935   
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23 P38 MAP 256 9141 0.34 73.9 90.4 98.4 187 215 241 0.904 0.959 0.999 0.766 0.923 0.991 
24 Fxa 142 5745 0.266 88.3 91.4 91.6 644 656 711 0.958 0.964 0.981 0.900 0.921 0.940 
25 FGFr1 118 4550 0.327 71.7 91.6 99.2 605 788 969 0.916 0.984 1.000 0.754 0.929 0.998 
26 EGFr 444 15996 0.412 83.8 91.6 92.8 173 202 213 0.992 0.996 0.997 0.921 0.959 0.967 
27 AR 74 2854 0.311 73.2 92.3 98.8 351 514 615 0.971 0.986 0.998 0.809 0.918 0.976 
28 PR 27 1041 0.338 78.3 93.0   717 851   0.949 0.991  0.875 0.996   
29 GPB 52 2140 0.489 92.8 94.1 85.0 304 523 650 0.967 0.969 0.961 0.891 0.920 0.907 
30 HSP90 24 979 0.365 64.0 94.4   640 887   0.905 0.998  0.664 0.975   
31 HMGA 35 1480 0.47 92.1 94.4 66.7 830 917 667 0.987 0.983 1.000 0.939 0.942 0.995 
32 NA 49 1874 0.355 95.7 94.6 100.0 749 893 1000 0.998 0.998 1.000 0.968 0.977 0.998 
33 PPAR γ 81 3127 0.439 95.4 95.6 93.2 896 898 884 0.988 0.988 0.986 0.961 0.963 0.956 
34 PNP 25 1036 0.5 82.2 96.5   778 864   0.986 0.999  0.890 0.983   
35 ACE 49 1797 0.345 82.6 96.6 88.2 434 673 882 0.995 0.998 0.999 0.917 0.969 0.985 
36 GART 21 879 0.465 99.4 98.7   907 936   1.000 1.000  0.996 0.997   
37 SAHH 33 1346 0.436 99.4 99.0 100.0 729 780 1000 0.999 0.999 1.000 0.983 0.987 0.996 
38 DHFR 201 8367 0.353 94.4 99.7 99.9 223 241 275 0.999 1.000 1.000 0.979 0.996 0.997 
39 ER antag 39 1448 0.296 65.4 100.0 100.0 562 976 1000 0.967 1.000 1.000 0.792 0.997 0.999 
40 RXR alpha 20 750 0.715 100.0 100.0   989 1000   1.000 1.000  0.999 1.000   
 Mean 81.0 3192 0.357 69.2 82.7 86.9 492 631 672 0.926 0.970 0.990 0.753 0.876 0.947 
 Std. Dev. 91.3 3432 0.108 23.8 17.1 20.3 253 247 279 0.082 0.039 0.014 0.214 0.134 0.071 
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4.3.2 Retrieval performance compared with other methods 
The retrieval performances of INDDEx, LASSO, PharmaGist and DOCK are compared against 
each other with the bar graphs showing mean enrichment factors in Figure 4.4 and Figure 4.5, and 
with the enrichment curves shown in Figure 4.6, from which the enrichment factors can be derived. 
INDDEx’s retrieval performance when trained using training datasets of 2, 4, 8, 16 and 32 actives were 
obtained over all forty DUD targets, and for each of the five training dataset sizes, the enrichment 
curves were vertically averaged over all forty targets. Figure 4.6 shows the averaged enrichment 
curves for INDDEx learning on training datasets of 2, 8 and 32 actives. The results for INDDEx are 
compared with enrichment factors and enrichment curves for LASSO as given in Reid et al (2008) and 
for PharmaGist and DOCK as given in Dror et al (2009). It should be noted that the PharmaGist paper 
only gave enrichment factor results for six DUD targets chosen to be representative (ADA, ALR2, ER 
antagonist, InhA, P38 and TK), so for the right-hand graph in Figure 4.4, INDDEx EF0.1 results are 
given for learning on the same six “representative” targets, and Figure 4.5 compares PharmaGist’s EF1 
results with INDDEx’s EF1 when both learning on the “representative” targets. 
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Figure 4.4. Two bar graphs showing enrichment factors at 1% (left- hand graph) and 0.1% (right-hand graph) for 
INDDEx, PharmaGist, LASSO and DOCK when learning from different training dataset size. The labels on the x-axis 
show the methodology name followed by the number of active ligands used in the training data. Data for PharmaGist and 
DOCK are taken from Dror et al (2009) and the results for LASSO are taken from Reid et al (2008). EF0.1 results for 
DOCK and LASSO were not given, but Figure 4.6 shows that they were very low. Error bars of one standard deviation are 
shown (except where separate results were not available, as in the cases of LASSO 8 at EF1 and of PharmaGist 5 & 10 at 
EF0.1). Versions of these bar graphs have been previously published in Reynolds et al. (2012). The data for the 1% graph is 
from learning on all targets except in the case of PharmaGist which only learned on six representative targets chosen by 
Dror (ADA, ALR2, ER antagonist, InhA, P38 and TK). The data for the 0.1% graph is from learning on the six 
representative targets only for both PharmaGist and INDDEx. 
 
Figure 4.5. Bar graph showing enrichment factors at 1% for PharmaGist learning from its six targets chosen as 
representative (ADA, ALR2, ER antagonist, InhA, P38 and TK) alongside the INDDEx EF1 values when learning from 
just those six representative targets. 
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Figure 4.6. Line graph showing enrichment curves for the INDDEx, LASSO, PharmaGist and DOCK methodologies 
compared in this chapter. Each enrichment curve show the retrieval of actives vertically averaged across all forty DUD 
targets from the pooled decoys in all of DUD (or six targets in the case of PharmaGist). The legend shows the methodology 
name followed by the number of active ligands used in the training data. Data for PharmaGist and DOCK are taken from 
Dror et al (2009) and the results for LASSO are taken from Reid et al (2008). A version of these enrichment curves has 
been previously published (Reynolds et al., 2012). 
4.3.3 INDDEx’s performance on individual targets 
Figure 4.7 compares the performance of INDDEx (defined as EF1 when learning on eight actives) 
on the individual DUD targets, with each other, with the total number of active ligands in the target 
datasets and with the mean similarity of those datasets (similarity measures as discussed in section 
1.8). These two factors were thought likely to have a strong effect on performance. The bar graph 
shows that as expected, the mean similarity is positively correlated with performance, but also shows 
the lack of a relationship between target set size and performance. The EF1 of INDDEx has a Pearson 
product-moment coefficient of 0.71 with the mean similarity of the target datasets, and is not 
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significantly different at 0.70 when only highly diverse datasets (mean similarity < 0.3) are considered 
for the correlation. Correlations between performance metrics and different methodologies are 
examined in more detail in section 4.3.4. 
 
Figure 4.7. Bar graph showing performance, mean similarity and number of active ligands in the set for each of the 40 
targets. Targets are ordered by performance. The Enrichment Factor is calculated when learning from eight actives. Data 
previously published (Reynolds et al., 2012). 
The precision/recall graph in Figure 4.8 shows how precision decreases with recall. It shows 
that the curve improves with increasing numbers of molecules in the training data, but the 
improvement drops off with increasing numbers of molecules in the training data, with there being no 
improvement when increasing from 16 to 32 actives in the training data. 
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Figure 4.8. Line graph of Precision-Recall curves. Data averaged across the 40 DUD targets. 
Figure 4.9 shows the F-measure plotted against the threshold used to classify the prediction 
value as active or inactive. F-measure gives a combined measure of precision and recall, giving an 
overall measure of information retrieval. It shows that the maximum information retrieval at the 
optimal cut-off point gets consistently better with increasing numbers of active molecules in the 
training data. Each doubling of the number of active molecules in the training data results in the F-
measure increasing by about 0.2. It also shows that the increasing proportion of actives in the training 
set is reflected in an increased activity prediction value for the members of the test set. 
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Figure 4.9. Line graph of F-measure plotted against the classification threshold used to classify a molecule as active or 
inactive. Data averaged across the 40 DUD targets. 
4.3.4 Correlation between metrics and methods 
In order to see which metrics were related to each other, the differing performances across 
different targets achieved by INDDEx, PharmaGist and DOCK, and whether they did relatively well 
or poorly on similar datasets, all of the metrics and methods were correlated against each other with 
linear regression using the Pearson product-moment coefficient, and the results are given in Table 4.4.  
Table 4.5 gives p-values calculated using Student’s t-test (see section 4.2.2) for the significance of 
each corresponding Pearson product-moment coefficient in Table 4.4. Values that are below the 
p-value for significance (0.05 corrected to 1.79 × 10-3 (3SF) by Bonferroni correction for 28 tests) are 
highlighted in red. The correlations with the numbers of actives (the first row) have their significance 
calculated as two-tailed, and the rest of the significances are calculated as one-tailed because the 
correlations are expected to be positive. Increasing numbers of actives are not necessarily positively 
correlated because the set as a whole could be more diverse.  
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Table 4.4. A matrix showing the correlation, quantified by the Pearson product-moment coefficient, between the various 
metrics and methods used. The AUROC, BEDROC EF1 and EF0.1 values for INDDEx are for training on eight actives. The 
PharmaGist values are for training on ten actives. 
  
Geometric mean 
similarity AUROC BEDROC INDDEx EF1 INDDEx EF0.1 PharmaGist DOCK 
Actives -0.17 -0.02 0.06 0.11 -0.56 -0.07 -0.28 
Geometric mean 
similarity 
 
0.58 0.64 0.64 0.50 0.48 0.45 
AUROC 
  
0.94 0.84 0.50 0.35 0.37 
BEDROC 
   
0.96 0.55 0.40 0.31 
INDDEx EF1 
    
0.57 0.44 0.31 
INDDEx EF0.1 
     
0.55 0.19 
PharmaGist 
      
0.12 
 
Table 4.5. Correlation significance matrix of the correlation coefficients in Table 4.4. Significance was calculated using 
Student’s t-test, and significant correlations are highlighted in red (uncorrected p-value of 0.05 corrected to 1.79 × 10-3 
(3SF) by Bonferroni correction for 28 tests). The correlations with the numbers of actives (the first row) have their 
significance calculated as two-tailed, and the rest of the significances are calculated as one-tailed because the correlations are 
expected to be positive. 
  
Geometric mean 
similarity AUROC BEDROC INDDEx EF1 INDDEx EF0.1 PharmaGist DOCK 
No. of actives 0.297 0.912 0.715 0.516 2.0×10-4 0.651 0.076 
Geometric mean 
similarity 
 
4.4×10-5 5.0×10-6 4.9×10-6 4.7×10-4 8.1×10-4 1.9×10-3 
AUROC 
  
3.1×10-19 5.0×10-12 4.7×10-4 1.4×10-2 9.6×10-3 
BEDROC 
   
2.2×10-23 1.0×10-4 4.9×10-3 2.7×10-2 
INDDEx EF1 
    
6.5×10-5 2.4×10-3 2.7×10-2 
INDDEx EF0.1 
     
1.3×10-4 0.121 
PharmaGist 
      
0.234 
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There are two key points that are shown by the correlation data. Firstly, the performances of 
INDDEx and PharmaGist are highly correlated with the mean similarity of the DUD target sets, but 
DOCK is not significantly correlated with similarity because INDDEX and PharmaGist learn 
predictive models on training sets while DOCK calculates affinity from structure according to a 
molecular mechanics force field. This shows that the ligand-based INDDEX and PharmaGist are 
advantaged by training sets containing many similar molecules but DOCK is structure-based so the 
similarity between the molecules is not related to performance (also shown in Figure 4.10). Secondly, 
DOCK shows less correlation with the INDDEx and PharmaGist methods than the INDDEx and 
PharmaGist methods do with each other, indicating that the ligand-based methods can perform more 
successfully on different targets than those that are successful in a structure-based method like DOCK. 
Figure 4.10 shows a scatter plot comparing the performance of the INDDEx and DOCK methods 
on all the targets to the mean similarity of the active molecules in those targets. As would be expected, 
in general, the more similar the active ligands within the target dataset, the better the performance on 
both methods, but even at low similarity there are still high rates of performance for INDDEx. 
 
Figure 4.10. Scatter plot showing, for each of the 40 DUD targets, the mean similarity of the target dataset against the 
mean 1% Enrichment Factors achieved by INDDEx v2.1 and DOCK. EF1 for INDDEx calculated when learning on eight 
actives. The plot also shows the mean similarity of the drug-like compounds in ZINC, 0.180, calculated from 600 
compounds randomly selected from the drug-like subset of the ZINC database. 
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4.3.5 Examples of Rules Found 
The rules derived by INDDEx take the form of a series of logical rules derived from the training 
data. Each of the rules has a correlation to the training data, and the rules are classed as positive or 
negative according to whether they have a positive or negative correlation. 
Examples of two of the rules derived by INDDEx are shown in Table 4.6. The rules shown are 
taken from the predictive model derived by INDDEx for the platelet derived growth factor receptor 
kinase (PDGFrb) target, learning from 16 active ligands. One positive and one negative rule are shown 
on examples of an active ligand and an inactive decoy respectively. 
Table 4.6. Examples of rules derived by INDDEx. The fit to training data is the Pearson correlation coefficient of the rule to 
the active and against the inactive molecules: 1.0 would indicate coverage of all actives only, 0.0 equal coverage of actives 
and inactives, −1.0 coverage of all inactives only. The two rules are shown on examples of two active ligands from the 
PDGFrb target data set that conform to the rules given in Table 4.6. The molecule visualisations and descriptions of the 
rule are direct output of INDDEx v2. 
Rule (all distances have a tolerance of ±1 
Ångström) 
Correlation of 
coverage to 
training data 
Description 
 
ZINC00600761 (active) 
0.586 Fragment one (shown in green) consists of a 
nitrogen atom connected to a carbon via an 
aromatic bond and a carbon via an aromatic 
bond; these atoms are connected to a total 
of one hydrogen. Fragment two (shown in 
red) consists of a carbon atom connected to 
a carbon via an aromatic bond and a carbon 
via an aromatic bond; these atoms are 
connected to a total of two hydrogens. The 
distance between the nitrogen in fragment 
one and the initial carbon in fragment two is 
4.80 ± 1.0 Å. 
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ZINC00290973 (inactive) 
-0.383 Fragment one (shown in green) consists of a 
carbon atom connected to a carbon via an 
aromatic bond and a carbon via an aromatic 
bond; these atoms are connected to a total 
of three hydrogens. Fragment two (shown 
in red) consists of a oxygen atom connected 
to a carbon via a double bond; none of 
these atoms are connected to any 
hydrogens. The distance between the initial 
carbon in fragment one and the oxygen in 
fragment two is 7.25 ± 1.0 Å. 
4.3.6 Scaffold-hopping 
The enrichment curves in Figure 4.11 show the performance of INDDEx in retrieving molecules 
structurally diverse from the molecules in the training data, giving an indication of INDDEx’s 
scaffold-hopping capability. By inspection, a pair of molecules with a Maximum Common 
Substructure Tanimoto similarity coefficient less than or equal to 0.5 are classified as being 
structurally different (see section 1.8). For each INDDEx run, a molecule in the screening data with 
Tanimoto similarity coefficient less than or equal to 0.5 to any molecule in the training data used to 
generate the INDDEx model is considered a scaffold-hopping challenge. Enrichment curves are 
constructed which only consider scaffold-hopping challenge molecules, so that the y-axis plots the 
percentage of known active scaffold-hopping challenge molecules ligands in the sample (scaffold-
hopping challenge activessample/ scaffold-hopping challenge activespopulation). Figure 4.11 shows that all training 
data sizes have a good enrichment of scaffold-hopping ability, and that scaffold-hopping ability is 
improved when increasing that training data size from 2 to 8, but there did not seem to be any 
improvement in performance when increasing training data size from 8 to 32. At a training data size 
of 32, there were very few scaffold-hopping challenge molecules in the screening data, giving a 
  143  Assessment of virtual screening power of INDDEx v2 
 
paucity of data and resulting in the irregular line on the graph. 
 
Figure 4.11. Scaffold-hopping. Enrichment curves calculated only considering molecules with less than 0.5 Tanimoto 
similarity to the any molecule in the training set. 
4.3.7 Speed and timing testing 
Tests were performed on an Intel i7-3820 CPU @ 3.60GHz, running on a single core, with all data 
reading/writing from a Samsung PM83 Solid state drive. To perform comparable tests between the 
speeds of INDDEx v1 and INDDEx v2.1, both versions learned a predictive model on the 
Cholecystokinin type B receptor training dataset of 21 molecules, and then screening was performed 
on both PubChem Bioassay 1458 (containing 464 molecules) and on the DUD database using a pooled 
dataset of all decoys and active ligands across all the DUD targets (containing 99,132 molecules). 
Fragmentation 2 (see section 2.4.3) was employed as a simple single-shell fragmentation method. 
Results for screening Bioassay 1458 were averaged over five screening runs, and the results for 
screening DUD are from a single run. There are no results for INDDEx v1 screening DUD because it 
crashes due to the number of molecules. Results for the screening times per molecule are compared in 
Figure 4.12. There is negligible difference between INDDEx v2’s screening time when it is not using 
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descriptors and when it is using pre-calculated descriptors. The total time taken for INDDEx v2 to 
screen the whole DUD database was 6,644 seconds when calculating descriptors on the fly and 360 
seconds when using pre-calculated descriptors. To screen the 38 million molecules in the ZINC 12 
database would take about 38 hours CPU time at this speed using pre-calculated descriptors. 
 
Figure 4.12. Bar graph of screening time per molecule in milliseconds, compared for INDDEx v1 and INDDEx v2.1. 
4.4 Discussion 
The structural homogeneity of the active ligands in the some of the DUD target datasets is a 
limitation because it gives a false impression of retrieval power. Decreasing topological diversity is 
strongly correlated with performance for ligand-based methods as shown in Table 4.4, and to a fair 
degree in the structure-based method DOCK, although to a lesser extent. However, calculating mean 
similarity of the target datasets as shown in Table 4.3 shows that some of the targets have mean 
similarity close to the 0.180 mean similarity calculated from randomly selected drug-like molecules 
from the ZINC database. Even in the most structurally diverse target sets, INDDEx gives strong 
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results in the various performance metrics. To overcome the structural similarity problem, the 
estimation of scaffold-hopping ability test was used, and showed that INDDEx still performed 
strongly when the most structurally similar molecules to the training data were ignored. This held 
true even when the training data contained low numbers of active compounds to derive positive rules 
from. 
The choice of methods to test INDDEx against and the choice of benchmarking method were 
limited by the requirement of being able to duplicate a method used in existing papers. Many 
software packages that are widely used in the pharmaceutical industry are not freely available and 
were prohibitively expensive to include in this assessment comparison. 
As noted in section 1.5, there is a difficulty in defining scaffold-hopping. The definition of a 
scaffold is highly subjective, and there is no real consensus in the chemoinformatics community about 
what constitutes scaffold-hopping. 
4.5 Conclusion 
This chapter reported a development process taking INDDEx v1 to INDDEx v2.1, and a 
subsequent assessment against other virtual screening methods. The key results are that when 
screening the DUD targets with INDDEx v2, using a training set of 8 active ligands, INDDEx v2.1 
achieved an EF1 of 82.7 (standard deviation of 20.3) and EF0.1 of 631 (standard deviation of 247). The 
EF1 compares with EF1s of 17.3 for DOCK learning on a crystal structure with bound ligand, 31.6 for 
PharmaGist learning on 10 molecules and 18.3 for LASSO learning on 8 molecules. INDDEx achieves 
an EF1 of 63.6 when only looking at structurally distinct molecules (less than 0.5 Tanimoto structural 
similarity to molecules in the training set). 
INDDEx v2 is faster than INDDEx v1, and is now able to manage memory usage to prevent 
memory overflow, particularly in the screening and rule generation processes, both of which are 
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memory intensive. INDDEx v2 has enhanced usability over INDDEx v1, both in providing the input 
and because of the graphical output of the rules, which project each rule onto an active molecule with 
an accompanying description of the rule automatically generated by the program. 
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Chapter 5 Incorporation of virtual synthetic reactions into INDDEx 
5.1 Summary 
This chapter describes the addition of a set of virtual reactions to the INDDEx program to 
produce a system, termed INDDEx v3, which explores synthetic space around potential hits. This 
chapter also introduces a new technique known as PLoRRS (Partial Logical-Rule Reactant Selection) 
which has been integrated into INDDEx v3. PLoRRS is a de novo design algorithm incorporated into 
the INDDEx methodology that combines logic-based virtual screening with virtual chemistry to 
explore theoretical synthetically accessible molecular space. 
In this chapter: 
Section 5.2 introduces the challenges of effectively exploring chemical space to find novel hits, 
and describes the methods developed in this chapter. 
Section 5.3 outlines how virtual reactions can extend the INDDEx method to search synthetic 
space. 
Section 5.4 explains the ChemAxon virtual reaction scheme, describing how a reaction is 
encoded (5.4.1), how rules are used to predict if a reaction can take place (5.4.2) and listing the 
reactions encoded in INDDEx v3 (5.4.3). 
Section 0 describes how the virtual reactions are integrated with the INDDEx virtual screening 
methodology and rules, giving an overview of the method (5.5.1), and how the INDDEx rules are 
incorporated into a scoring system to guide the selection of reactants (5.5.2). 
Section 5.6 describes how the reaction descriptors are used to convert reactants to a predicted 
product, summarising the process (5.6.1) and giving an example of how the structural transformation 
takes place ( 5.6.2); from initial reactant molecule (5.6.3) with partner reactant (5.6.4) to product (5.6.5). 
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Section 5.7 gives the details and results of an assessment designed to quantify the extent to 
which the virtual reaction method opens up search space. 
Section 5.8 describes the method developed to filter the newly-opened up synthetic search space 
to allow more efficient searching. 
Section 5.9 details an assessment of the PLoRRS method that was carried out using the target 
sets of the DUD database, using held back data to estimate how well INDDEx v3 can retrieve 
molecules similar to known hits that were not included in the training data. 
Section 5.10 provides the results of tests comparing the speed of INDDEx v3 to that of 
INDDEx v2. 
Section 5.11 summarises the achievements of the work (5.11.1) and the results of the two 
assessments (5.11.2 and 5.11.3), comparing the work in this chapter to previous work in the same area. 
5.2 Introduction 
Drug development typically involves a two-phase process of finding hits that are based on 
chemically available molecules, followed by synthetic modification to obtain a molecule with 
improved properties known as a “lead.” This was the process followed for the assessment described 
in Chapter 3. Often the hit to lead process is guided by the experience of a medicinal chemist and their 
knowledge of synthetic reactions. Small molecule chemical space is too large to be fully explored (see 
section 1.6), and in addition, there are often leaps in activity between hit and lead resulting in a hit 
with relatively low activity being the precursor to a highly active lead. There is a possibility that such 
a hit would not have been identified and prioritised for lead series exploration in a typical in silico 
chemical screening process. 
Cost is also an important concern when exploring potential leads. Often individual molecules 
can be purchased for under a hundred pounds, and pharmaceutical companies possess in-house 
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screening libraries of hundreds of thousands of molecules. In contrast, the cost of synthesising a 
molecule is far greater; typically, a commercial price is at least one thousand pounds. The cost of 
exploration prevents the exploration of a large chemical space of leads. It would therefore be valuable 
to develop a method to predict the activity of leads rather than hits. 
This chapter describes the development of a new method known as known as PLoRRS (Partial 
Logical-Rule Reactant Selection), which combines a system of virtual synthetic reactions with the 
logical rules derived by INDDEx so that rules identified by the program can be used to simulate in 
silico the exploration of potential leads. Simulation allows a far more thorough exploration of potential 
synthetic space than could ever be achieved in vitro, and will allow the identification of molecules 
where a single synthetic step could produce large increases in activity. 
An implementation of PLoRRS was developed whereby INDDEx scanned a molecular database 
for potential molecules that had low activity in themselves, but used the INDDEx rules to identify 
those that had a high potential for their synthetic derivatives to have high activity. These potential 
molecules are used to participate in virtual addition reactions with a specified fragment to generate 
synthetically feasible product molecules following computationally formalised synthetic rules from 
ChemAxon. Molecules with a high measurement of potential for being synthetically modified into 
active molecules, or “partial limited matches” can be passed into the new reaction simulation 
program, so that focussed libraries of new, modified, molecules are generated around these partial 
matches. 
Several other groups have explored methods of incorporating the concept of theoretically 
synthetically accessible molecules into virtual screening methods. Previous work in this area is 
described in sections 1.10 and 1.11 of the introduction. 
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5.3 Using virtual reactions to extend INDDEx 
The available methods of computational chemical reactions and synthesis were reviewed in 
section 1.11 and the ChemAxon method was selected as being the easiest to integrate, not a black-box 
technology, and easy to expand upon. In order to add in chemical synthesis into INDDEx it was 
necessary to develop bespoke code to produce products given reactants and the ChemAxon rules. A 
Java module was written that takes SMIRKS (Simple Molecular Input Reaction Kinetic Strings) 
transformations and matches up molecular structures to the reactants in the transformation. If the 
reactants match, they are joined together according to the SMIRKS transformation to make a product 
molecule. Another module was written to parse the ChemAxon data on reaction exclusion, reactivity 
and selectivity from the data files, and to apply them to a molecule to see if it can participate as a 
reactant in the reaction. These programs have been integrated into INDDEx to apply this process to 
the molecules that are found to have high predicted activities. Synthesisable derivatives can be 
generated from the high-scoring molecule found by INDDEx (for clarity this will henceforth be 
termed the initial reactant) and a fragment-like co-reactant (henceforth termed the partner reactant). 
The product molecule can be rescored using the INDDEx model. The PLoRRS method concentrates on 
the use of fragment-like molecules to improve activity, and indeed, fragment-based drug discovery 
has attracted a lot of recent attention (Hajduk and Greer, 2007; Murray and Rees, 2009) and has been 
discussed in section 1.9. 
A flowchart detailing the new process developed in this chapter is shown in Figure 5.1. This 
project will concentrate on screening the dataset of purchasable molecules that fulfil some, but not all, 
of the rules (those molecules are termed “partial limited matches”), and subsequently altering the 
molecules to fit the remaining rules using a database of organic chemical synthesis reactions to 
combine these molecules with the dataset of fragment-like molecules. Even if the virtual reaction 
program is not perfect, molecules that would be difficult to synthesise can be removed by examination 
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by a chemist as long as there are not too many. By this method, the program will be able to move to 
new, synthetically accessible compounds from the standard library of compounds. By using virtual 
synthesis methods, the program can computationally explore a far greater section of synthetically 
accessible chemical space. 
 
Figure 5.1. Flowchart summarising the steps in the INDDEx v3 virtual reaction and rescreening process. 
Because the virtual syntheses are performing addition reactions, there is the problem of 
generating virtual products that have molecular weights that are above the molecular weight criterion 
in drug likelihood profiles: 95% of drug weights fall below 625 daltons (Bickerton et al., 2012) (see 
section 1.3.2). To avoid this, and to cut down on search space, during this assessment only the 
fragment-like subset of ZINC (the “Frags now” dataset used in these assessments contains 474,770 
molecules) was screened for initial reactants, subsequently modifying each initial reactant using the 
entire fragment-like subset as potential partner reactants. 
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This step uses reaction data knowledge to take a molecule (in this case, one found by partial 
matching to the derived rules), and obtain a list of all the reactions it could participate in. Once this 
has been achieved, the program searches for suitable molecules that can participate as partner 
reactants in the reaction(s). The next step is to use a reaction transformation scheme to take the 
molecules involved as initial reactant and partner reactant, and produce a product molecule that 
might be expected as the result of the reaction. Molecular structure, molecular substructure patterns, 
and chemical reactions are described using a system of related chemical notation systems known as 
SMILES, SMARTS and SMIRKS respectively. 
5.4 The ChemAxon virtual reaction scheme 
5.4.1 Describing a virtual reaction using SMIRKS 
Virtual reactions are carried out with the Simple Molecular Input Reaction Kinetic Strings 
(SMIRKS) (James et al., 2005), which allow synthetic reactions to be expressed as transformations 
between reactant and product SMILES (Simplified Molecular Input Line Entry System) with numbers 
mapping corresponding atoms before and after the transformation (see Figure 5.2). ChemAxon’s 
Reactor tool (Pirok et al., 2006) contains a library of SMIRKS along with rules relating the presence or 
absence of elements of substructure, hydrogen donors/acceptors, aromatic ring systems and partial 
charges on atoms to whether a molecule can participate in a reaction or not. 
 
Figure 5.2. The Baylis-Hillman Alkylation reaction, with the numbers that map to the atoms in the reactants and the 
corresponding atoms in the product. 
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5.4.2 Predicting a virtual reaction with ChemAxon rules 
ChemAxon Reactor (Pirok et al., 2006) contains a database of 145 reactions, with each of the 
reactions assigned its own SMIRKS description (an example of which is shown in Figure 5.3), giving 
the atomic transformation between reactants and products, along with a series of chemical rules that 
the reactants need to obey for the reaction have the possibility of occurring. The ChemAxon rules are 
divided into two sets: “Exclude” which exclude reactants containing functional groups that would 
interfere with the reaction process, and “Reactivity” which checks that the atoms in the reactants hold 
sufficient nucleophilicity and electrophilicity to react together. Almost all of these rules take the form 
of SMARTS (SMiles ARbitrary Target Specification) expressions, which can be matched up to the 
substructure of a molecule. These rules are used to check which reactions can take place on an initial 
reactant. A third set of rules, “Selectivity,” gives an expression for the favourability of the reaction, so 
if the reaction has more than one outcome, this allows the products to be ranked. A tolerance value is 
used as a cut-off, indicating where reactions become too unfavourable to occur. All reactions have 
additional information such as yield, temperature, time taken and solvent type. An example of some 
of the rules as displayed in the ChemAxon Reactor viewer is shown in Figure 5.4. 
Integrating the knowledge data contained in ChemAxon Reactor into INDDEx v2 allows scope 
for additional checks of the molecules and reaction rules, and eliminates the need to convert 
molecules between the Java Objects and flat files. It is relatively easy to add new rules, data and whole 
new reactions to the ChemAxon database, as it uses an XML format to store the data, where XML tags 
mark the reaction SMIRKS and reaction rules. The reaction data files also give percentage ranges for 
reaction yield that can be used to guide choice of reactions. 
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Figure 5.3. A reaction transformation for the Baeyer-Villiger carbonyl oxidation, as displayed in ChemAxon Reactor, and 
written as a SMIRKS expression below. 
 
Figure 5.4. Examples of some exclusion rules in ChemAxon Reactor and a reaction transformation, both for the Baeyer-
Villiger carbonyl oxidation. 
5.4.3 Reactions encoded in INDDEx v3 
Table 5.1 lists the 26 two-reactant addition reactions taken from ChemAxon Reactor that have 
been included in INDDEx v3 reaction module. These are used throughout the tests and assessments 
described in this chapter. 
  
 
[H,C][C:1](=O)[H,C:2] >> [H,C][C:1](=O)[O:3][H,C:2] 
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Table 5.1. List of the 26 virtual reactions provided by ChemAxon that are incorporated in INDDEx v3. 
Acid azide synthesis Houben Hoesch phenol acylation 
Baylis-Hillman vinyl alkylation Imino ester synthesis 
Benary conjugated carbonyl synthesis Isocyanate with nucleophile 
Borch reductive amination Knoevenagel condensation 
Chan Lam coupling Kumada coupling 
Darzens epoxide synthesis Perkin reaction 
Fischer indole synthesis Quellet chloroalkylation 
Friedel-Crafts acylation Ritter reaction of alcohols 
Goldberg coupling Ritter reaction of alkenes 
Grignard addition to carbonyl compounds Stille carbonyl synthesis 
Guaresky Thorpe pyridone synthesis Stille coupling 
Heck reaction Suzuki coupling 
Henry nitro condensation Ullmann condensation 
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5.5 Integrating virtual reactions with INDDEx 
5.5.1 Overview of method 
Figure 5.5 shows the stages and materials involved in the INDDEx v3 process. It is a 
development of the visualisation of the previous version of INDDEx shown in Figure 2.1. 
 
Figure 5.5. Graphical visualisation of the additions to the INDDEx process. Stock images in this collage provided by 
iStockphoto®. 
The stages in the procedure shown in Figure 5.5 are: 
1. The INDDEx SVILP algorithm generates a QSAR model of weighted rules, as described in 
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section 2.4.2. 
2. A molecular database is screened. 
3. Molecules are scored according to their “partial limited matches,” using the logical rules from 
step 1, and the molecules with the highest partial limited matches are selected. 
4. The selected molecules are modified through the application of all viable virtual reactions. 
5. The derivative product molecules resulting from the virtual reactions are rescreened and 
scored for predicted activity using the SVILP model derived in step 1. 
5.5.2 Fulfilment 
So that the number of molecules to be explored can be reduced to a manageable number, a 
fulfilment score was developed that uses the INDDEx logical rules without support vector weighting 
to give a score of the potential of a molecule to form active compounds one synthetic step away. 
INDDEx uses the following scoring criteria to identify molecules that could potentially have 
more logic-based rules fulfilled after undergoing a reaction: INDDEx takes the top 100 positive rules 
that have the highest Pearson product-moment correlation with the data and that are in the format 
“Fragment A must be x Ångströms distant from Fragment B.” One point is assigned to a molecule for 
any rule only half-filled (only Fragment A or only Fragment B match on the molecule), when the 
distance x between the fragments in the rule is at least two Ångströms. The distance requirement 
x ≥ 2 Å eliminates rules that are looking for the presence of a single contiguous substructure rather 
than two distinct fragments. The molecules are then rank ordered from highest to lowest score. If a 
molecule matches both Fragment A and Fragment B of a rule, the rule is ignored by the scoring 
system as it is already considered to be fulfilled. 
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5.6 Performing the structural transformation of reactants to products 
5.6.1 The virtual reaction process 
The virtual reaction process has the following steps: 
1. Test a list of reactions to determine whether the molecule can participate as the initial reactant. 
2. If it can, test a library of fragment-like molecules to see which of them can participate as the 
partner reactant. 
3. Where there are matches for both reactants, map them to a product molecule. 
4. Carry out energetic minimisation on the 3D structure of the product molecule. 
5.6.2 Describing an example of a reaction structural transformation 
Once the virtual reaction has been confirmed by the ChemAxon rules as being able to take place, 
then INDDEx v3 needs to generate the 3D product molecule using the SMIRKS reaction 
transformation. This section describes the method for product structure generation from a virtual 
reaction that is programmed into INDDEx v3. An example reaction (Baylis-Hillman alkylation), initial 
reactant (a morphine derivative) and partner reactant (a fragment-like molecule) are shown in Figure 
5.6, Figure 5.7, Figure 5.8, Figure 5.9 and Figure 5.10. 
5.6.3 Initial reactant molecule 
The initial reactant molecule is a molecule found by INDDEx that is to undergo a series of 
reactions with partner reactants. The initial reactant has passed the ChemAxon rules and so is 
predicted to be able to participate in the reaction. Figure 5.6 shows an example initial reactant 
molecule that has been predicted by the ChemAxon rules to be able to participate in the 
Baylis-Hillman alkylation reaction. 
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Figure 5.6. An example of an initial reactant molecule. A molecule predicted by INDDEx to have high activity and selected 
for virtual synthesis modification. 
5.6.4 Combining with partner reactant 
After the initial reactant has been tested against all the reactions to see which ones it can 
participate in, partner reactants to form a product must be found. This is performed by examining the 
bond and charges in the reactants, and guided by the SMIRKS rules, generate a product. Figure 5.7 
shows an example initial reactant and partner reactant selected to participate in a Baylis-Hillman 
reaction. 
 
+ 
 
Figure 5.7. An example of two reactant molecules. Reactant atoms that participate in the Baylis-Hillman reaction are 
labelled according to Figure 5.2. 
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5.6.5 Product 
The reactants are joined together according to the atom and bond transformations described in 
the SMIRKS to form the bond and atom graph of the predicted product, as shown in Figure 5.8. Atoms 
that form secondary products are discarded. 
 
Figure 5.8. Example of two example reactants joined together into a product molecule with correct bond and atom graph 
but without any attempt to alter the structure into an energetically favourable conformation. 
Because the INDDEx rules describe distances, it is important that the product is formed into an 
approximately energetically favourable conformation. To achieve this, the molecules are moved 
together so that new bonds formed between the reactants are of the correct length, and the second 
reactant is rotated to preserve maximum steric separation of the two reactants. Figure 5.9 shows the 
transformed product. 
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Figure 5.9. Example of an initial product molecule, orientated so that bond lengths are correct and the joined reactants have 
low steric clash. Reactant atoms that participate in the Baylis-Hillman reaction are labelled according to the reaction scheme 
shown in Figure 5.2. 
The product molecule can then be optionally minimised using the MMFF94 Merck molecular 
force field (Halgren, 1996), as shown in Figure 5.10. This has the advantage of forming a more 
energetically correct conformation, but has the disadvantage of requiring a lot of extra processing time 
(see speed testing in section 5.10). 
 
Figure 5.10. Example of an energetically minimised virtual product molecule. 
5.7 Assessment 1: Exploring the extent to which the virtual reactions open up search space 
In order to estimate the total search space opened up by the synthetic reactions, the following 
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method was devised: 
1. Take a series of 100 randomly chosen test molecules. Results are averaged over these 
molecules. The random selection was done from both the entire ZINC database, and from 
just the fragment-like subset of ZINC, resulting in one test dataset for all molecules, and 
another for fragment-like molecules only. 
2. For each of these test molecules, run the reaction checker on it to find out how many 
reactions this molecule can participate in. 
3. For each of these reactions, test all molecules in the ZINC fragment database to see which 
ones can participate in the reaction. 
4. For each of the participatory fragment molecules, the reaction algorithm was run to generate 
all products. 
Table 5.2. Values found when estimating the average number of reactions, reactant partners and total products from a 
dataset of random molecules. 
 All ZINC Fragments only 
Random test molecules used as initial reactants 100 100 
Average reactions per molecule 2.28 1.98 
Average reactant partners per molecule 27,228 24,033 
Average total virtual products per molecule 53,450 66,329 
The values found from these tests are shown in Table 5.2. Note that the average total number of 
virtual products is not equivalent to the product of average reactions and average reactant partners, 
firstly because some reaction/reactant combinations have multiple products, and secondly because 
the sum of the products of two variables that are always greater than zero will always be less than the 
product of the sum of each variable: ∑ 𝑎𝑖𝑏𝑖 <  ∑ 𝑎𝑖 ∙ ∑ 𝑏𝑖𝑛𝑖=0𝑛𝑖=0  {𝑎, 𝑏 ∈ ℝ>0}𝑛𝑖=0 . These values allow an 
estimate that the potential space opened up by the use of virtual synthetic reactions is the 53,450 
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average products calculated from the test dataset, multiplied by the number of molecules in the ZINC 
database (19,607,982 as of January 2013). A similar calculation can be done for the fragment-like 
molecules, where there are 66,329 average products and 525,686 molecules in the fragment-like subset 
of the ZINC database. Therefore, the potential space is 1.048 × 1012 molecules using all ZINC 
molecules or 3.487 × 1010 using only fragment-like molecules, either of which would be an intractable 
number to screen. This new space is intractable to brute-force search. Based on the timings in section 
4.3.7, it would take 1.9 × 107 hours CPU time when calculating descriptors on the fly, and 1.0 × 106 
hours when using pre-calculated descriptors. It would take even longer because of the time taken to 
do the virtual reactions. Based on the time of 107ms to produce and test a molecule given in section 
5.10, it would take 3.1 × 107 hours of CPU time. 
The potential space is shown visually in Figure 5.11 in comparison with other estimations of 
synthetic space as described in section 1.6 of the introduction. 
 
Figure 5.11. Log scale comparison of estimates of chemical space and the size of known databases (see section 1.6) as shown 
previously in Figure 1.3, and now including the synthetic space potentially searched by INDDEx v3 (1.048 × 1012 
molecules) shown as a red circle. Estimates with upper and lower bounds are represented by concentric circles of dark blue 
(lower bound) and light blue (upper bound). The bounds of the estimates are also shown on the linear scale by solid 
rectangles; coloured grey, green, violet and black to aid discrimination. For comparison is the estimated number of grains of 
sand on earth (sand texture is “File:Sand.jpg” from WikiCommons). 
Number of molecules 
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5.8 Methodology for reducing search space 
In order to reduce the search space, there has to be a method of selecting molecules to modify. 
INDDEx v3 picks molecules that are expected to yield molecules with high activity when modified. 
The results of this approach will be compared to the naïve method of picking molecules with high 
predicted values from the SVILP process. 
The INDDEx rules can be used to score the “partial limited matches” of molecules, and hence to 
select highly unfulfilled compounds. Only considering compounds with corresponding fulfilments 
reduces CPU time sufficiently to allow the screening of a significantly larger proportion of 
compounds. When iterating through a database of fragment-like molecules to search for partner 
reactants, a cut-off of fulfilling the unfulfilled half of at least three rules was used before considering a 
reactant. 
5.9 Assessment 2: Estimating the virtual screening power of INDDEx v3 
5.9.1 Quantifying the power of INDDEx v3 
The aim of this assessment is to quantify how well INDDEx v3 can explore synthetic space and 
identify molecules that are active but would not be found by a search of an existing database, and to 
compare the exploration incorporating the PLoRRS method to a method not using PLoRRS (Figure 
5.12). This comparison was performed on the DUD database, as in the assessment described in 
Chapter 4, by dividing the known actives into two sets: a small training set of eight compounds, and 
the remaining known active compounds forming a held-back test set of known actives to be found. 
Rather than trying to retrieve the test set from a large set of decoys as in Chapter 4, INDDEx v3 was 
used to attempt to recreate members of the test set de novo from a database of molecules structurally 
dissimilar to the held-back dataset. All the molecules in DUD are taken from ZINC, so the structurally 
dissimilar database was formed from the ZINC fragment-like subset (a set of small molecules, suitable 
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for participating in reactions to synthesise new compounds) filtered so that it only includes molecules 
that are structurally dissimilar from any members of the held-back dataset. A molecule is here defined 
as structurally dissimilar if it has a maximum common substructure Tanimoto value of less than 0.5 to 
any of the molecules in the test dataset. 
5.9.2 Assessment methodology 
Figure 5.12 shows a benchmarking method to test how much predictive power is added by 
using ILP rules to direct chemical synthesis over the naïve selection of the best molecules predicted by 
SVILP, or by pooling the results of the two approaches. 
 
Figure 5.12. Flowchart showing the process used for the assessment of the power of the PLoRRS method against a naïve use 
of the SVILP method. 
  166  Incorporation of virtual synthetic reactions into INDDEx 
 
The null hypothesis is that there is no enrichment over SVILP provided by using the fulfilment 
process. For this assessment, the 40 datasets from the DUD database were used as the test sets (see 
section 4.2.8 for details of the DUD target sets). 
1. INDDEx learned on a randomly selected training set of eight compounds from the known 
actives. From this, an SVILP model was generated. 
2. The screening dataset for each target is the ZINC fragment-like database filtered to remove 
all molecules with 0.5 or more MCCS Tanimoto similarity (as defined in section 1.8) to any of 
the molecules in the test set of active molecules. 
3. INDDEx screened this dataset to assign each molecule a predicted activity and a PLoRRS 
score. 
4. At this point, three assessments of synthetic exploration are run in parallel. One that uses the 
PLoRRS method, one that does not, and a consensus of these two. The assessment using the 
PLoRRS method ranks the molecules from the preceding step by PLoRRS score, and moves 
down the ranked list, using each molecule as an initial reactant and exploring the synthetic 
space of each in turn. The assessment without the PLoRRS method ranks the molecules from 
the preceding step by predicted activity according to the SVILP model. A third method of 
assessment is to consider the consensus approach, which merges the results of the PLoRRS 
method and naïve SVILP. The total number of molecules in the consensus set is the sum of 
the number of molecules in the PLoRRS and SVILP sets. 
5. When exploring synthetic space using virtual reactions, the PLoRRS method reduces search 
by only considering partner reactant molecules that match the unfulfilled PLoRRS rules. The 
non-PLORRS method must consider all partner reactant molecules. To generate in the order 
of hundreds of thousands of products, the virtual reaction process explored the top 150 
PLoRRS-ranked molecules but only the top 20 SVILP-ranked molecules, and these sets were 
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combined in the consensus. 
6. Each virtual product tested was assigned a predicted activity value using the SVILP model, 
and was tested to find the maximum similarity value to any of the compounds in the 
training dataset, and its maximum similarity to any of the known actives not included in the 
training set. The similarity values explain how closely the virtual products resemble known 
actives and hence if they are likely to be active themselves. In this study, the assumption is 
that structurally similar molecules will have similar activities, although this is a 
generalisation and simplification of the complex structure-activity relationship. The aim of 
this assessment is to see if the virtual reaction method can generate virtual products 
resembling active molecules from fragment-like precursors that do not resemble the known 
actives, thus giving an estimate of the virtual reaction methods usefulness in generating 
unknown active molecules. 
5.9.3 Amount of synthetic space explored 
In step 5 of the previous section, a large number of virtual products are generated for each 
target. Figure 5.13 compares the distribution of the total number of virtual products generated for the 
forty targets, visualising the amount of search space explored. It shows that the SVILP method 
generally has to search through a much larger number of derivatives than the PLoRRS method even 
though fewer initial reactants are searched, because there is no filtering of the partner reactants 
considered. 
  168  Incorporation of virtual synthetic reactions into INDDEx 
 
 
Figure 5.13. Two box and whisker plots showing differing distributions of the number of virtual products generated across 
the forty targets. The left-hand plot gives the distribution of virtual products when using the PLoRRS method and the 
right-hand plot gives the distribution when using SVILP without PLoRRS. Box and whisker plots visually represent a five-
number summary of a numerical set. The three horizontal lines making up the box mark the lower quartile, median and 
upper quartile of the set, and the whiskers coming out of the box extend to the maximum and minimum values of the set. 
5.9.4 Filtering of synthetic search space 
As described in section 5.8, when using the PLoRRS filter, only reactants that fulfil at least three 
unfulfilled rules are considered for partner reactants. This filter reduces the number of partner 
reactants that need to be considered as compared the naïve SVILP method, which has no way of 
filtering and must consider every molecule in the database as a potential partner reactant. Figure 5.14 
visualises the reduction of search space by showing percentage of the 525,686 molecules in the 
fragment-like database that needed to be considered as partner reactants after applying the PLoRRS 
filter. The median percentage of molecules considered as partner reactants was 2.6% (a 97.4% 
reduction). 
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Figure 5.14. Bar chart showing, for each DUD target, the percentage of fragment-like molecules that are considered possible 
partner reactants after PLoRRS filtering. This chart shows what fraction of the database remains after applying the filter of 
at least three unfulfilled rules. The values are calculated from the partner reactants considered for the first-ranked initial 
molecule screened for each target. 
5.9.5 Results of PLoRRS vs. SVILP vs. a consensus of the two 
As described in 5.9.2, there are three methods to compare: the PLoRRS methodology using 
logical rules, the naïve use of SVILP with the virtual reactions, and a consensus of the two methods, 
where the products of both approaches are merged. The data are shown in Figure 5.15, Figure 5.16, 
Figure 5.17, Figure 5.18 and Figure 5.19, which display graphs of progressively increasing similarity to 
held-back actives for each of the forty targets. For each graph, the x-axis is the rank order of all the 
generated virtual products, as predicted by the SVILP model after generation. The y-axis is the 
maximum MCSS Tanimoto similarity of any virtual product, up to and including this rank, to any of 
the held-back actives.  
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Figure 5.15. Graphs of retrieval at different similarity levels from ACE to COMT. The full target names and details are 
given in Appendix B. 
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Figure 5.16. Graphs of retrieval at different similarity levels from COX-1 to Fxa. The full target names and details are 
given in Appendix B. 
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Figure 5.17. Graphs of retrieval at different similarity levels from GART to InhA. The full target names and details are 
given in Appendix B. 
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Figure 5.18. Graphs of retrieval at different similarity levels from MR to PPAR gamma. The full target names and details 
are given in Appendix B. 
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Figure 5.19. Graphs of retrieval at different similarity levels from PR to VEGFr2. The full target names and details are 
given in Appendix B. 
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Table 5.3 tabulates the data in the graphs shown in Figure 5.15, Figure 5.16, Figure 5.17, Figure 5.18 and Figure 5.19, giving the best 
similarity to known actives achieved within the first 10, 100 and 1000 ranked molecules. Any similarity achieved over 0.5 is a level of 
similarity not present in the database of molecules that was screened. Similarities above 0.6, 0.7 and 0.8 have been highlighted to show 
increasingly close similarities to known actives. Within the top 1000 ranked molecules, PLoRRS achieves similarities above 0.7 for the targets 
COX-1, COX-2, AR, and EGFr; SVILP achieves good similarities for the target PPAR gamma; a consensus achieves good similarities for all of 
those targets, COX-1, COX-2, AR, EGFr and PPAR gamma. 
Table 5.3. Summary of results for the virtual screening power assessment. Explanations of the abbreviations for the targets in the second column, and a description of each 
target’s abbreviations and biological functions are defined in Appendix B. Mean similarity is calculated as the geometric mean of the Maximum Common Substructure 
Tanimoto coefficient. Similarities are shown to two decimal places, and those above 0.6 are highlighted in green, above 0.7 in orange, and above 0.8 in red. 
ID 
Target 
dataset 
Active 
ligands 
Mean 
similarity 
Max similarity achieved 
by rank using PLoRRS 
Max similarity achieved 
by rank using SVILP 
Max similarity achieved 
by rank using consensus 
10 100 1000 10 100 1000 10 100 1000 
1 HIVRT 40 0.219 0.31 0.31 0.31 0.41 0.45 0.45 0.41 0.45 0.45 
2 VEGFr2 74 0.199 0.18 0.18 0.18 0.27 0.27 0.27 0.27 0.27 0.27 
3 CDK2 50 0.198 0.47 0.57 0.57 0.32 0.32 0.32 0.32 0.32 0.32 
4 PDE5 51 0.204 0.24 0.24 0.24 0.31 0.31 0.31 0.31 0.31 0.31 
5 COX-1 25 0.276 0.29 0.40 0.78 0.30 0.30 0.30 0.39 0.42 0.78 
6 ALR2 26 0.255 0.21 0.21 0.29 0.37 0.64 0.64 0.37 0.64 0.64 
7 PDGFrb 157 0.262 0.18 0.18 0.18 0.39 0.42 0.42 0.39 0.42 0.42 
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8 InhA 85 0.254 0.17 0.17 0.34 0.35 0.35 0.35 0.17 0.17 0.17 
9 SRC 155 0.286 0.27 0.27 0.27 0.19 0.19 0.19 0.19 0.19 0.19 
10 COMT 11 0.265 0.15 0.15 0.30 0.15 0.17 0.24 0.15 0.17 0.24 
11 thrombin 65 0.347 0.22 0.22 0.30 0.28 0.28 0.41 0.28 0.28 0.41 
12 ER agonist 67 0.345 0.49 0.54 0.67 0.28 0.28 0.28 0.29 0.29 0.54 
13 AChE 105 0.353 0.33 0.33 0.33 0.22 0.22 0.22 0.33 0.33 0.33 
14 trypsin 44 0.384 0.36 0.36 0.36 0.25 0.25 0.32 0.36 0.36 0.36 
15 HIVPR 53 0.248 0.64 0.64 0.64 0.40 0.43 0.51 0.64 0.64 0.64 
16 COX-2 348 0.278 0.57 0.83 0.85 0.26 0.26 0.26 0.50 0.57 0.83 
17 FGFr1 118 0.327 0.16 0.16 0.16 0.33 0.33 0.35 0.33 0.33 0.35 
18 ER antag. 39 0.296 0.43 0.44 0.44 0.31 0.31 0.31 0.31 0.31 0.44 
19 ADA 23 0.415 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.26 
20 GR 78 0.346 0.32 0.32 0.49 0.55 0.55 0.55 0.55 0.55 0.55 
21 AmpC 21 0.409 0.26 0.30 0.30 0.28 0.28 0.32 0.28 0.28 0.32 
22 HSP90 24 0.365 0.36 0.52 0.57 0.24 0.24 0.24 0.36 0.52 0.57 
23 TK 22 0.554 0.29 0.29 0.29 0.21 0.21 0.28 0.21 0.21 0.28 
24 P38 MAP 256 0.340 0.19 0.19 0.19 0.35 0.35 0.35 0.35 0.35 0.35 
25 AR 74 0.311 0.60 0.70 0.70 0.30 0.49 0.54 0.53 0.60 0.70 
26 MR 15 0.452 0.36 0.36 0.46 0.30 0.62 0.68 0.30 0.62 0.68 
27 PR 27 0.338 0.28 0.28 0.28 0.29 0.29 0.29 0.29 0.29 0.29 
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28 PARP 33 0.498 0.19 0.19 0.19 0.23 0.23 0.23 0.19 0.19 0.19 
29 EGFr 444 0.412 0.32 0.32 0.83 0.39 0.45 0.45 0.32 0.32 0.79 
30 Fxa 142 0.266 0.33 0.33 0.33 0.24 0.49 0.51 0.33 0.33 0.49 
31 PNP 25 0.500 0.28 0.28 0.28 0.37 0.37 0.37 0.37 0.37 0.37 
32 ACE 49 0.345 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 0.21 
33 HMGA 35 0.470 0.33 0.33 0.39 0.43 0.46 0.58 0.43 0.46 0.58 
34 GPB 52 0.489 0.30 0.30 0.30 0.32 0.32 0.32 0.32 0.32 0.32 
35 PPAR γ 81 0.439 0.23 0.43 0.45 0.68 0.73 0.78 0.68 0.73 0.78 
36 NA 49 0.355 0.28 0.28 0.28 0.26 0.26 0.26 0.28 0.28 0.28 
37 DHFR 201 0.353 0.31 0.50 0.57 0.33 0.33 0.33 0.33 0.33 0.50 
38 GART 21 0.465 0.38 0.38 0.46 0.26 0.26 0.28 0.26 0.26 0.28 
39 SAHH 33 0.436 0.29 0.29 0.29 0.25 0.25 0.25 0.29 0.29 0.29 
40 RXR alpha 20 0.715 0.50 0.62 0.62 0.26 0.26 0.26 0.50 0.50 0.62 
Number of targets with 
a similarity value 
greater than 
0.6 1 4 7 1 3 3 2 4 9 
0.7 0 2 4 0 1 1 0 1 5 
0.8 0 1 2 0 0 0 0 0 1 
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Table 5.4 shows the p-values when comparing the performance of the methods from Table 5.3 
using the Mann–Whitney U statistical test (Mann and Whitney, 1947). The Mann–Whitney U test tests 
the hypothesis that one population tends to have greater values than another population, with a null 
hypothesis that the two populations are the same and any differences are caused by chance. The 
performance was compared both over the top 100 molecules ranked by INDDEx predicted activity 
and the top 1000. Table 5.4 shows that the consensus method performs better at the 5% significance 
level than using pure SVILP when looking at the top 1000 ranked molecules. 
Table 5.4. One-tailed p-values from the Mann–Whitney U test comparing the three methods when looking at the maximum 
similarity in both the top 100 and the top 1000 ranked virtual products. Results are shown to three decimal places, and 
results with a significance level of less than 5% are highlighted in red. 
 SVILP rank 100 Consensus rank 100 SVILP rank 1000 Consensus rank 1000 
PLoRRS rank 100 0.464 0.214   
SVILP rank 100  0.203   
PLoRRS rank 1000   0.283 0.152 
SVILP rank 1000    0.039 
5.9.6 Case studies of the virtual product results 
This section examines two cases from the screening results (COX-2 and EGFr) where virtual 
products were formed that had high similarity to known actives. 
In the COX-2 target screening, a virtual product ranked 90th with a similarity of 0.834 to a known 
active molecule held back from the training data. The initial reactant molecule, described in step 3 of 
the assessment methodology in section 5.9.2, was ZINC04369096 (shown in Figure 5.20). The 
exploration of synthetic space described in step 5 of the assessment methodology found a matching 
partner reactant ZINC21985593 (shown in Figure 5.20). These reactants were determined to be able to 
participate as reactants in six of the available reactions (Heck reaction, Isocyanate with nucleophile, 
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Stille carbonyl synthesis, Stille coupling, Suzuki coupling, Ullmann condensation), and it was with the 
Heck reaction that they were predicted to form the product shown in Figure 5.21. 
  
ZINC04369096 ZINC21985593 
Figure 5.20. The initial reactant (left) and partner reactant (right) found during the screening process that were used to 
form the virtual product shown in Figure 5.21. 
 
Figure 5.21. The virtual product predicted to be formed from the reactants in Figure 5.20 using the Heck reaction. 
Comparing the similarities of this virtual product and the held back actives, this virtual product 
is most similar to ZINC03959950. Figure 5.22 shows the virtual product and ZINC03959950 side by 
side, highlighting their common substructure in red. Noticeably the fluorine is substituted for a 
chlorine atom in the virtual product, which, as they are both halogens, is an additional similarity not 
taken into account by the common substructure. 
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Figure 5.22. The structure of the COX-2 virtual product molecule (left) and the closest match in the held-back actives, 
ZINC03959950 (right), with the common substructure highlighted in red. 
Figure 5.23 shows the most similar molecule in the training data. The cylopentene between the 
phenyl groups breaks up the common substructure. The virtual product retains the fluorine 
substitutions learned from this active molecule, providing additional evidence that the fluorine-
chlorine substitution in the virtual compound would not hinder activity. 
  
Figure 5.23. The structure of the COX-2 virtual product molecule (left) and the closest match in the held-back actives, 
ZINC03814740 (right), with the common substructure highlighted in red. 
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The matrix in Table 5.5 compares the Tanimoto MCSS similarity between the molecules 
involved in the formation of the COX-2 virtual product, and the most similar molecules in the training 
and held-back actives. Table 5.5 shows that both the initial and partner reactants had low structural 
similarity to any of the molecules in the training data and any of the active molecules held back. The 
eventual virtual product had very high similarity to a molecule held back from the training data 
(0.834), despite only having a much lower similarity of 0.502 to the most similar molecule in the 
training data. There are many structural features in common, and the overall shape, comprising two 
joined phenyl rings, is similar. This demonstrates the way that the SVILP logical rules are able to 
recognise shape and feature similarity from the relational positions of substructure in a way that 
considering only structural similarity cannot. 
Table 5.5. COX-2 virtual product similarity matrix. This matrix displays the Tanimoto MCSS similarity between the 
COX-2 reactants, the most similar molecules in the training and held-back actives, and the virtual product of the two 
reactants. All similarities shown to three decimal places. 
 
ZINC04369096 
(Initial reactant) 
ZINC21985593 
(Partner reactant) 
ZINC03814740 
(Most similar 
training data active) 
ZINC03959950 
(Most similar 
held-back active) 
COX-2 virtual 
product 
ZINC04369096 1.000 0.316 0.317 0.385 0.392 
ZINC21985593  1.000 0.329 0.445 0.572 
ZINC03814740   1.000 0.453 0.502 
ZINC03959950    1.000 0.834 
COX-2 virtual product     1.000 
In the EGFr target screening, a virtual product ranked 308th with a similarity of 0.791 to a known 
active molecule held back from the training data. The initial reactant molecule, described in step 3 of 
the assessment methodology in section 5.9.2, was ZINC26894451 (shown in Figure 5.24). The 
exploration of synthetic space described in step 5 of the assessment methodology found a matching 
partner reactant ZINC20357555 (shown in Figure 5.24). These reactants were determined to be able to 
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participate as reactants in four of the available reactions (Stille carbonyl synthesis, Stille coupling, 
Suzuki coupling, Ullmann condensation), and it was with the Ullmann condensation reaction that 
they were predicted to form the product shown in Figure 5.25. 
  
ZINC26894451 ZINC20357555 
Figure 5.24. The initial reactant (left) and partner reactant (right) found during the screening process that were used to 
form the virtual product shown in Figure 5.25. 
 
Figure 5.25. The virtual product predicted to be formed from the reactants in Figure 5.24 using the Heck reaction. 
Comparing the similarities of this virtual product and the held-back actives, this virtual product 
is most similar to ZINC03815386. Figure 5.26 shows the virtual product and ZINC03815386 side by 
side, highlighting their common substructure in red. It can be seen that the ZINC03815386 structure is 
a subgraph of the virtual product; the differences in the virtual product are the additions of an amine 
and a bulky trifluoromethyl group. 
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Figure 5.26. The structure of the EGFr virtual product molecule (left) and the closest match in the held-back actives, 
ZINC03815386 (right), with the common substructure highlighted in red. 
Figure 5.27 shows the most similar molecule in the training data. The secondary amine replacing 
the ether between the phenyl and the quinazoline breaks up the common substructure, and the 
trifluoromethyl group is attached to the phenyl rather than the quinazoline. 
  
Figure 5.27. The structure of the EGFr virtual product molecule (left) and the closest match in the held-back actives, 
ZINC03815044 (right), with the common substructure highlighted in red. 
The matrix in Table 5.6 compares the Tanimoto MCSS similarity between the molecules 
involved in the formation of the EGFr virtual product, and the most similar molecules in the training 
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and held-back actives. Table 5.6 shows that both the initial and partner reactants had low structural 
similarity to any of the molecules in the training data and any of the active molecules held back. The 
eventual virtual product had high similarity to a molecule held back from the training data (0.791), 
but a very low similarity to the most similar molecule in the training data (0.266). The product 
molecule has retained features such as the trifluoromethyl group and quinazoline, again 
demonstrating the way that the SVILP logical rules are able to recognise shape and feature similarity. 
Table 5.6. EGFr virtual product similarity matrix. This matrix displays the Tanimoto MCSS similarity between the EGFr 
reactants, the most similar molecules in the training and held-back actives, and the virtual product of the two reactants. All 
similarities shown to three decimal places. 
 
ZINC26894451 
(Initial reactant) 
ZINC20357555 
(Partner reactant) 
ZINC03815044 
(Most similar 
training data active) 
ZINC03815386 
(Most similar 
held-back active) 
EGFr virtual 
product 
ZINC26894451 1.000 0.325 0.339 0.437 0.580 
ZINC20357555  1.000 0.250 0.401 0.376 
ZINC03815044   1.000 0.304 0.266 
ZINC03815386    1.000 0.791 
EGFr virtual product     1.000 
5.10 Speed and timing testing 
Tests were performed on an Intel i7-3820 CPU @ 3.60GHz, running on a single core, with all data 
reading/writing from a Samsung PM83 solid-state drive. 
The time taken to check molecule for reactant substructure and to check whether it participates 
in a reaction takes an average of 1.0 ms (most non-reacting molecules can be rejected very quickly). To 
produce a single derivative and calculate a predicted score for it takes 107ms. To minimise the 
structure takes an additional average 460 ms. 
Assuming an average number of 53,450 products per molecules, as calculated in section 5.7, this 
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gives a time of 5,727 seconds to explore a single molecule (95 minutes) without filtration. Using the 
PLoRRS filtration method to achieve a 97.4% reduction in search space, as estimated in section 5.9.4, 
would take 2.47 minutes. 
Given the values in Table 5.2, the estimated time to scan the for the 474,770 molecules of the 
“Frags now” fragment-like molecular database for partner reactants for a single initial reactant, is, on 
average 1,686 seconds (28.1 minutes) without minimisation and 26,299 seconds (about 7 hours 18 
minutes) with minimisation. Using the PLoRRS filtration method to achieve a 97.4% reduction in 
search space, as estimated in section 5.9.4, takes 748 seconds (12.5 minutes) without minimisation and 
1,388 seconds (23.1 minutes) with minimisation. 
5.11 Discussion 
5.11.1 Achievements 
There remains an absence of software to go from hit to lead and exploring the lead space and the 
work described in this chapter was to address the issue. This chapter described the implementation of 
a virtual reaction module into INDDEx, incorporating a variety of reactions and a library of reactants. 
Virtual reactions were implemented in INDDEx in a format that allows only those reactions that are 
predicted to take place to have products generated, and to carry out those reactions on a molecule 
highly scored by the PLoRRS method to generate a new derivative product that is rescored by the 
INDDEx SVILP model. There are two parts to this methodology: the virtual reactions that open up 
synthetic space for exploration, and the ability of PLoRRS to direct the exploration effectively. 
5.11.2 Assessment 1: Exploring search space 
Section 5.7 shows that the virtual reactions open up an area of synthetic space more than four 
orders of magnitude larger than the ZINC database, and that this space is intractable to brute force 
searching, making necessary a further method to choose reactions and reactants. 
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5.11.3 Assessment 2: Estimating virtual screening power 
These results show a statistically significant advantage in using the consensus of PLoRRS and 
naïve SVILP, so that for a target screening, using the methods described in this chapter improve the 
chances of finding a novel hit. The methods also provide the advantage of the hit being formed by a 
synthetic reaction between two molecules, so that the hit is likely to have a completely novel structure. 
The results were significant only when comparing the top 1000 ranked molecules. 
In a real-world situation, synthesising in the order of a thousand products would usually be 
prohibitive, but further refinements to the model, and the introduction of a system to filter the 
product molecules using drug likelihood profiles could help to eliminate false positives from the 
rankings and without eliminating true positives. As the assessments described in Chapter 5 were 
proof of concepts, filtration was not considered; further testing would be needed to determine the 
optimum values and criteria for filtering. 
Two assumptions are being made for this assessment. The first assumption is that structural 
similarity to known actives implies activity and structural dissimilarity implies inactivity. This is a 
simplification of the structure-activity relationship, and includes false positives that have similar 
structure but no activity, and ignores the true negative space of unknown actives that have dissimilar 
structure but high activity. The second assumption is that the molecules being searched for are 
accessible by the virtual reactions, in other words, that the virtual synthetic space being searched 
includes the held-back active compounds. The graphs of some of the targets (see Figure 5.15, Figure 
5.16, Figure 5.17, Figure 5.18 and Figure 5.19) show that eventually products with high similarity are 
produced, which means that the failure of detection is due to inaccurate activity ranking, but in many 
cases, no product with high similarity is produced, which could indicate a case where success is 
impossible because the necessary reactants and reactions to generate a similar product do not exist in 
the database.  
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Chapter 6 Discussion and Conclusion 
6.1 Introduction 
This chapter concludes and summarises the work described in this thesis. Section 6.2 
summarises the developments achieved in the research and the results obtained in the assessments. 
Areas for further research and development are identified in section 6.3, and concluding remarks are 
presented in section 6.4. 
6.2 Summary of research and results 
6.2.1 Development of INDDEx 
Chapter 2 reported the developments of INDDEx v1 to yield INDDEx v2.0 and v2.1 that were 
employed in Chapter 3 and Chapter 4. Improvements to INDDEx v1 include the incorporation of 
Support Vector Machines, which now replace Partial Least Squares as the regression method, and 
increased in computational efficiency as assessed in Chapter 4. 
6.2.2 Application to finding new leads 
Chapter 3 reported the application of INDDEx to a typical hit-to-lead drug development study, 
in this case, for the inhibition of SIRT2. INDDEx produced a model from a small set of existing active 
molecules, and used it to scan a molecular database, and out of eight molecules tested, two new 
molecules were found to have activity (a hit rate of 25%), neither of which showed similarity to 
molecules in the training set or with each other. One of these molecules showed an activity of 0.67µM, 
which made it more active than any molecule in the training set, and making it an ideal starting point 
for lead development. 
6.2.3 Assessment of predictive power 
Chapter 4 reported an assessment of the predictive power of the virtual screening method in 
  188  Discussion and Conclusion 
 
INDDEx v2.1. This is the most extensive benchmark performed on INDDEx’s predictive power. In 
addition, computational speed of screening has been increased 10-fold, and steps previously 
conducted manually have been automated. 
6.2.4 Incorporation of virtual synthetic reactions 
Chapter 5 reported the implementation of both a method to incorporate virtual chemical 
synthesis into INDDEx, and a strategy to direct the choice of reactions and reactants used in the 
virtual synthesis known as Partial Logical-Rule Reactant Selection (PLoRRS). A first assessment of the 
ability of the strategy to explore virtual synthetic space showed that the potential amount of molecules 
opened up by exploring synthetic space is 1.048 × 1012 molecules, as compared to the 1.961 × 107 
molecules in the ZINC database; an increase of more than four orders of magnitude. A second 
assessment of the power of the strategy to identify active molecules qualified the PLoRRS used in 
consensus with SVILP method as significantly better than naïve use of the SVILP model. 
6.3 Outlook for future development 
6.3.1 Application to finding new hits and leads 
The main strand of further work will be the development of INDDEx for hit and lead finding, 
with on-going research devoted to increasing the predictive power of INDDEx. A high priority is to 
incorporate INDDEx into a user-friendly package with a graphical interface. 
The use of two complementary methods in Chapter 3 has proved successful in identifying a 
novel model with inhibitory properties, but a useful study would be to benchmark the entire 
approach to assess its generality and then formalise the procedure. This could be done using a cross-
validated approach on a benchmarking database. 
INDDEx could be used to develop models that could be applied to other properties connected 
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with chemoinformatics, notably the ADMET features; the absorption, distribution, metabolism, 
excretion and toxicity of a compound in an organism; all of which are important factors to consider 
when developing a pharmaceutical compound. SVILP has already been used to carry out some initial 
work on toxicology using the DSSTox dataset (Amini et al., 2007a), so toxicology is known to be a 
tractable subject for INDDEx. Further work could be done applying the current version of INDDEx to 
the DSSTox set and other toxicology problems, such as inhibition of the human Ether-à-go-go-Related 
Gene channel that promiscuously binds to small molecules causing cardiotoxicity (Recanatini et al., 
2005). INDDEx could also be used to optimise selectivity by giving each molecule a measure of 
selectivity derived from activity on the molecule to be selected for, divided by activity on the molecule 
to be selected against. 
6.3.2 Assessment of predictive power 
Further benchmarking could be performed on different datasets and compared to widely used 
methods. Other datasets that could be used for benchmarking include MUV (Rohrer and Baumann, 
2009), which is known to have less structural homogeneity than the DUD (Rohrer and Baumann, 
2009), and ChEMBL (Gaulton et al., 2011), which currently lacks benchmarking methods but contains 
a large amount of unexploited, high quality data that could be used for blind testing of virtual 
screening methods. There is a need for an extensive evaluation of scaffold-hopping to quantify 
scaffold-hopping in a more sophisticated way. 
6.3.3 Incorporation of virtual synthetic reactions 
Section 5.11.3 has already addressed the need for a filtration system based on drug-likelihood 
profiles to filter the virtual products down to a number where the logistics of synthesis are no longer 
prohibitive. Further refinements would also be made to improve the power of the PLoRRS method 
itself. Currently PLoRRS calculates the potential of molecules purely from the rules they only half-
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fulfilled, using the assumption that molecules that fulfil fully existing rules will be identified by the 
SVILP score. However, a molecule that fully fulfils a large number of rules but only half-fulfils a few 
important ones might have more potential that a molecule that does not fully fulfil any rules but half-
fulfils many less important ones. Future work would develop a more detailed and informative scoring 
system for defining the potential of molecules. The PLoRRS method can be refined further to select the 
optimum reactions and reactants to apply to a molecule in order to fulfil the derived rules. This would 
cut down on the search space, and allow the program to test a wider variety of initial and partial 
reactants. Further refinement and efficiency in directing the choice of reactions would eventually 
allow the program to use two consecutive virtual reaction forward is to use two steps. 
More reaction schemata can be continuously added to the Java program, enlarging the database 
of 39 currently included in INDDEx v3. Although ChemAxon Reactor has 145 of the most widely used 
synthetic reactions in its database, there are many more which synthetic chemists find useful; by 
describing more synthetic reactions using the ChemAxon rules, the program’s search space for new 
molecules will be widened, hopefully resulting in an improved prediction ability. 
Finally a real-world test would be performed, where the virtual product compounds predicted 
were synthesised and tested in vitro. The assessments described in Chapter 5 used the ZINC database 
of fragments to search for the initial reactants and partner reactants, but a pharmaceutical company 
could use databases of their in-house libraries of compounds to allow for the quick synthesis of virtual 
products predicted. 
6.4 Conclusion 
The work reported in this thesis highlights the need for extensive benchmarks for the 
development and comparative testing of methods. The availability of the DUD database was central in 
the benchmarking, both for the assessment of INDDEx v2.1 described in Chapter 4 and for the 
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assessment of the virtual reaction method described in Chapter 5. However, there would be a benefit 
of having more community-wide databases to assess methods, and a standardised approach so that 
methods could be easily compared. A community standard is also needed for scaffold-hopping, and 
there need to be benchmarking methods specifically designed for the comparative assessment of 
virtual chemical synthesis methods. 
This thesis reported the development of INDDEx v1 into INDDEx v2.0, INDDEx v2.1 and 
INDDEx v3, robustly benchmarked them and showed them to be a competitive method of screening. 
The application of INDDEx v2.0 in combination with docking has been shown in a blind trial and a 
new lead series against the SIRT2 protein has been opened up. Virtual reactions have been integrated 
into the existing INDDEx methodology and shown to be an effective and useful method of exploring 
synthetic space. 
The long-term aim is to implement structure-based docking, INDDEx and virtual chemical 
synthesis; integrating both ligand and structure-based methods so that the result will be an automated 
approach to ligand and structure based lead discovery. The procedure needs to be automated so it can 
be robustly tested to provide confidence for its use as a tool for virtual lead discovery. 
  192  Development of a drug 
 
Appendix A. Development of a drug 
The stages in the development of a drug are shown in Figure A.1. The total cost of bringing a 
drug to market can be $500 million to $2 billion (Adams and Brantner, 2006), so it is important that the 
drug discovery phase is able to find valid leads. Research for drug development tends to follow a 
multiple phase paradigm (Paul et al., 2010). In experimental drug discovery, the number of molecules 
being considered is reduced from 10,000 at the drug discovery phase to 250 by the pre-clinical phase. 
The hit to lead process takes an average of 4.5 years and cost $219 million in 2010 (Paul et al., 2010). 
 
Figure A.1. The process of creating a drug and bringing it to market. The bars at the bottom show the different stages of the 
drug development cycle, proportioned by time taken. The red area is logarithmically scaled by the units on the left y-axis 
and shows the number of compounds being considered at each stage. The gold vertical bars are scaled by the units on the 
right y-axis, and show the cost at each stage. Data on cycle time and cost from Paul et al. (2010) and data on compound 
numbers considered at each stage from Steinmeyer (2006). 
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Appendix B. The DUD target sets 
The DUD database contains forty datasets, each consisting of ligand activity against a different protein target. Table B.1 gives a list of 
all the protein targets, along with a description of each protein’s role. 
Table B.1. The DUD targets (Huang et al., 2006), together with a description of their biochemical roles. 
Abbreviation Full name Description 
ACE Angiotensin-converting 
enzyme 
An exopeptidase that converts angiotensin in the renin-angiotensin system, and so increases 
extracellular pressure (Crackower et al., 2002). 
ACHE Acetylcholine esterase A serine protease involved in neuronal signalling that hydrolyses the acetylcholine 
neurotransmitter to end an action potential at a synapse (Quinn, 1987). 
ADA Adenosine deaminase A hydrolase which deaminates adenosine, it is involved in both the digestive system and nucleic 
acid degradation within cells. They are also thought to have a diverse range of secondary functions 
(Moriwaki et al., 1999), particularly in the immune system (Cristalli et al., 2001). 
ALR2 Aldose reductase An oxidoreductase which catalyses the reduction of many carbonyl compounds. Its most important 
function is to reduce glucose to sorbitol as part of glucose metabolism (Bohren et al., 1989). 
AmpC AmpC-type beta-lactamase A hydrolase present in bacteria which confers immunity to a broad spectrum of cephalosporin-class 
beta-lactam antibiotics, by hydrolysing the lactam ring (Powers et al., 2002). 
AR Androgen receptor A nuclear receptor that acts as a ligand-activated transcription factor involved in regulating gene 
expression for the development and function of multiple male phenotypes (Heemers and Tindall, 
2007). It is also involved in the kinase-signalling network and increasing intracellular calcium 
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concentration (Heinlein and Chang, 2002). 
CDK2 Cyclin dependent kinase 2 A transferase involved in cell growth and division, it controls centrosome duplication (Matsumoto 
et al., 1999) and the Gap 1 to Synthesis transition in the interphase of the cell cycle (Rosenblatt et 
al., 1992). 
COMT Catechol O-methyltransferase A transferase involved in the degradation of neurotransmission. It catalyses the transfer of a methyl 
group onto a variety of catecholamine neurotransmitter compounds, resulting in their inactivation. 
It is involved in a variety of psychiatric disorders (Gogos et al., 1998). 
COX-1 Cyclooxygenase 1 An oxidoreductase that oxygenises the fatty acid arachidonic acid to prostaglandin H2, which is the 
precursor of the prostanoids, which mediate autoimmune responses, including inflammation. 
Cyclooxygenase comes in two forms: COX-1 is produced constitutively expressed, and COX-2 is 
produced at inflammation sites (Dubois et al., 1998). 
COX-2 Cyclooxygenase 2 
DHFR Dihydrofolate reductase A reductase that reduces dihydrofolic acid to tetrahydrofolic acid, driven by the oxygenation of 
NADPH (Chen et al., 1984). 
EGFr Epidermal growth factor 
receptor kinase 
A tyrosine kinase cell-surface receptor involved in cellular signalling; it is activated by a variety of 
growth factor ligands (Herbst, 2004), and overexpression is associated with cancer (Zhang et al., 
2007). 
ER agonist Estrogen receptor agonist An intracellular receptor activated by the estrogen hormone. When activated by the binding of 
estrogen binds, the receptor bindings to DNA to regulate gene transcription (Levin, 2005). Estrogen 
receptors are involved in the development or progression of various types of cancers and other 
diseases (Deroo and Korach, 2006). 
ER antag Estrogen receptor antagonist 
FGFr1 Fibroblast growth factor A tyrosine kinase receptor involved in intercellular signalling. Fibroblast growth factors bind to the 
receptor to trigger a signalling cascade controlling cell proliferation and differentiation. Mutations 
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receptor 1 in FGFr1 are associated with a variety of developmental defects (Pitteloud et al., 2006), and 
inhibition of FGFr1 has antitumour effects (Wang and Becker, 1997). 
FXa Factor Xa A serine endopeptidase involved in the blood coagulation cascade. With Factor Va it forms the 
prothrombinase complex, which catalyses the cleavage of prothrombin to thrombin (Tracy et al., 
1985). 
GART Glycinamide ribonucleotide 
transformylase 
A transferase involved in the purine nucleotide biosynthetic pathway. It catalyses the transfer of a 
formyl group to the glycinamide ribonucleotide. Inhibition of GART to block the purine biosynthesis 
pathway is one means of chemotherapy (Manieri et al., 2007). 
GPB Glycogen phosphorylase beta A transferase involved in the metabolism. It cleaves and phosphorylates a glucose unit from a 
glycogen chain to produce glucose phosphate. Inhibition of Glycogen phosphorylase is a target for 
treating diabetes (Somsák et al., 2003). 
GR Glucocorticoid receptor A nuclear receptor. It is the binding target of glucocorticoid hormones. It regulates the expression 
of a variety of genes, but principally those involved in the immune response (Rhen and Cidlowski, 
2005). 
HIVPR HIV protease A retroviral aspartyl protease that is integral in the replication of the Human Immunodeficiency 
Virus (Brik and Wong, 2003). 
HIVRT HIV reverse transcriptase The reverse transcriptase used for the transcription of HIV RNA (Baltimore, 1970; Temin and 
Mizutani, 1970). 
HMGR Hydroxymethylglutaryl-
coenzyme-A reductase 
An oxidoreductase that oxidises mevalonate to hydroxy-3-methylglutaryl-coenzyme-A while 
reducing NADP+ to NADPH. It is involved in the synthesis of cholesterol (Alberts et al., 1980). 
HSP90 Human heat shock protein 90 A molecular chaperone and a member of the heat shock protein family. Protects proteins from heat 
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kinase denaturation by assisting in the folding, stabilisation and degradation of cytosolic proteins (Picard, 
2002). 
InhA Enoyl-acyl carrier protein 
reductase 
A reductase found in the metabolism, involved in type II fatty acid synthesis (Rozwarski, 1999). 
MR Mineralocorticoid receptor A nuclear receptor with affinity for mineralocorticoids and glucocorticoids, most notably, 
aldosterone. In response to ligand binding, the receptor migrates into the nucleus and regulates 
gene expression, with the regulation varying with tissue type (Fuller and Young, 2005). 
NA Neuraminidase A hydrolase that catalyses the hydrolysis of the glycoside bond in neuraminic acids. Viral 
neuraminidase is a drug target for the prevention of influenza by preventing the virus budding off 
from a host cell (Gubareva et al., 2000). 
P38 P38 mitogen activated protein 
kinase 
A mitogen-activated protein kinase. Involved in cellular signalling, and the regulation of 
proinflammatory cytokines that activate in response to cellular stress stimuli (Kumar et al., 2003). 
PARP Poly(ADP-ribose) polymerase A family of transferases involved in the preservation of gene integrity. It binds to DNA at DNA 
breaks, and synthesises a poly(ADP-ribose) chain as a signal to DNA repair enzymes (Strosznajder et 
al., 2005). 
PDE5 Phosphodiesterase V Also known as cGMP-specific phosphodiesterase type 5. A hydrolase involved in intracellular 
signalling that regulates signal transduction by cleaving the phophodiester bonds in cyclic GMP 
(Guanosine monophosphate). Inhibition of PDE5 enhances the physiological effects mediated by 
GMP, most notably penile erection (Lugnier, 2006). 
PDGFrb Platelet-derived growth factor 
receptor kinase beta 
A tyrosine kinase receptor involved in cellular signalling. It regulates cell division and proliferation 
(Williams, 1989), and actin-filament controlled cell shape alteration and motility (Heldin and 
Westermark, 1999). There are two genes that encode for the kinase, alpha and beta. This target is 
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the beta version. 
PNP Purine nucleoside 
phosphorylase 
A phosphorylase transferase that metabolises the purine nucleosides by cleaving them into ribose 
phosphate and a purine nucleobase. It is an important part of nucleotide salvage pathways, and 
deficiency causes immunodeficiency (Markert, 1991). 
PPAR γ Peroxisome proliferator-
activated receptor gamma 
A type II nuclear receptor, regulating the glucose metabolism, lipid storage and adipogenesis (Jones 
et al., 2005). 
PR Progesterone receptor A nuclear receptor that is activated by the progesterone hormone and a variety of other ligands, 
and binds to DNA, regulating expression of target genes (Lydon et al., 1995). 
RXR alpha Retinoic X receptor alpha A auxiliary nuclear receptor. It interacts with the thyroid hormone and retinoic acid nuclear 
receptors forming heterodimers, which bind to DNA and regulate transcription of target genes 
(Zhang et al., 1992).  
SAHH S-adenosyl-homocysteine 
hydrolase 
A hydrolase for the metabolisation of the amino acid derivative S-Adenosyl-L-homocysteine, by 
catalysing hydrolysis of the derivative to L-homocysteine and adenosine (Palmer and Abeles, 1979). 
SRC Tyrosine kinase SRC Tyrosine kinases are highly expressed in the cellular signalling network, and function by transferring 
phosphate groups from ATP to protein substrates. Tyrosine kinase SRC is involved in pathways that 
lead to oncogenesis through cell proliferation (Porter and Vaillancourt, 1998), and is essential for 
bone resorption (Susa and Teti, 2000). 
thrombin Thrombin A serine protease involved in the blood coagulation cascade, converting fibrinogen to insoluble 
fibrin (Brummel, 2002). 
TK Thymidine kinase (type-1) A phosphotransferase kinase involved in DNA synthesis, both replication and repair (Munch-
Petersen et al., 1995). It is a vital protein for cell division and proliferation in almost all living 
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organisms. 
trypsin Trypsin A serine protease involved in the digestive system (Rawlings and Barrett, 1994). 
VEGFr2 Vascular endothelial growth 
factor receptor kinase 
A tyrosine kinase cell surface receptor involved in a cellular signalling network which mediates cell 
division and migration (Gille et al., 2001). 
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